

Second consensus statement on the diagnosis of multiple sclerosis

Neurology

71, 670-676

DOI: [10.1212/01.wnl.0000324625.00404.15](https://doi.org/10.1212/01.wnl.0000324625.00404.15)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epidemiology of multiple system atrophy. <i>Neurological Sciences</i> , 2001, 22, 97-99.	1.9	52
2	Sporadic cerebellar ataxia associated with gluten sensitivity. <i>Brain</i> , 2001, 124, 1013-1019.	7.6	142
3	T2-low signal intensity in the cortex in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2003, 211, 85-88.	0.6	9
4	Laryngeal Stridor in Multiple System Atrophy. <i>European Neurology</i> , 2003, 49, 154-159.	1.4	83
6	Evaluation of the Autonomic Nervous System. , 2005, , 407-423.		0
7	Ocular tilt reaction and anterior inferior cerebellar artery syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1742-1743.	1.9	26
8	Prevalence of <i>FMR1</i> Repeat Expansions in Movement Disorders. <i>Neuroepidemiology</i> , 2006, 26, 151-155.	2.3	37
9	Visuospatial functions in atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 454-456.	1.9	88
10	Multiple System Atrophy with Progressive Nocturnal Hypoxemia: Case Report with Polysomnography and Continuous Positive Airway Pressure Treatment. <i>European Neurology</i> , 2006, 56, 258-260.	1.4	8
12	Parkinson-Plus Disorders. , 2008, , 157-175.		1
14	Genetic Variants of the α -Synuclein Gene SNCA Are Associated with Multiple System Atrophy. <i>PLoS ONE</i> , 2009, 4, e7114.	2.5	144
15	Sleep, Breathing, and Neurologic Disorders. , 2009, , 436-498.		2
16	Usefulness of Diffusion-Weighted MRI for Differentiation between Parkinson's Disease and Parkinson Variant of Multiple System Atrophy. <i>Journal of Movement Disorders</i> , 2009, 2, 64-68.	1.3	20
17	Cognitive Impairment in Spinocerebellar Degeneration. <i>European Neurology</i> , 2009, 61, 257-268.	1.4	57
18	Spinocerebellar Degenerations in Japan. <i>Neuroepidemiology</i> , 2009, 32, 184-185.	2.3	11
19	Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. <i>Brain</i> , 2009, 132, 1810-1819.	7.6	98
20	Hyposmia in pure autonomic failure. <i>Neurology</i> , 2009, 72, 1677-1681.	1.1	49
21	Sleep and Neurodegenerative Diseases. <i>Seminars in Neurology</i> , 2009, 29, 446-467.	1.4	45

#	ARTICLE	IF	CITATIONS
22	Dopamine cell loss in the periaqueductal gray in multiple system atrophy and Lewy body dementia. <i>Neurology</i> , 2009, 73, 106-112.	1.1	40
23	Prevalence of Spinocerebellar Degenerations in the Hokuriku District in Japan. <i>Neuroepidemiology</i> , 2009, 32, 176-183.	2.3	18
24	Multiple system atrophy: an update. <i>Lancet Neurology</i> , The, 2009, 8, 1172-1178.	10.2	406
25	Arginine test is not reliable for diagnosing cerebellar multiple system atrophy. <i>Annals of Neurology</i> , 2010, 67, 404-408.	5.3	6
26	¹²³ I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2009, 24, S732-41.	3.9	95
27	Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study. <i>Movement Disorders</i> , 2009, 24, 1312-1318.	3.9	110
28	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2009, 24, S711-20.	3.9	49
29	MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonismâ€predominant multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 1650-1655.	3.9	56
30	A validation exercise on the new consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 2272-2276.	3.9	100
31	Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy. <i>Journal of Neural Transmission</i> , 2009, 116, 861-866.	2.8	17
32	Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2009, 256, 1438-1446.	3.6	48
33	Recent developments in multiple system atrophy. <i>Journal of Neurology</i> , 2009, 256, 1791-1808.	3.6	86
34	A negative electroretinogram (ERG) in a case of probable multiple system atrophy (MSA). <i>Documenta Ophthalmologica</i> , 2009, 118, 247-256.	2.2	5
35	Animal Models of Human Cerebellar Ataxias: a Cornerstone for the Therapies of the Twenty-First Century. <i>Cerebellum</i> , 2009, 8, 137-154.	2.5	39
36	Dementia in multiple system atrophy: does it exist?. <i>European Journal of Neurology</i> , 2009, 16, 551-552.	3.3	8
37	Neuropathology of Lewy body disorders. <i>Brain Research Bulletin</i> , 2009, 80, 203-210.	3.0	59
38	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. <i>Neuroscience Letters</i> , 2009, 467, 208-211.	2.1	19
39	Biological fluid biomarkers in neurodegenerative parkinsonism. <i>Nature Reviews Neurology</i> , 2009, 5, 561-570.	10.1	66

#	ARTICLE	IF	CITATIONS
40	Neurological Aspects of Syncope and Orthostatic Intolerance. <i>Medical Clinics of North America</i> , 2009, 93, 427-449.	2.5	14
41	Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy. <i>Journal of Urology</i> , 2009, 182, 1453-1457.	0.4	124
42	Cognitive and Neuropsychiatric Profile of the Synucleinopathies. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 365-370.	1.3	104
43	A 74-year-old woman with progressive right-hand tremor and inability to use her right side. <i>Neurology</i> , 2009, 73, 1399-1405.	1.1	2
44	Prospective Differentiation of Multiple System Atrophy From Parkinson Disease, With and Without Autonomic Failure. <i>Archives of Neurology</i> , 2009, 66, 742-50.	4.5	133
45	Cerebellar ataxias. <i>Current Opinion in Neurology</i> , 2009, 22, 419-429.	3.6	169
46	Visual aspects of neurologic protein misfolding disorders. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 482-489.	2.9	7
47	Past, Present and Future Therapeutics for Cerebellar Ataxias. <i>Current Neuropharmacology</i> , 2010, 8, 41-61.	2.9	43
48	OVERVIEW OF RARE MOVEMENT DISORDERS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 49-76.	0.8	2
49	Parkinsonian Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 57-79.	0.8	1
50	Ventilatory and Cardiovascular Responses to Hypercapnia and Hypoxia in Multiple-System Atrophy. <i>Archives of Neurology</i> , 2010, 67, 211-6.	4.5	13
51	Classification of Cerebellar Atrophy Using Voxel-based Morphometry and SPECT with an Easy Z-score Imaging System. <i>Internal Medicine</i> , 2010, 49, 535-541.	0.7	16
52	Prevalence of Autosomal Dominant Cerebellar Ataxia in Aomori, the Northernmost Prefecture of Honshu, Japan. <i>Internal Medicine</i> , 2010, 49, 2409-2414.	0.7	4
54	Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 300-318.	1.4	116
55	Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2154-2164.	6.4	43
57	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. <i>Acta Neuropathologica</i> , 2010, 119, 703-713.	7.7	258
58	Pappalantos inclusions and the pathogenesis of multiple system atrophy: an update. <i>Acta Neuropathologica</i> , 2010, 119, 657-667.	7.7	128
59	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	3.6	140

#	ARTICLE	IF	CITATIONS
60	A young patient with type C multiple system atrophy and hereditary hemochromatosis. <i>Journal of Neurology</i> , 2010, 257, 294-295.	3.6	3
61	The close relationship between life-threatening breathing disorders and urine storage dysfunction in multiple system atrophy. <i>Journal of Neurology</i> , 2010, 257, 1287-1292.	3.6	13
62	Myocardial MIBG scintigraphy: a useful clinical tool?. <i>Neurological Sciences</i> , 2010, 31, 403-406.	1.9	17
63	Intérêt de l'exploration du système nerveux autonome dans les troubles vésicosphinctériens. <i>Lettre De Medecine Physique Et De Readaptation</i> , 2010, 26, 74-80.	0.1	0
64	Sporadic ataxia with adult onset: classification and diagnostic criteria. <i>Lancet Neurology</i> , The, 2010, 9, 94-104.	10.2	204
65	Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. <i>Brain Research</i> , 2010, 1361, 140-145.	2.2	26
66	<i>SNCA</i> variants and multiple system atrophy. <i>Annals of Neurology</i> , 2010, 67, 554-555.	5.3	27
67	Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1505-1506.	3.9	12
68	Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 924-927.	3.9	14
69	Tremulous arytenoid movements predict severity of glottic stenosis in multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1418-1423.	3.9	17
70	Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: Case report and literature review. <i>Movement Disorders</i> , 2010, 25, 1506-1509.	3.9	21
71	Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. <i>Movement Disorders</i> , 2010, 25, 2225-2228.	3.9	11
72	Rare and serious cardiac side effects during ropinirole titration. <i>Movement Disorders</i> , 2010, 25, 1509-1510.	3.9	8
73	Valproate-induced reversible hemichorea. <i>Movement Disorders</i> , 2010, 25, 1511-1512.	3.9	15
74	Facial tic associated with lamotrigine in adults. <i>Movement Disorders</i> , 2010, 25, 1512-1513.	3.9	10
75	Primary progressive freezing gait in a patient with CO ₂ -induced parkinsonism. <i>Movement Disorders</i> , 2010, 25, 1513-1515.	3.9	14
76	Multiple system atrophy and colon inertia. <i>Movement Disorders</i> , 2010, 25, 1515-1516.	3.9	0
77	Multiple system atrophy presenting with low rectal compliance and bowel pain. <i>Movement Disorders</i> , 2010, 25, 1516-1518.	3.9	3

#	ARTICLE	IF	CITATIONS
78	Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. <i>Movement Disorders</i> , 2010, 25, 1519-1520.	3.9	43
79	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. <i>Movement Disorders</i> , 2010, 25, 1520-1523.	3.9	6
80	Parkinsonism and cognitive decline in a fragile X mosaic male. <i>Movement Disorders</i> , 2010, 25, 1523-1524.	3.9	12
81	Olfactory dysfunction in Japanese patients with idiopathic REM sleep behavior disorder: Comparison of data using the university of Pennsylvania smell identification test and odor stick identification test for Japanese. <i>Movement Disorders</i> , 2010, 25, 1524-1526.	3.9	11
82	A comparison of two brief screening measures of cognitive impairment in Huntington's disease. <i>Movement Disorders</i> , 2010, 25, 2229-2233.	3.9	42
83	Putaminal magnetic resonance imaging features at various magnetic field strengths in multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1916-1923.	3.9	33
84	Parkinsonism and motor neuron diseases: Twenty-seven patients with diverse overlap syndromes. <i>Movement Disorders</i> , 2010, 25, 1868-1875.	3.9	63
85	Pathological laughter in Gilles de la Tourette syndrome: An unusual phonic tic. <i>Movement Disorders</i> , 2010, 25, 2233-2239.	3.9	21
86	Long-term effects of coordinative training in degenerative cerebellar disease. <i>Movement Disorders</i> , 2010, 25, 2239-2246.	3.9	148
87	No increased risk of obstructive sleep apnea in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2246-2249.	3.9	114
88	Psychiatric symptoms associated with focal hand dystonia. <i>Movement Disorders</i> , 2010, 25, 2249-2252.	3.9	42
89	Typical cerebral metabolic patterns in neurodegenerative brain diseases. <i>Movement Disorders</i> , 2010, 25, 2395-2404.	3.9	221
90	Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. <i>Movement Disorders</i> , 2010, 25, 2621-2626.	3.9	25
91	Sleep disorders in neurodegenerative diseases. <i>European Journal of Neurology</i> , 2010, 17, 1326-1338.	3.3	56
92	Basal ganglia cellular pathology in multiple system atrophy, progressive supranuclear palsy and Parkinson disease. Can quantitative magnetic resonance spectroscopic imaging make the difference?. <i>European Journal of Neurology</i> , 2010, 17, 1111-1112.	3.3	4
93	A harsh noise in the night. , 0, , 17-22.		0
94	Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. <i>Drugs and Therapy Studies</i> , 2010, 1, 6.	0.6	2
96	Multiple system atrophy. , 0, , 206-219.		0

#	ARTICLE	IF	CITATIONS
97	Morphometry MRI in the differential diagnosis of parkinsonian syndromes. Arquivos De Neuro-Psiquiatria, 2010, 68, 333-338.	0.8	30
98	Multiple System Atrophy. Blue Books of Neurology, 2010, 34, 340-359.	0.1	0
99	Parkinsonism: Genetics. , 2010, , 413-416.		0
100	The phenotype spectrum of Japanese multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1253-1255.	1.9	50
101	Autonomic Testing. Neurologist, 2010, 16, 215-222.	0.7	62
102	Combined Striatal Binding and Cerebral Influx Analysis of Dynamic ¹¹ C-Raclopride PET Improves Early Differentiation Between Multiple-System Atrophy and Parkinson Disease. Journal of Nuclear Medicine, 2010, 51, 588-595.	5.0	39
103	Multiple system atrophy: current and future approaches to management. Therapeutic Advances in Neurological Disorders, 2010, 3, 249-263.	3.5	52
104	Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain, 2010, 133, 2382-2393.	7.6	266
105	Shyâ€“Drager Syndrome. , 2010, , 111-114.		0
106	In vivo visualization of A-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain, 2010, 133, 1772-1778.	7.6	101
107	Motor activation in multiple system atrophy and Parkinson disease: A PET study. Neurology, 2010, 75, 1174-1180.	1.1	23
108	The Value of the Dopamine D _{2/3} Receptor Ligand ¹⁸ F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. Journal of Nuclear Medicine, 2010, 51, 581-587.	5.0	51
109	Multiple-System Atrophy with Cerebellar Predominance Presenting as Respiratory Insufficiency and Vocal Cords Paralysis. Case Reports in Medicine, 2010, 2010, 1-4.	0.7	4
110	Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology, 2010, 74, 1416-1423.	1.1	151
112	Riluzole in cerebellar ataxia. Neurology, 2010, 74, 839-845.	1.1	171
113	Transcranial Sonography for the Discrimination of Idiopathic Parkinsonâ€™s Disease from the Atypical Parkinsonian Syndromes. International Review of Neurobiology, 2010, 90, 121-146.	2.0	31
114	Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy. Revue Neurologique, 2010, 166, 829-833.	1.5	24
115	Brain Magnetic Resonance Imaging Techniques in the Diagnosis of Parkinsonian Syndromes. Neuroimaging Clinics of North America, 2010, 20, 29-55.	1.0	91

#	ARTICLE	IF	CITATIONS
116	The clinical use of structural MRI in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 67-77.	10.1	1,505
117	Vertical wrinkling of the forehead or Procerus sign in Progressive Supranuclear Palsy. <i>Journal of the Neurological Sciences</i> , 2010, 298, 148-149.	0.6	12
118	Autonomic innervation in multiple system atrophy and pure autonomic failure. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1327-1335.	1.9	69
119	Hot-Cross Bun Sign. , 2010, , 26.		0
120	Differential involvement of the periaqueductal gray in multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010, 158, 111-117.	2.8	27
121	Multiple system atrophy masking multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 59-61.	1.4	7
122	Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy – a comparative study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 275-279.	2.2	98
123	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. <i>Progress in Neurobiology</i> , 2010, 92, 316-329.	5.7	106
124	Review of Neurologic Diseases for the Urologist. <i>Urologic Clinics of North America</i> , 2010, 37, 517-526.	1.8	30
125	Targeted overexpression of human α -synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. <i>Experimental Neurology</i> , 2010, 224, 459-464.	4.1	65
126	Nonmotor presentations of multiple system atrophy. <i>Nature Reviews Neurology</i> , 2011, 7, 295-298.	10.1	43
127	Spinocerebellar degenerations. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 100, 113-140.	1.8	22
128	Neurodegenerative Disorders. , 2011, , .		11
129	Sign of the cross and MSA-C. <i>Neurología (English Edition)</i> , 2011, 26, e1-e2.	0.4	1
130	Involvement of pontine transverse and longitudinal fibers in multiple system atrophy: A tractography-based study. <i>Journal of the Neurological Sciences</i> , 2011, 303, 61-66.	0.6	18
131	Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences. <i>Journal of the Neurological Sciences</i> , 2011, 310, 133-138.	0.6	68
132	Basal Ganglia. , 2011, , 495-564.		3
133	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. <i>American Journal of Pathology</i> , 2011, 178, 1509-1516.	3.8	97

#	ARTICLE	IF	CITATIONS
134	Heterozygous exon 3 deletion in the Parkin gene in a patient with clinical and radiological MSA-C phenotype. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 404-406.	1.4	12
135	The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy. <i>Clinical Neurophysiology</i> , 2011, 122, 1812-1815.	1.5	17
136	Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α -synuclein fibril formation. <i>Neuroscience Letters</i> , 2011, 491, 48-52.	2.1	15
138	Multiple system atrophy: a clinical and neuropathological perspective. <i>Trends in Neurosciences</i> , 2011, 34, 581-590.	8.6	130
139	Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 160-165.	2.2	25
140	Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 698-700.	2.2	31
141	REM behaviour disorder and neurodegenerative diseases. <i>Sleep Medicine</i> , 2011, 12, S54-S58.	1.6	25
142	Parkinsonism Plus Syndromes. , 2011, , 181-196.		0
143	Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. <i>Neuroradiology</i> , 2011, 53, 471-481.	2.2	49
144	Language Processing in Parkinson's Disease Patients Without Dementia. , 2011, , .		6
145	Multiple system atrophy. , 0, , 1-15.		0
146	Cerebellar disorders. , 2011, , 198-216.		6
147	Estudio de correlación clínico-radiológica, sensibilidad y especificidad de ecotomografía transcraneana en enfermedad de Parkinson y otros trastornos del movimiento. <i>Revista Medica De Chile</i> , 2011, 139, 54-59.	0.2	2
148	Cognitive impairment in multiple system atrophy: Changing concepts. <i>Dementia E Neuropsychologia</i> , 2011, 5, 303-309.	0.8	3
151	Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS " PARKINSON PLUS SCALE. <i>PLoS ONE</i> , 2011, 6, e22293.	2.5	67
152	New insights into atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2011, 24, 331-338.	3.6	27
153	PSP as Distinguished from CBD, MSA-P and PD by Clinical and Imaging Differences at an Early Stage. <i>Internal Medicine</i> , 2011, 50, 2775-2781.	0.7	38
154	TDP-43 pathology occurs infrequently in multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2011, 37, 358-365.	3.2	27

#	ARTICLE	IF	CITATIONS
155	OBSTRUCTIVE SLEEP APNEA AND ITS TREATMENT IN RECIPIENTS OF HOME HEALTH SERVICES: UNITED STATES, 2007-2008. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1355-1356.	2.6	0
156	A Report of Atypical Autopsy-Confirmed Multiple System Atrophy. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1354-1355.	2.6	0
157	Priorities in Parkinson's disease research. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 377-393.	46.4	364
158	Signo de la cruz y AMS-C. <i>Neurología</i> , 2011, 26, e1-e2.	0.7	0
159	Î±-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 230-240.	10.2	573
160	Pregnancy in multiple system atrophy: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 599.	0.8	4
161	The cerebellar cognitive profile. <i>Brain</i> , 2011, 134, 3672-3686.	7.6	224
162	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	7.7	357
163	Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). <i>Journal of Neurology</i> , 2011, 258, 2248-2253.	3.6	44
164	Reduced bowel sounds in Parkinson's disease and multiple system atrophy patients. <i>Clinical Autonomic Research</i> , 2011, 21, 181-184.	2.5	16
166	Distinct Neurochemical Profiles of Spinocerebellar Ataxias 1, 2, 6, and Cerebellar Multiple System Atrophy. <i>Cerebellum</i> , 2011, 10, 208-217.	2.5	78
167	Association of Metallothionein-III with Oligodendroglial Cytoplasmic Inclusions in Multiple System Atrophy. <i>Neurotoxicity Research</i> , 2011, 19, 115-122.	2.7	21
168	Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. <i>Molecular Brain</i> , 2011, 4, 24.	2.6	37
169	Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild. <i>Movement Disorders</i> , 2011, 26, 65-72.	3.9	86
170	Serum insulin-like system alterations in patients with spinocerebellar ataxia type 3. <i>Movement Disorders</i> , 2011, 26, 731-735.	3.9	35
171	Clinical correlates of quality of life in Tourette syndrome. <i>Movement Disorders</i> , 2011, 26, 735-738.	3.9	103
172	Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. <i>Movement Disorders</i> , 2011, 26, 739-742.	3.9	38
173	Instability of syllable repetition in Parkinson's disease: Influence of levodopa and deep brain stimulation. <i>Movement Disorders</i> , 2011, 26, 728-730.	3.9	34

#	ARTICLE	IF	CITATIONS
174	Somatosensory temporal discrimination tested in patients receiving botulinum toxin injection for cervical dystonia. <i>Movement Disorders</i> , 2011, 26, 742-746.	3.9	40
175	<i>LINGO1</i> gene analysis in Parkinson's disease phenotypes. <i>Movement Disorders</i> , 2011, 26, 722-727.	3.9	17
176	Phenotype of the 202 adenine deletion in the <i>parkin</i> gene: 40 years of follow-up. <i>Movement Disorders</i> , 2011, 26, 719-722.	3.9	8
177	Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. <i>Movement Disorders</i> , 2011, 26, 713-718.	3.9	77
178	Levodopa is not a useful treatment for Lesch-Nyhan disease. <i>Movement Disorders</i> , 2011, 26, 746-749.	3.9	29
179	Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more. <i>Movement Disorders</i> , 2011, 26, 750-753.	3.9	75
180	Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype. <i>Movement Disorders</i> , 2011, 26, 753-755.	3.9	17
181	Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome. <i>Movement Disorders</i> , 2011, 26, 892-895.	3.9	35
182	Brainstem metabolites in multiple system atrophy of cerebellar type: 3.0T magnetic resonance spectroscopy study. <i>Movement Disorders</i> , 2011, 26, 1297-1302.	3.9	21
183	A new familial syndrome with dystonia and lower limb action myoclonus. <i>Movement Disorders</i> , 2011, 26, 896-900.	3.9	9
184	Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson's Disease. <i>Movement Disorders</i> , 2011, 26, 889-892.	3.9	145
185	Survival of Korean patients with multiple system atrophy. <i>Movement Disorders</i> , 2011, 26, 909-912.	3.9	62
186	Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 901-905.	3.9	3
187	An intragenic duplication in guanosine triphosphate cyclohydrolase-1 gene in a dopa-responsive dystonia family. <i>Movement Disorders</i> , 2011, 26, 905-909.	3.9	12
188	Progression of striatal and extrastriatal degeneration in multiple system atrophy: A longitudinal diffusion-weighted MR study. <i>Movement Disorders</i> , 2011, 26, 1303-1309.	3.9	47
189	Substantia nigra hyperechogenicity with <i>LRRK2</i> G2019S mutations. <i>Movement Disorders</i> , 2011, 26, 885-888.	3.9	31
190	Milestones in atypical and secondary Parkinsonisms. <i>Movement Disorders</i> , 2011, 26, 1083-1095.	3.9	74
191	The <i>Movement Disorders</i> task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Movement Disorders</i> , 2011, 26, 1985-1992.	3.9	52

#	ARTICLE	IF	CITATIONS
192	Comparison of cerebellar ataxias: A three-year prospective longitudinal assessment. <i>Movement Disorders</i> , 2011, 26, 2081-2087.	3.9	55
193	Pelvic organ dysfunction is more prevalent and severe in MSA compared to parkinson's disease. <i>Neurourology and Urodynamics</i> , 2011, 30, 102-107.	1.5	23
194	Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic parkinson syndrome and healthy controls. <i>Human Brain Mapping</i> , 2011, 32, 1905-1915.	3.6	122
195	Floppy epiglottis as a contraindication of CPAP in patients with multiple system atrophy. <i>Neurology</i> , 2011, 76, 1841-1842.	1.1	41
196	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. <i>Brain</i> , 2011, 134, 856-862.	7.6	66
197	MRI measurements predict PSP in unclassifiable parkinsonisms. <i>Neurology</i> , 2011, 77, 1042-1047.	1.1	74
199	A cross-sectional study contrasting olfactory function in autonomic disorders. <i>Neurology</i> , 2011, 76, 456-460.	1.1	42
200	Differentiation of Typical and Atypical Parkinson Syndromes by Quantitative MR Imaging. <i>American Journal of Neuroradiology</i> , 2011, 32, 2087-2092.	2.4	78
201	<i>MAPT</i> H1 haplotype is a risk factor for essential tremor and multiple system atrophy. <i>Neurology</i> , 2011, 76, 670-672.	1.1	68
202	Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach. <i>Journal of Nuclear Medicine</i> , 2011, 52, 733-740.	5.0	79
203	Ataxia. , 2011, , 465-475.		3
204	Î±-Synuclein in Parkinson disease and other neurodegenerative disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 403-408.	2.3	63
205	Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. , 2011, , 197-240.		2
206	Referring Patients for Deep Brain Stimulation. <i>Archives of Neurology</i> , 2011, 68, 1027.	4.5	39
207	Utility of the Fluid-Attenuated Inversion Recovery Sequence in Detecting a Hyperintense Putaminal Rim in Multiple System Atrophy-Parkinsonism: A Preliminary Study. <i>European Neurology</i> , 2011, 66, 42-46.	1.4	3
208	Comparisons of acoustic function in SCA31 and other forms of ataxias. <i>Neurological Research</i> , 2011, 33, 427-432.	1.3	15
209	Multiple-System Atrophy and Medications: How to Minimize the Risk of Falling. <i>The Consultant Pharmacist</i> , 2011, 26, 190-196.	0.4	1
210	Deep Brain Stimulation of the Pedunculo-pontine Nucleus in a Patient with Freezing of Gait. <i>Stereotactic and Functional Neurosurgery</i> , 2011, 89, 214-219.	1.5	14

#	ARTICLE	IF	CITATIONS
211	Diagnostic challenges in parkinsonism. Expert Review of Neurotherapeutics, 2011, 11, 1099-1101.	2.8	4
212	Retinal Nerve Fibre Layer and Macular Thinning in Spinocerebellar Ataxia and Cerebellar Multisystem Atrophy. Neuro-Ophthalmology, 2011, 35, 108-114.	1.0	63
213	A Hot Cross Bun sign from diffusion tensor imaging and tractography perspective. Neurology India, 2011, 59, 266.	0.4	13
214	The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain, 2011, 134, 3146-3166.	7.6	174
215	A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1025-1032.	1.9	28
216	Evaluation of "Dizziness" in the Neurology Office. Seminars in Neurology, 2011, 31, 029-041.	1.4	9
217	Protein Disulfide Isomerase Immunopositive Glial Cytoplasmic Inclusions in Patients With Multiple System Atrophy. International Journal of Neuroscience, 2011, 121, 543-550.	1.6	14
218	SPECT Molecular Imaging in Parkinson's Disease. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-11.	3.0	37
219	Neuro-ophthalmology of movement disorders. Current Opinion in Ophthalmology, 2012, 23, 491-496.	2.9	19
220	Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Associated Disorders, 2012, 26, 213-216.	1.3	105
221	Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008870-a008870.	6.2	288
223	Phosphorylated α -Synuclein in Parkinson's Disease. Science Translational Medicine, 2012, 4, 121ra20.	12.4	223
224	MP 3...The basal ganglia in perceptual timing: timing performance in multiple system atrophy and Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.36-e1.	1.9	3
225	Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 453-459.	1.9	97
226	Sleep and Neurologic Disorders. , 2012, , 631-646.		0
227	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. Imaging in Medicine, 2012, 4, 411-421.	0.0	3
228	A Further Case of Nicotine Sensitivity in Multiple System Atrophy. Clinical Neuropharmacology, 2012, 35, 51-52.	0.7	5
229	Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health Registers. Neuroepidemiology, 2012, 38, 186-193.	2.3	58

#	ARTICLE	IF	CITATIONS
230	Molecular Imaging in Parkinson's Disease. <i>NeuroMethods</i> , 2012, , 359-375.	0.3	1
232	Prevalence and Clinical Course of Olfactory Hallucinations in Idiopathic Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 199-205.	2.8	19
233	Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. <i>Scientific Reports</i> , 2012, 2, 953.	3.3	38
234	Evaluation of the Autonomic Nervous System. , 2012, , 455-473.		1
235	Immunohistochemical localization of aggresomal proteins in glial cytoplasmic inclusions in multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 559-571.	3.2	40
236	Postural disorders in Parkinson's disease: clinical characteristics, frequency, pathophysiology and management. <i>Neurodegenerative Disease Management</i> , 2012, 2, 577-588.	2.2	6
237	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	3.9	18
238	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naïve PD patients. <i>Journal of Neurology</i> , 2012, 259, 1808-1813.	3.6	60
239	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	2.8	7
240	A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. <i>Practical Neurology</i> , 2012, 12, 14-24.	1.1	28
241	Sporadic adult-onset ataxia of unknown etiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 103, 253-262.	1.8	23
242	Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 441-447.	1.9	81
243	Screening for C9ORF72 repeat expansion in FTLD. <i>Neurobiology of Aging</i> , 2012, 33, 1850.e1-1850.e11.	3.1	46
244	Animal models of multiple system atrophy. <i>Neuroscience</i> , 2012, 211, 77-82.	2.3	34
245	Parkinsonism and dropped head: Dystonia, myopathy or both?. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 30-34.	2.2	30
246	Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 69-72.	2.2	39
247	Deep brain stimulation response in pathologically confirmed cases of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 86-88.	2.2	16
248	Analysis of colonic alpha-synuclein pathology in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 893-895.	2.2	51

#	ARTICLE	IF	CITATIONS
249	Sleep Dysfunction in Multiple System Atrophy. <i>Current Treatment Options in Neurology</i> , 2012, 14, 464-473.	1.8	41
250	Binding of neuronal α -synuclein to β -III tubulin and accumulation in a model of multiple system atrophy. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 1170-1175.	2.1	22
251	Treatment of multiple system atrophy using intravenous immunoglobulin. <i>BMC Neurology</i> , 2012, 12, 131.	1.8	42
252	Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 399-406.	5.0	227
253	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	7.6	325
254	Distinct patterns of cognitive impairment in multiple system atrophy patients of cerebellar and parkinsonian predominance. <i>Basal Ganglia</i> , 2012, 2, 91-96.	0.3	1
255	α -Synuclein accumulation reduces GABAergic inhibitory transmission in a model of multiple system atrophy. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 348-353.	2.1	18
256	"Hot cross bun" sign in multiple system atrophy with predominant cerebellar ataxia: A comparison between proton density-weighted imaging and T2-weighted imaging. <i>European Journal of Radiology</i> , 2012, 81, 2848-2852.	2.6	25
257	Quantifying cerebellar atrophy in multiple system atrophy of the cerebellar type (MSA-C) using three-dimensional gyrification index analysis. <i>NeuroImage</i> , 2012, 61, 1-9.	4.2	12
258	Spinocerebellar ataxia type 31 exists in Northeast China. <i>Journal of the Neurological Sciences</i> , 2012, 316, 164-167.	0.6	14
259	The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2012, 317, 92-96.	0.6	46
260	Young-onset multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2012, 319, 168-170.	0.6	24
261	Is peripheral neuron degeneration involved in multiple system atrophy? A clinical and electrophysiological study. <i>Journal of the Neurological Sciences</i> , 2012, 319, 81-85.	0.6	13
263	Improving the diagnostic accuracy in parkinsonism: a three-pronged approach. <i>Practical Neurology</i> , 2012, 12, 77-87.	1.1	32
264	Prevalence of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism, Cervical Dystonia and Essential Tremor. <i>European Neurology</i> , 2012, 68, 318-321.	1.4	44
265	Molecular Imaging in the Clinical Neurosciences. <i>NeuroMethods</i> , 2012, , .	0.3	3
266	Optical Coherence Tomography in Parkinsonian Syndromes. <i>PLoS ONE</i> , 2012, 7, e34891.	2.5	145
267	Biosignatures for Parkinson's Disease and Atypical Parkinsonian Disorders Patients. <i>PLoS ONE</i> , 2012, 7, e43595.	2.5	52

#	ARTICLE	IF	CITATIONS
268	123I-FP-CIT SPECT imaging of the dopaminergic state. <i>Nuklearmedizin - NuclearMedicine</i> , 2012, 51, 244-251.	0.7	9
269	Non-Gaussianity of Low Frequency Heart Rate Variability and Sympathetic Activation: Lack of Increases in Multiple System Atrophy and Parkinson Disease. <i>Frontiers in Physiology</i> , 2012, 3, 34.	2.8	32
270	Multiple System Atrophy (MSA). , 0, , 121-122.		0
271	Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy. <i>Journal of Movement Disorders</i> , 2012, 5, 42-47.	1.3	13
272	Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia. <i>Journal of Movement Disorders</i> , 2012, 5, 1-4.	1.3	10
273	Management of Lower Urinary Tract Dysfunction in Patients with Neurological Disorders. <i>Korean Journal of Urology</i> , 2012, 53, 583.	1.2	11
274	Drugs and Orthostatic Hypotension: Evidence from Literature. <i>Journal of Hypertension: Open Access</i> , 2012, 01, .	0.2	23
275	Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease. <i>BMC Medical Genetics</i> , 2012, 13, 3.	2.1	33
276	Co-occurrence of Different Pathologies in Dementia: Implications for Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 909-917.	2.6	31
277	Can imaging separate multiple system atrophy from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 3-5.	3.9	9
278	Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2012, 27, 851-857.	3.9	27
279	Multiple system atrophyâ€“parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2012, 27, 1186-1190.	3.9	164
280	Receiver operating characteristic analysis of sphincter electromyography for parkinsonian syndrome. <i>Neurourology and Urodynamics</i> , 2012, 31, 1128-1134.	1.5	24
281	Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. <i>Annals of Neurology</i> , 2012, 72, 4-5.	5.3	11
282	Republished: A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. <i>Postgraduate Medical Journal</i> , 2012, 88, 407-417.	1.8	0
284	Sleep-Disordered Breathing in Neurodegenerative Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 205-217.	4.2	82
285	Spinocerebellar Ataxia: A Rational Approach to Aetiological Diagnosis. <i>Cerebellum</i> , 2012, 11, 289-299.	2.5	16
287	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I] ¹²³ I-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1012-1020.	6.4	40

#	ARTICLE	IF	CITATIONS
288	Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study. <i>Journal of Neurology</i> , 2012, 259, 929-935.	3.6	30
289	Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism. <i>Journal of Neurology</i> , 2012, 259, 1206-1214.	3.6	15
290	Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the ¹³ C-acetate breath test. <i>Journal of Neurology</i> , 2012, 259, 1448-1452.	3.6	21
291	Laryngeal dystonia in the course of multiple system atrophy: a cause of postoperative respiratory insufficiency. <i>Neurological Sciences</i> , 2012, 33, 681-683.	1.9	7
292	Extensive distribution of glial cytoplasmic inclusions in an autopsied case of multiple system atrophy with a prolonged 18-year clinical course. <i>Neuropathology</i> , 2012, 32, 69-76.	1.2	18
293	The neuropathology, pathophysiology and genetics of multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 4-24.	3.2	218
294	Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 361-368.	10.2	201
295	Brain monoamine systems in multiple system atrophy: A positron emission tomography study. <i>Neurobiology of Disease</i> , 2012, 46, 130-136.	4.4	34
296	The role of α -synuclein in neurodegeneration – An update. <i>Translational Neuroscience</i> , 2012, 3, .	1.4	16
297	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. <i>Movement Disorders</i> , 2012, 27, 227-235.	3.9	75
298	Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2012, 27, 65-71.	3.9	72
299	Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease. <i>Movement Disorders</i> , 2012, 27, 439-442.	3.9	14
300	Mutations in rare ataxia genes are uncommon causes of sporadic cerebellar ataxia. <i>Movement Disorders</i> , 2012, 27, 442-446.	3.9	27
301	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. <i>Movement Disorders</i> , 2012, 27, 446-449.	3.9	57
302	Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. <i>Movement Disorders</i> , 2012, 27, 1552-1555.	3.9	5
303	Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotoxicity Research</i> , 2012, 21, 393-404.	2.7	96
305	Predictive value of dopamine transporter SPECT imaging with [¹²³ I]PE2I in patients with subtle parkinsonian symptoms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 242-250.	6.4	28
306	Visual assessment of dopaminergic degeneration pattern in ¹²³ I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 251-260.	3.6	38

#	ARTICLE	IF	CITATIONS
307	Neuronal vulnerability, pathogenesis, and Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 41-50.	3.9	199
308	Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 44-51.	1.0	57
309	Screening of Toll-Like Receptors Expression in Multiple System Atrophy Brains. <i>Neurochemical Research</i> , 2013, 38, 1252-1259.	3.3	37
310	Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. <i>Neuroradiology</i> , 2013, 55, 483-492.	2.2	70
311	Degeneration of the Brainstem. <i>Seminars in Ultrasound, CT and MRI</i> , 2013, 34, 142-152.	1.5	2
312	Neurological Syndromes. , 2013, , .		16
313	Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue?. <i>Neurological Sciences</i> , 2013, 34, 1875-1878.	1.9	33
314	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. <i>Journal of Neurology</i> , 2013, 260, 2212-2219.	3.6	106
315	Abnormal ghrelin secretion contributes to gastrointestinal symptoms in multiple system atrophy patients. <i>Journal of Neurology</i> , 2013, 260, 2073-2077.	3.6	8
316	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730.	3.6	45
317	Brain glucose metabolism in neuropathologically confirmed multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 1922-1924.	3.6	4
318	An exceptional case of MSA-P. <i>Journal of Neurology</i> , 2013, 260, 1171-1173.	3.6	1
319	Mutations in PDYN are not responsible for multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 927-928.	3.6	4
320	Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 475-483.	3.6	18
321	Basal Ganglia Disorders. , 2013, , 1-39.		0
323	A decision tree for differentiating multiple system atrophy from Parkinson's disease using 3-T MR imaging. <i>European Radiology</i> , 2013, 23, 1459-1466.	4.5	49
324	Peripheral nerve involvement in hereditary cerebellar and multisystem degenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 115, 907-932.	1.8	12
325	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013, 120, 613-618.	2.8	75

#	ARTICLE	IF	CITATIONS
326	Neuronal vulnerability, pathogenesis, and Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 715-724.	3.9	145
327	Mutations in <i>COQ2</i> in Familial and Sporadic Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2013, 369, 233-244.	27.0	308
328	Hereditaire Ataxien. <i>Medizinische Genetik</i> , 2013, 25, 235-248.	0.2	1
329	Enhanced temporal pain processing in multiple system atrophy. <i>Neuroscience Letters</i> , 2013, 555, 203-208.	2.1	12
330	Atrofia multisistémica tipo C: signo de la cruz (hot cross bun sign). <i>Neurologia Argentina</i> , 2013, 5, 285-286.	0.3	0
331	Clinical Neurogenetics. <i>Neurologic Clinics</i> , 2013, 31, 987-1007.	1.8	78
332	The interrelationship between non-motor symptoms in Atypical Parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013, 327, 15-21.	0.6	26
333	Confounders of Vasovagal Syncope. <i>Cardiology Clinics</i> , 2013, 31, 89-100.	2.2	34
334	Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1149-1151.	2.2	43
335	Central control of autonomic function and involvement in neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 45-57.	1.8	100
336	Multiple system atrophy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 229-241.	1.8	31
337	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. <i>Journal of Comparative Neurology</i> , 2013, 521, 4339-4355.	1.6	47
338	Diffusion Tensor Imaging in Idiopathic Parkinson's Disease and Multisystem Atrophy (Parkinsonian) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	1.4	17
339	Immunotherapy for neurodegenerative diseases: Focus on α -synucleinopathies. , 2013, 138, 311-322.		115
340	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855.	3.6	83
341	Het cerebrale glucose-metabolisme bij neurodegeneratieve hersenaandoeningen. <i>Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie</i> , 2013, 1, 51-59.	0.1	0
342	The periaqueductal grey area and control of blood pressure in neurodegeneration. <i>Clinical Autonomic Research</i> , 2013, 23, 215-219.	2.5	3
343	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. <i>Neurogenetics</i> , 2013, 14, 161-166.	1.4	38

#	ARTICLE	IF	CITATIONS
344	Electroencephalogram slowing in rapid eye movement sleep behavior disorder is associated with mild cognitive impairment. <i>Sleep Medicine</i> , 2013, 14, 1059-1063.	1.6	63
345	Markedly asymmetric presentation in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 901-905.	2.2	21
346	Plasma matrix metalloproteinase-3 correlates with the clinical severity in men with multiple system atrophy. <i>Neurology and Clinical Neuroscience</i> , 2013, 1, 69-77.	0.4	3
347	The potential prognostic role of cardiovascular autonomic failure in α -synucleinopathies. <i>European Journal of Neurology</i> , 2013, 20, 231-235.	3.3	61
348	Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 136-140.	1.9	51
349	Multiple System Atrophy (MSA). , 2013, , 2119-2141.		0
350	Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 235-241.	1.9	17
351	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. <i>Brain</i> , 2013, 136, 385-391.	7.6	143
352	Le cervelet. , 2013, , .		4
353	The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 923-928.	2.6	10
354	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. <i>Experimental Neurology</i> , 2013, 247, 531-536.	4.1	46
355	Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital. <i>Revue Neurologique</i> , 2013, 169, 121-125.	1.5	6
356	A milestone on the way to therapy for MSA. <i>Lancet Neurology</i> , The, 2013, 12, 222-223.	10.2	2
357	Supine-to-standing transcranial Doppler test in patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 539-542.	2.2	6
358	Skin temperature of the hand in multiple system atrophy and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 560-562.	2.2	11
359	In vivo evaluation of gray and white matter volume loss in the parkinsonian variant of multiple system atrophy using SPM8 plus DARTEL for VBM. <i>NeuroImage: Clinical</i> , 2013, 2, 491-496.	2.7	35
360	Parabrachial nucleus involvement in multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 177, 170-174.	2.8	9
361	Eye movements in patients with neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2013, 9, 74-85.	10.1	243

#	ARTICLE	IF	CITATIONS
363	Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). <i>Revue Neurologique</i> , 2013, 169, 53-58.	1.5	5
364	Magnetic Resonance Imaging Biomarkers in Patients with Progressive Ataxia: Current Status and Future Direction. <i>Cerebellum</i> , 2013, 12, 245-266.	2.5	25
365	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	10.2	602
366	Clinical and imaging characteristics of dementia in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 617-621.	2.2	54
368	Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in North East Scotland: The PINE study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 515-521.	2.2	81
369	<i>Neurodegenerative Diseases.</i> , 2013, , 151-173.		1
370	Genetic association study of glucocerebrosidase gene L444P mutation in essential tremor and multiple system atrophy in mainland China. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 217-219.	1.5	24
371	Progressive supranuclear palsy phenotype mimicking synucleinopathies. <i>Journal of the Neurological Sciences</i> , 2013, 329, 34-37.	0.6	5
372	<i>Handbook of Parkinson's Disease.</i> , 2013, , .		14
373	Levodopa challenge test and ¹²³ I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 160-165.	2.1	8
374	The spectrum of preclinical gait disorders in early Parkinson's disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking. <i>Journal of Neural Transmission</i> , 2013, 120, 1665-1672.	2.8	29
375	Atypical atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy A diagnostic guide. <i>Movement Disorders</i> , 2013, 28, 1184-1199.	3.9	167
376	Acoustic impairment is a distinguishable clinical feature of Asidan/SCA36. <i>Journal of the Neurological Sciences</i> , 2013, 324, 109-112.	0.6	22
377	A randomized clinical trial of lithium in multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 458-461.	3.6	36
378	Topographic distribution of cortical thinning in subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 970-974.	2.2	15
379	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1143-1148.	2.2	3
380	Elevated titers of anti-thyropoxidase antibodies in patients with multiple system atrophy: A pilot study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2348-2350.	1.4	2
381	Validation of parkinsonian disease-related metabolic brain patterns. <i>Movement Disorders</i> , 2013, 28, 547-551.	3.9	94

#	ARTICLE	IF	CITATIONS
382	New horizons in the pathogenesis, assessment and management of movement disorders. Age and Ageing, 2013, 42, 2-10.	1.6	7
383	Models of Multiple System Atrophy. Current Topics in Behavioral Neurosciences, 2013, 22, 369-393.	1.7	16
384	Twenty-Four Hour Non-Invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease. Frontiers in Neurology, 2013, 4, 49.	2.4	57
385	123I-Iodobenzamide SPECT Is Not an Independent Predictor of Dopaminergic Responsiveness in Patients with Suspected Atypical Parkinsonian Syndromes. Journal of Nuclear Medicine, 2013, 54, 2081-2086.	5.0	8
386	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. Journal of Parkinson's Disease, 2013, 3, 415-459.	2.8	68
387	Parkinsonian Syndromes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1189-1212.	0.8	65
388	Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open, 2013, 3, e002613.	1.9	55
389	Neuromelanin Magnetic Resonance Imaging in Parkinson's Disease and Multiple System Atrophy. European Neurology, 2013, 70, 70-77.	1.4	106
390	Kognitif Affektif Serebellar Sendrom ve Psikoz Bulgularıyla Ortaya Çıkan bir Multisistem Atrofi (MSA-C) Olgusu. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2013, 19, 107-110.	0.3	1
391	No Difference in Sleep and RBD between Different Types of Patients with Multiple System Atrophy: A Pilot Video-Polysomnographical Study. Sleep Disorders, 2013, 2013, 1-7.	1.4	33
392	Approach to hypohidrosis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 799-804.	2.4	32
393	No association of <i>GBA</i> mutations and multiple system atrophy. European Journal of Neurology, 2013, 20, e61-2.	3.3	28
394	An autopsy case of preclinical multiple system atrophy (MSA-C). Neuropathology, 2013, 33, 667-672.	1.2	27
395	Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools. Acta Neurologica Scandinavica, 2013, 127, 362-370.	2.1	35
396	Somatosensory temporal discrimination threshold may help to differentiate patients with multiple system atrophy from patients with Parkinson's disease. European Journal of Neurology, 2013, 20, 714-719.	3.3	35
397	Assessment of sensory perception and processing using current perception threshold in Parkinson's disease. Neurology and Clinical Neuroscience, 2013, 1, 209-213.	0.4	2
398	Disrupted cerebellar connectivity reduces whole-brain network efficiency in multiple system atrophy. Movement Disorders, 2013, 28, 362-369.	3.9	25
399	Clinical syndromes: Parkinsonian gait. Movement Disorders, 2013, 28, 1552-1559.	3.9	73

#	ARTICLE	IF	CITATIONS
400	Therapeutic Response to Pramipexole in a Patient with Multiple System Atrophy with Predominant Parkinsonism: Positron Emission Tomography and Pharmacokinetic Assessments. <i>Internal Medicine</i> , 2013, 52, 1731-1735.	0.7	2
401	L-DOPS and the treatment of neurogenic orthostatic hypotension. <i>Future Neurology</i> , 2013, 8, 381-397.	0.5	1
404	Rehabilitation of parkinsonian syndromes. , 0, , 152-161.		0
406	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
407	Magnetic resonance imaging of multiple system atrophy. , 0, , 167-203.		0
409	Bladder dysfunction in a transgenic mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2013, 28, 347-355.	3.9	50
410	Early Clinical Features Differentiate Cerebellar Variant MSA and Sporadic Ataxia. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 252-254.	0.5	3
412	Preliminary Report of Multiple Cell Therapy for Patients with Multiple System Atrophy. <i>Cell Transplantation</i> , 2013, 22, 93-99.	2.5	14
413	4. Spinocerebellar Degeneration: Recent Progress. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2013, 102, 129b-129b.	0.0	0
415	Neurodegenerative disorders. , 0, , 23-71.		0
416	FDG- PET Imaging in Neurodegenerative Brain Diseases. , 2013, , .		1
417	Saccades during Attempted Fixation in Parkinsonian Disorders and Recessive Ataxia: From Microsaccades to Square-Wave Jerks. <i>PLoS ONE</i> , 2013, 8, e58535.	2.5	70
418	Diagnostic Accuracy of Apparent Diffusion Coefficient and 123I-Metaiodobenzylguanidine for Differentiation of Multiple System Atrophy and Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e61066.	2.5	33
419	Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach. <i>PLoS ONE</i> , 2013, 8, e69237.	2.5	39
420	Clinical Factors Associated with Abnormal Postures in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e73547.	2.5	20
421	Differential Diagnosis Tool for Parkinsonian Syndrome Using Multiple Structural Brain Measures. <i>Computational and Mathematical Methods in Medicine</i> , 2013, 2013, 1-10.	1.3	11
422	Automated Volumes-of-Interest Identification for Classical and Atypical Parkinsonian Syndrome Differentiation Using T2-weighted MR Imaging. <i>Methods of Information in Medicine</i> , 2013, 52, 128-136.	1.2	3
423	Degeneration of Brainstem Respiratory Neurons in Dementia with Lewy Bodies. <i>Sleep</i> , 2014, 37, 373-378.	1.1	29

#	ARTICLE	IF	CITATIONS
424	Multiple system atrophy. <i>British Journal of Neuroscience Nursing</i> , 2014, 10, 112-115.	0.2	0
425	Multiple System Atrophy. , 2014, , 164-168.		0
426	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1003.	2.2	12
427	Exploring Myelin Dysfunction in Multiple System Atrophy. <i>Experimental Neurobiology</i> , 2014, 23, 337-344.	1.6	33
429	Cognition in a multiple system atrophy series of cases from Argentina. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 773-776.	0.8	11
430	Autonomic dysfunction. , 0, , 415-436.		0
431	Cerebrospinal fluid α -synuclein in the differential diagnosis of parkinsonian syndromes. <i>Future Neurology</i> , 2014, 9, 525-532.	0.5	8
432	Opsoclonus-myoclonus syndrome associated with multiple system atrophy. <i>Cerebellum and Ataxias</i> , 2014, 1, 15.	1.9	1
433	The merit of proton magnetic resonance spectroscopy in the longitudinal assessment of spinocerebellar ataxias and multiple system atrophy-cerebellar type. <i>Cerebellum and Ataxias</i> , 2014, 1, 17.	1.9	20
434	An update on the cerebellar subtype of multiple system atrophy. <i>Cerebellum and Ataxias</i> , 2014, 1, 14.	1.9	16
435	Abnormal metabolic network activity in REM sleep behavior disorder. <i>Neurology</i> , 2014, 82, 620-627.	1.1	151
436	<i>LRRK2</i> exonic variants and risk of multiple system atrophy. <i>Neurology</i> , 2014, 83, 2256-2261.	1.1	46
437	Candidate biomarkers of multiple system atrophy in cerebrospinal fluid. <i>Reviews in the Neurosciences</i> , 2014, 25, 653-62.	2.9	6
438	Parkinson's Disease and the Claustrum. , 2014, , 277-297.		4
439	Increase of the plasma α -synuclein levels in patients with multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 375-379.	3.9	20
440	Neuropathology of multiple system atrophy: New thoughts about pathogenesis. <i>Movement Disorders</i> , 2014, 29, 1720-1741.	3.9	146
441	Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes. <i>Physiological Reports</i> , 2014, 2, e12209.	1.7	5
442	Time-dependent changes and gender differences in urinary dysfunction in patients with multiple system atrophy. <i>Neurourology and Urodynamics</i> , 2014, 33, 516-523.	1.5	21

#	ARTICLE	IF	CITATIONS
443	The circulating level of leptin and blood pressure in patients with multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2014, 347, 349-351.	0.6	6
444	SNCA variants rs2736990 and rs356220 as risk factors for Parkinson's disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. <i>Neurobiology of Aging</i> , 2014, 35, 2882.e1-2882.e6.	3.1	30
445	The value of putaminal diffusion imaging versus 18F-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 380-387.	3.9	54
446	Î±-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 471-478.	3.7	40
447	The COQ2 mutations in Japanese multiple system atrophy: Impact on the pathogenesis and phenotypic variation. <i>Movement Disorders</i> , 2014, 29, 184-184.	3.9	7
448	Visual signs and symptoms of multiple system atrophy. <i>Australasian journal of optometry</i> , The, 2014, 97, 483-491.	1.3	24
449	Multiple system atrophy: Prognostic indicators of survival. <i>Movement Disorders</i> , 2014, 29, 1151-1157.	3.9	76
450	Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 388-395.	3.9	29
451	Role of Urodynamics in the Evaluation of Elderly Voiding Dysfunction. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 350-363.	0.5	5
452	Analysis of COQ2 gene in multiple system atrophy. <i>Molecular Neurodegeneration</i> , 2014, 9, 44.	10.8	40
454	Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions in C9orf72. <i>JAMA Neurology</i> , 2014, 71, 771.	9.0	66
455	Multiple System Atrophy. <i>Seminars in Neurology</i> , 2014, 34, 174-181.	1.4	24
456	Neuropathologic Changes of Multiple System Atrophy and Diffuse Lewy Body Disease. <i>Seminars in Neurology</i> , 2014, 34, 210-216.	1.4	15
457	Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism. <i>Frontiers in Neurology</i> , 2014, 5, 85.	2.4	12
458	Preliminary Results of Cord Blood Mononuclear Cell Therapy for Multiple System Atrophy: A Report of Three Cases. <i>Medical Principles and Practice</i> , 2014, 23, 282-285.	2.4	2
459	Cognitive and Sleep Features of Multiple System Atrophy: Review and Prospective Study. <i>European Neurology</i> , 2014, 72, 349-359.	1.4	36
461	The basal ganglia in perceptual timing: Timing performance in Multiple System Atrophy and Huntington's disease. <i>Neuropsychologia</i> , 2014, 52, 73-81.	1.6	74
462	An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis. <i>Journal of the Neurological Sciences</i> , 2014, 340, 174-177.	0.6	5

#	ARTICLE	IF	CITATIONS
463	Age-, and gender-specific incidence of vascular parkinsonism, progressive supranuclear palsy, and parkinsonian-type multiple system atrophy in North East Scotland: The PINE study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 834-839.	2.2	39
464	Cerebellar dentate nucleus in progressive supranuclear palsy. <i>Clinical Neurology and Neurosurgery</i> , 2014, 118, 32-36.	1.4	8
465	The value of novel MRI techniques in Parkinson-plus syndromes: Diffusion tensor imaging and anatomical connectivity studies. <i>Revue Neurologique</i> , 2014, 170, 266-276.	1.5	8
466	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	5.7	35
468	A reappraisal of the ten steps test for identifying atypical parkinsonism. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 1-3.	1.4	6
469	Cystatin C Triggers Neuronal Degeneration in a Model of Multiple System Atrophy. <i>American Journal of Pathology</i> , 2014, 184, 790-799.	3.8	10
470	Dysarthrie et troubles de lâ€™Ã©quilibre chez un homme de 54ans. <i>Pratique Neurologique - FMC</i> , 2014, 5, 168-175.	0.1	0
471	Medullo-ponto-cerebellar white matter degeneration altered brain network organization and cortical morphology in multiple system atrophy. <i>Brain Structure and Function</i> , 2014, 219, 947-958.	2.3	11
472	Differential diagnosis of parkinsonism with visual inspection of posture and gait in the early stage. <i>Gait and Posture</i> , 2014, 39, 1138-1141.	1.4	5
473	Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 268-275.	10.2	95
474	SHC2 gene copy number in multiple system atrophy (MSA). <i>Clinical Autonomic Research</i> , 2014, 24, 25-30.	2.5	26
475	Orthostatic hypotension and cognitive impairment: a dangerous association?. <i>Neurological Sciences</i> , 2014, 35, 951-957.	1.9	42
476	Torpedo Formation and Purkinje Cell Loss: Modeling their Relationship in Cerebellar Disease. <i>Cerebellum</i> , 2014, 13, 433-439.	2.5	46
477	Dementia in Parkinsonâ€™s Disease and Atypical Parkinsonism. , 2014, , 179-197.		1
478	Nocturnal manifestations of atypical and vascular parkinsonism: How do they differ from Parkinsonâ€™s disease?. <i>Journal of Neural Transmission</i> , 2014, 121, 69-77.	2.8	5
479	Multiple system atrophy of the cerebellar type: Clinical state of the art. <i>Movement Disorders</i> , 2014, 29, 294-304.	3.9	121
480	Alzheimer's and Parkinson's diseases: An environmental proteomic point of view. <i>Journal of Proteomics</i> , 2014, 104, 24-36.	2.4	7
481	Neuropathological features of multiple system atrophy with cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 884-888.	3.9	38

#	ARTICLE	IF	CITATIONS
482	A Cross-Sectional Study on Drug Use in Multiple System Atrophy. <i>CNS Drugs</i> , 2014, 28, 483-490.	5.9	9
483	<scp>EFNS</scp>/<scp>ENS</scp> Consensus on the diagnosis and management of chronic ataxias in adulthood. <i>European Journal of Neurology</i> , 2014, 21, 552-562.	3.3	79
484	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	2.2	32
485	Is brain gliosis a characteristic of chronic methamphetamine use in the human?. <i>Neurobiology of Disease</i> , 2014, 67, 107-118.	4.4	32
486	Enteric <scp>GFAP</scp> expression and phosphorylation in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2014, 130, 805-815.	3.9	148
487	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	3.9	193
489	The clinical approach to autonomic failure in neurological disorders. <i>Nature Reviews Neurology</i> , 2014, 10, 396-407.	10.1	51
490	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 217-221.	2.2	25
491	Î±-Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	2.2	272
492	Update on novel familial forms of Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S29-S34.	2.2	84
493	Antidepressants reduce neuroinflammatory responses and astroglial alphaâ€šsynuclein accumulation in a transgenic mouse model of multiple system atrophy. <i>Glia</i> , 2014, 62, 317-337.	4.9	58
494	Clinical Features in Association with Neurodegenerative Diseases and Malignancies. <i>European Neurology</i> , 2014, 71, 99-105.	1.4	4
495	Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival. <i>Journal of Neural Transmission</i> , 2014, 121, 507-512.	2.8	75
496	Should genetic testing for SCAs be included in the diagnostic workup for MSA?. <i>Neurology</i> , 2014, 83, 1733-1738.	1.1	41
497	A Middle-Aged Woman Falls in the Emergency Department. <i>Journal of Emergency Nursing</i> , 2014, 40, 613-615.	1.0	3
498	Blinking in patients with clinically probable multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 415-420.	3.9	15
499	Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1157-1160.	2.2	7
500	Identification of FXTAS presenting with SCA 12 like phenotype in India. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1089-1093.	2.2	9

#	ARTICLE	IF	CITATIONS
501	Functional neuroimaging in the diagnosis of patients with parkinsonism: Update and recommendations for clinical use. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 215-226.	0.2	8
502	63-Year-Old Woman with Dysphonia, Dysphagia, and Sleep Apnea. <i>Brain Pathology</i> , 2014, 24, 423-424.	4.1	0
503	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2112-2118.	3.6	37
504	Genomic aspects of sporadic neurodegenerative diseases. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 221-225.	2.1	20
505	Structural and Functional Imaging in Parkinsonian Syndromes. <i>Radiographics</i> , 2014, 34, 1273-1292.	3.3	74
507	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	3.6	47
508	Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. <i>Journal of Neurology</i> , 2014, 261, 1575-1583.	3.6	37
509	Multiple compulsive behaviors in multiple system atrophy: The importance of predisposition to addiction. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 355-357.	2.2	8
511	The role of the cerebellum in the pathogenesis of cortical myoclonus. <i>Movement Disorders</i> , 2014, 29, 437-443.	3.9	110
512	Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 157-161.	2.2	9
513	Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 212-216.	2.2	37
514	A novel α -synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. <i>Neurobiology of Aging</i> , 2014, 35, 2180.e1-2180.e5.	3.1	396
515	Computer-assisted system for diagnosing degenerative dementia using cerebral blood flow SPECT and 3D-SSP: a multicenter study. <i>Japanese Journal of Radiology</i> , 2014, 32, 383-390.	2.4	16
516	Management of Lower Urinary Tract Dysfunction in Parkinson's Disease: a Review of Recent Treatment Options. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 214-220.	0.5	0
517	Sensorimotor gating deficits in multiple system atrophy: Comparison with Parkinson's disease and idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 297-302.	2.2	18
518	Postganglionic sudomotor denervation in patients with multiple system atrophy. <i>Neurology</i> , 2014, 82, 2223-2229.	1.1	45
519	Tract based spatial statistics in multiple system atrophy: A comparison between clinical subtypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1050-1055.	2.2	9
520	An association analysis of the rs1572931 polymorphism of the <i>RAB7L1</i> gene in Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in China. <i>European Journal of Neurology</i> , 2014, 21, 1337-1343.	3.3	21

#	ARTICLE	IF	CITATIONS
522	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.8	167
523	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854.	2.2	60
524	Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 755-760.	2.2	121
525	Increased CSF α -synuclein levels in Alzheimer's disease: Correlation with tau levels. <i>Alzheimer's and Dementia</i> , 2014, 10, S290-8.	0.8	69
526	Imaging of olfactory bulb and gray matter volumes in brain areas associated with olfactory function in patients with Parkinson's disease and multiple system atrophy. <i>European Journal of Radiology</i> , 2014, 83, 564-570.	2.6	55
527	Nocturnal Manifestations of Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2014, 4, 223-236.	2.8	8
528	Cognitive profiling in relation to short latency afferent inhibition of frontal cortex in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 632-636.	2.2	21
529	Discontinuation of continuous positive airway pressure treatment in multiple system atrophy. <i>Sleep Medicine</i> , 2014, 15, 1147-1149.	1.6	23
530	A retrospective study of the clinical and electrophysiological characteristics of 32 patients with orthostatic myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 889-893.	2.2	33
531	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	2.2	18
532	Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study. <i>Neuropharmacology</i> , 2014, 85, 284-289.	4.1	8
536	Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2014, 4, 693-698.	2.8	10
537	Dysautonomia in movement disorders. , 2014, , 363-382.		1
538	Atypical Parkinsonism: Making the case for a neuropalliative rehabilitation approach. <i>International Journal of Therapy and Rehabilitation</i> , 2014, 21, 176-182.	0.3	5
539	Imaging in multiple system atrophy. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 178-187.	0.4	10
540	Late onset ataxia: MSA or SCA 17? A gene penetrance dilemma. <i>Movement Disorders</i> , 2014, 29, 36-38.	3.9	26
541	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	3.9	74
542	Commentary. <i>Movement Disorders</i> , 2014, 29, 38-39.	3.9	0

#	ARTICLE	IF	CITATIONS
543	Dilated Virchow-Robin Space and Dopamine Transporter Imaging in the Striatum of Patients with Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 248-254.	0.5	12
544	Dysphagia in spinocerebellar ataxia and multiple system atrophy-cerebellar. <i>Speech, Language and Hearing</i> , 2015, 18, 39-43.	1.0	5
545	Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis. <i>Brain and Behavior</i> , 2015, 5, e00329.	2.2	44
546	Intraventricular cerebrospinal fluid temperature analysis using MR diffusion-weighted imaging thermometry in Parkinson's disease patients, multiple system atrophy patients, and healthy subjects. <i>Brain and Behavior</i> , 2015, 5, e00340.	2.2	21
547	Differential Progression of Dysphagia in Hereditary and Sporadic Ataxias Involving Multiple Systems. <i>European Neurology</i> , 2015, 74, 237-242.	1.4	12
548	2. Elucidation of Molecular Bases of Brain Diseases Based on Personal Genome Analyses. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 1924-1929.	0.0	0
549	Dynamic Cerebrospinal Fluid Flow on MRI in Cortical Cerebellar Atrophy and Multiple System Atrophy-cerebellar Type. <i>Internal Medicine</i> , 2015, 54, 1717-1723.	0.7	2
551	Non-Motor Correlates of Smoking Habits in <i>de Novo</i> Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 913-924.	2.8	10
552	Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. <i>Npj Parkinson's Disease</i> , 2015, 1, 15007.	5.3	26
553	Neurourology. <i>Contemporary Neurosurgery</i> , 2015, 37, 1-4.	0.1	0
554	Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 17-23.	1.5	9
555	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.	3.9	70
556	Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1688-1692.	3.9	91
557	Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. <i>Sleep</i> , 2015, 38, 1529-1535.	1.1	76
558	Chewing-induced hypertension in afferent baroreflex failure: a sympathetic response?. <i>Experimental Physiology</i> , 2015, 100, 1269-1279.	2.0	11
559	Mutation Analysis of <i>COQ2</i> in Chinese Patients with Cerebellar Subtype of Multiple System Atrophy. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 626-630.	3.9	16
560	Restricted disease propagation in multiple system atrophy with prolonged survival. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 681-685.	3.2	4
561	Sphincter electromyography in diabetes mellitus and multiple system atrophy. <i>Neurourology and Urodynamics</i> , 2015, 34, 669-674.	1.5	8

#	ARTICLE	IF	CITATIONS
562	Validating novel tau positron emission tomography tracer <sc>[Fâ€18]â€AVâ€1451 (T807)</sc> on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	5.3	535
563	Genetic variability of the retromer cargo recognition complex in parkinsonism. <i>Movement Disorders</i> , 2015, 30, 580-584.	3.9	23
564	Dorsolateral nigral hyperintensity on 3.0T susceptibilityâ€weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015, 30, 1068-1076.	3.9	125
565	Minimal change multiple system atrophy: An aggressive variant?. <i>Movement Disorders</i> , 2015, 30, 960-967.	3.9	45
566	Progressive retinal structure abnormalities in multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1944-1953.	3.9	34
567	Comparison of automatic versus manual procedures for the quantification of dopamine D2 receptor availability using I-123-IBZM-SPECT. <i>Nuclear Medicine Communications</i> , 2015, 36, 1120-1126.	1.1	5
568	Quantitative pathological changes in the cerebellum of multiple system atrophy. <i>Folia Neuropathologica</i> , 2015, 3, 193-202.	1.2	1
569	Diagnosis of Parkinson’s disease: progress and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 0, , 19.	0.8	3
570	Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 104.	4.1	31
571	Neuroinflammation in Multiple System Atrophy: Response to and Cause of Î±-Synuclein Aggregation. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 437.	3.7	77
572	Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. <i>Frontiers in Computational Neuroscience</i> , 2015, 9, 137.	2.1	23
573	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. <i>Frontiers in Neurology</i> , 2015, 6, 91.	2.4	60
574	Potential Interactions between the Autonomic Nervous System and Higher Level Functions in Neurological and Neuropsychiatric Conditions. <i>Frontiers in Neurology</i> , 2015, 6, 182.	2.4	23
575	Distinctive Features of NREM Parasomnia Behaviors in Parkinsonâ€™s Disease and Multiple System Atrophy. <i>PLoS ONE</i> , 2015, 10, e0120973.	2.5	7
576	The Pathogenic Role of Low Range Repeats in SCA17. <i>PLoS ONE</i> , 2015, 10, e0135275.	2.5	23
577	Plasma Homocysteine, Vitamin B12 and Folate Levels in Multiple System Atrophy: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0136468.	2.5	6
578	Involvement of Peripheral Nerves in the Transgenic PLP-Î±-Syn Model of Multiple System Atrophy: Extending the Phenotype. <i>PLoS ONE</i> , 2015, 10, e0136575.	2.5	17
579	Medical Record Review to Differentiate between Idiopathic Parkinsonâ€™s Disease and Parkinsonism: A Danish Record Linkage Study with 10 Years of Follow-Up. <i>Parkinson's Disease</i> , 2015, 2015, 1-9.	1.1	10

#	ARTICLE	IF	CITATIONS
580	Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	1.1	33
581	Classification of Parkinsonian Syndromes from FDG-PET Brain Data Using Decision Trees with SSM/PCA Features. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-10.	1.3	42
582	Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study. <i>Disease Markers</i> , 2015, 2015, 1-6.	1.3	25
583	Use of a new generation of adaptive servo ventilation for sleep-disordered breathing in patients with multiple system atrophy. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014206372.	0.5	8
584	Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2015, 372, 1371-1374.	27.0	18
585	Expanding the spectrum of neuronal pathology in multiple system atrophy. <i>Brain</i> , 2015, 138, 2293-2309.	7.6	178
586	Phosphorylated α -synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. <i>Brain</i> , 2015, 138, 2310-2321.	7.6	116
587	Effect of Repetitive Transcranial Magnetic Stimulation on fMRI Resting-State Connectivity in Multiple System Atrophy. <i>Brain Connectivity</i> , 2015, 5, 451-459.	1.7	33
588	Lower urinary tract dysfunction in patients with parkinsonism and other neurodegenerative disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2015, 130, 335-356.	1.8	34
589	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , The, 2015, 14, 710-719.	10.2	243
590	Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2015, , .	1.7	13
591	Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2015, 372, 1374-1376.	27.0	53
592	Quitting smoking: An early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 216-220.	2.2	19
593	Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease. <i>Brain and Behavior</i> , 2015, 5, e00320.	2.2	32
594	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
595	Dyskinésies dopa-induites dans l'atrophie multi-systématisée de type parkinsonienne. <i>Pratique Neurologique - FMC</i> , 2015, 6, 218-222.	0.1	1
596	Neocortical Neuronal Loss in Patients with Multiple System Atrophy: A Stereological Study. <i>Cerebral Cortex</i> , 2017, 27, bhv228.	2.9	44
597	POTS (postural orthostatic tachycardia syndrome) in a young patient: An unusual presentation of MSA (multiple system atrophy) type P. <i>Indian Journal of Medical Specialities</i> , 2015, 6, 177-180.	0.1	1

#	ARTICLE	IF	CITATIONS
598	Clinical Reasoning: A 72-year-old man with nocturnal stridor. <i>Neurology</i> , 2015, 85, e136-9.	1.1	1
599	The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 929-937.	2.2	26
600	PR Prolongation and Cardiac ^{123}I -MIBG Uptake Reduction in Parkinson's Disease. <i>European Neurology</i> , 2015, 74, 107-111.	1.4	12
601	The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. <i>Neurobiology of Aging</i> , 2015, 36, 1221.e1-1221.e6.	3.1	39
602	Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12. <i>Journal of the Neurological Sciences</i> , 2015, 349, 243-245.	0.6	2
603	Diagnosis and differential diagnosis of MSA: boundary issues. <i>Journal of Neurology</i> , 2015, 262, 1801-1813.	3.6	21
604	A short clinical history of multiple system atrophy. <i>Clinical Autonomic Research</i> , 2015, 25, 3-7.	2.5	13
605	Mutation scanning of the COQ2 gene in ethnic Chinese patients with multiple-system atrophy. <i>Neurobiology of Aging</i> , 2015, 36, 1222.e7-1222.e11.	3.1	37
606	Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neurology</i> , 2015, 262, 992-1001.	3.6	115
607	Putaminal hypointensity on T2*-weighted MR imaging is the most practically useful sign in diagnosing multiple system atrophy: A preliminary study. <i>Journal of the Neurological Sciences</i> , 2015, 349, 174-178.	0.6	21
608	Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism. <i>American Journal of Neuroradiology</i> , 2015, 36, 454-460.	2.4	44
609	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1240-1247.	1.9	196
610	Clinical trials for multiple system atrophy. <i>Lancet Neurology</i> , The, 2015, 14, 126-127.	10.2	4
611	Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2015, 372, 249-263.	27.0	600
612	Ancillary investigations to diagnose parkinsonism: a prospective clinical study. <i>Journal of Neurology</i> , 2015, 262, 346-356.	3.6	34
613	Assessment of the efficacy of early phase parameters by ^{123}I -MIBG dynamic imaging for distinguishing Lewy body-related diseases from Parkinson's syndrome. <i>Annals of Nuclear Medicine</i> , 2015, 29, 149-156.	2.2	3
614	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	10.2	90
615	Multiple system atrophy: the application of genetics in understanding etiology. <i>Clinical Autonomic Research</i> , 2015, 25, 19-36.	2.5	20

#	ARTICLE	IF	CITATIONS
616	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 6-16.	1.5	24
617	L'atrophie multisystématisée. <i>Pratique Neurologique - FMC</i> , 2015, 6, 115-123.	0.1	0
618	Animal models of multiple system atrophy. <i>Clinical Autonomic Research</i> , 2015, 25, 9-17.	2.5	55
619	Impaired peripheral vasoconstrictor response to orthostatic stress in patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 917-922.	2.2	11
620	Cerebral Peduncle Angle: An Objective Criterion for Assessing Progressive Supranuclear Palsy Richardson Syndrome. <i>American Journal of Roentgenology</i> , 2015, 205, 386-391.	2.2	11
621	White matter differences between multiple system atrophy (parkinsonian type) and Parkinson's disease: A diffusion tensor image study. <i>Neuroscience</i> , 2015, 305, 109-116.	2.3	30
622	Esophageal Involvement in Multiple System Atrophy. <i>Dysphagia</i> , 2015, 30, 669-673.	1.8	18
623	Multiple system atrophy in the USA: another piece in the jigsaw. <i>Lancet Neurology</i> , The, 2015, 14, 672-674.	10.2	0
624	Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1013-1022.	2.2	30
625	Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 533-535.	2.2	6
626	Multiple system atrophy—new insight from prospective studies. <i>Nature Reviews Neurology</i> , 2015, 11, 430-431.	10.1	2
627	Cognitive Impairment and Its Structural Correlates in the Parkinsonian Subtype of Multiple System Atrophy. <i>Neurodegenerative Diseases</i> , 2015, 15, 294-300.	1.4	45
628	Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 477-482.	2.2	44
629	C9orf72 hexanucleotide expansion analysis in Chinese patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 811-812.	2.2	6
630	When DLB, PD, and PSP masquerade as MSA. <i>Neurology</i> , 2015, 85, 404-412.	1.1	272
631	Skin biopsy and ¹²³ I MIBG scintigraphy findings in idiopathic Parkinson's disease and parkinsonism: A comparative study. <i>Movement Disorders</i> , 2015, 30, 986-989.	3.9	22
632	Selective changes of ocular vestibular myogenic potentials in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 584-589.	3.9	29
633	Use of ¹¹ C-PE2I PET in Differential Diagnosis of Parkinsonian Disorders. <i>Journal of Nuclear Medicine</i> , 2015, 56, 234-242.	5.0	41


#	ARTICLE	IF	CITATIONS
634	Variants associated with Gaucher disease in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 417-426.	3.7	90
636	Simultaneous assessment of cognitive and affective functions in multiple system atrophy and cortical cerebellar atrophy in relation to computerized touch-panel screening tests. <i>Journal of the Neurological Sciences</i> , 2015, 351, 24-30.	0.6	20
637	Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. <i>Journal of the Neurological Sciences</i> , 2015, 352, 84-87.	0.6	46
638	Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. <i>Neuroradiology</i> , 2015, 57, 655-669.	2.2	38
639	Potential diagnostic value of regional myocardial adrenergic imaging using 123I-MIBG SPECT to identify patients with Lewy body diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1043-1051.	6.4	9
640	Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy. <i>Journal of Neurology</i> , 2015, 262, 1433-1439.	3.6	41
641	Failure to confirm benefit of acetyl-dl-leucine in degenerative cerebellar ataxia: a case series. <i>Journal of Neurology</i> , 2015, 262, 1373-1375.	3.6	14
642	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. <i>Neurogenetics</i> , 2015, 16, 201-213.	1.4	18
643	Leptin upregulation in advanced multiple system atrophy with hypocholesterolemia and unexpected fat accumulation. <i>Neurological Sciences</i> , 2015, 36, 1471-1477.	1.9	2
644	Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study. <i>Clinical Autonomic Research</i> , 2015, 25, 47-52.	2.5	11
645	Increased bilirubin levels in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 954-959.	3.3	29
646	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	4.4	71
647	Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with β -synuclein. <i>Acta Neuropathologica</i> , 2015, 130, 93-105.	7.7	65
648	Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 567-572.	2.2	20
649	Epidemiology of Multiple System Atrophy in Hokkaido, the Northernmost Island of Japan. <i>Cerebellum</i> , 2015, 14, 682-687.	2.5	17
650	Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. <i>Clinical Autonomic Research</i> , 2015, 25, 69-75.	2.5	103
651	Differentiation among parkinsonisms using quantitative diffusion kurtosis imaging. <i>NeuroReport</i> , 2015, 26, 267-272.	1.2	15
652	Parkinsonian Syndromes. , 2015, , 769-785.		3

#	ARTICLE	IF	CITATIONS
653	Differentiating multiple-system atrophy from Parkinson's disease. <i>Clinical Radiology</i> , 2015, 70, 555-564.	1.1	30
654	Role of Semiquantitative Assessment of Regional Binding Potential in 123I-FP-CIT SPECT for the Differentiation of Frontotemporal Dementia, Dementia With Lewy Bodies, and Alzheimer's Dementia. <i>Clinical Nuclear Medicine</i> , 2015, 40, e27-e33.	1.3	16
655	Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 455-460.	2.2	46
656	Application of diffusion tensor imaging in multiple system atrophy: the involvement of pontine transverse and longitudinal fibers. <i>International Journal of Neuroscience</i> , 2015, 125, 18-24.	1.6	12
657	Differential diagnosis of sporadic adult-onset ataxia: The role of REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 640-643.	2.2	9
658	The utility of cerebral perfusion SPECT analysis using SPM8, eZIS and vbSEE for the diagnosis of multiple system atrophy-parkinsonism. <i>Annals of Nuclear Medicine</i> , 2015, 29, 206-213.	2.2	4
659	Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31. <i>Neurological Sciences</i> , 2015, 36, 1897-1902.	1.9	29
660	Clinical features and autonomic testing predict survival in multiple system atrophy. <i>Brain</i> , 2015, 138, 3623-3631.	7.6	118
661	Cardiovascular responses during cold pressor test are different in Parkinson disease and multiple system atrophy with parkinsonism. <i>Clinical Autonomic Research</i> , 2015, 25, 219-224.	2.5	6
662	Filamentous aggregations of phosphorylated α -synuclein in Schwann cells (Schwann cell cytoplasmic) Tj ETQq1 1 0.784314 rgBT /Over 5.2 49		
663	Accuracy and cutoff values of delayed heart to mediastinum ratio with 123I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses. <i>BMC Neurology</i> , 2015, 15, 83.	1.8	9
664	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. <i>Neuroradiology</i> , 2015, 57, 1079-1091.	2.2	37
665	The role of neuroimaging in the diagnosis of the atypical parkinsonian syndromes in clinical practice. <i>Neurologia I Neurochirurgia Polska</i> , 2015, 49, 421-431.	1.2	25
666	Cystatin C is differentially involved in multiple system atrophy phenotypes. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 507-519.	3.2	7
667	The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1264-1268.	2.2	25
668	Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes. <i>Journal of Neurology</i> , 2015, 262, 1876-1882.	3.6	33
669	Survival in synucleinopathies. <i>Neurology</i> , 2015, 85, 1554-1561.	1.1	84
670	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. <i>Journal of Neurology</i> , 2015, 262, 2498-2503.	3.6	25

#	ARTICLE	IF	CITATIONS
672	Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5308-17.	7.1	578
673	Propagation of prions causing synucleinopathies in cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4949-58.	7.1	191
674	Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. Parkinsonism and Related Disorders, 2015, 21, 1273-1277.	2.2	24
675	Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson's disease and multiple system atrophy in a Chinese population. Journal of Neurology, 2015, 262, 2478-2483.	3.6	18
676	Differentiation of Parkinsonism-Predominant Multiple System Atrophy from Idiopathic Parkinson Disease Using 3T Susceptibility-Weighted MR Imaging, Focusing on Putaminal Change and Lesion Asymmetry. American Journal of Neuroradiology, 2015, 36, 2227-2234.	2.4	29
677	Role for the microtubule-associated protein tau variant p.A152T in risk of α -synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
678	Are there treatments for atypical parkinsonism? An update on actual options. Reviews in the Neurosciences, 2015, 26, 547-553.	2.9	2
679	Autonomic failure and reduced survival in multiple system atrophy. Brain, 2015, 138, 3466-3468.	7.6	6
680	Retrospective analysis of parkinsonian patients exhibiting normal 123I-MIBG cardiac uptake. Journal of the Neurological Sciences, 2015, 359, 236-240.	0.6	10
681	Prognosis of Neurological Diseases. , 2015, , .		1
682	Diagnostic value of combined assessment of olfaction and substantia nigra hyperechogenicity for Parkinson's disease. Neurologia (English Edition), 2015, 30, 496-501.	0.4	3
683	Association of serum uric acid level with cognitive function among patients with multiple system atrophy. Journal of the Neurological Sciences, 2015, 359, 363-366.	0.6	13
684	Voxelwise meta-analysis of gray matter anomalies in Parkinson variant of multiple system atrophy and Parkinson's disease using anatomic likelihood estimation. Neuroscience Letters, 2015, 587, 79-86.	2.1	45
685	Diagnosis and Management of Autonomic Failure in Neurodegenerative Disorders. European Neurology, 2015, 73, 126-133.	1.4	12
686	Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. International Journal of Neuroscience, 2015, 125, 645-654.	1.6	145
687	Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 205-210.	2.2	31
688	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0
689	Presence and progression of non-motor symptoms in relation to uric acid in <i>de novo</i> Parkinson's disease. European Journal of Neurology, 2015, 22, 93-98.	3.3	49

#	ARTICLE	IF	CITATIONS
690	SNP rs11931074 of the <i>SNCA</i> gene may not be associated with multiple system atrophy in Chinese population. <i>International Journal of Neuroscience</i> , 2015, 125, 612-615.	1.6	12
691	Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. <i>Human Brain Mapping</i> , 2015, 36, 1165-1179.	3.6	51
692	The role of transcriptional control in multiple system atrophy. <i>Neurobiology of Aging</i> , 2015, 36, 394-400.	3.1	10
693	Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy – A stereological study. <i>Neurobiology of Disease</i> , 2015, 74, 104-113.	4.4	65
694	Atypical Parkinsonism. <i>Neurologic Clinics</i> , 2015, 33, 39-56.	1.8	34
695	Valor de la evaluación combinada de olfacción e hipercogenicidad de sustancia negra en el diagnóstico de la enfermedad de Parkinson. <i>Neurología</i> , 2015, 30, 496-501.	0.7	10
696	Consensus Paper: Radiological Biomarkers of Cerebellar Diseases. <i>Cerebellum</i> , 2015, 14, 175-196.	2.5	42
697	Neuropsychiatric Symptoms of Movement Disorders. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , .	0.3	0
698	Ataxia. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , 277-292.	0.3	0
699	Atypical Parkinsonian Syndromes. , 2016, , .		0
700	Possible Treatments of Atypical Parkinsonism. , 2016, , .		0
701	Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson's Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2016, 81, 363-369.	1.0	36
702	Diffusion tensor imaging in the characterization of multiple system atrophy. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2181-2187.	2.2	13
703	Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party?. <i>Dementia and Neurocognitive Disorders</i> , 2016, 15, 49.	1.4	1
704	Can neurodegenerative disease be defined by four – primary determinants™: anatomy, cells, molecules, and morphology?. <i>Folia Neuropathologica</i> , 2016, 2, 89-104.	1.2	3
705	Comparison Study of Polysomnographic Features in Multiple System Atrophy-cerebellar Types Combined with and without Rapid Eye Movement Sleep Behavior Disorder. <i>Chinese Medical Journal</i> , 2016, 129, 2173-2177.	2.3	4
706	Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	1.1	3
707	The Differential Diagnosis and Treatment of Atypical Parkinsonism. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 61-9.	0.9	135

#	ARTICLE	IF	CITATIONS
708	Cardiovagal Baroreflex Sensitivity in Parkinson's Disease and Multiple-System Atrophy. Journal of		



#	ARTICLE	IF	CITATIONS
727	Combination therapies: The next logical Step for the treatment of synucleinopathies?. <i>Movement Disorders</i> , 2016, 31, 225-234.	3.9	45
728	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP. <i>Movement Disorders</i> , 2016, 31, 653-662.	3.9	60
729	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Movement Disorders</i> , 2016, 31, 235-240.	3.9	9
730	Imaging synucleinopathies. <i>Movement Disorders</i> , 2016, 31, 814-829.	3.9	33
731	Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses. <i>NeuroImage: Clinical</i> , 2016, 12, 234-240.	2.7	41
732	MAPT haplotype diversity in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 40-45.	2.2	23
733	Neurovestibular analysis and falls in Parkinson's disease and atypical parkinsonism. <i>European Journal of Neuroscience</i> , 2016, 43, 1636-1646.	2.6	51
734	Accumulation of phosphorylated α -synuclein in subpial and periventricular astrocytes in multiple system atrophy of long duration. <i>Neuropathology</i> , 2016, 36, 157-167.	1.2	38
735	Prediction of orthostatic hypotension in multiple system atrophy and Parkinson disease. <i>Scientific Reports</i> , 2016, 6, 21649.	3.3	13
737	Oxidative Stress and Environmental Exposures are Associated with Multiple System Atrophy in Chinese Patients. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 703-709.	0.5	19
739	Diagnostic utility of CSF α -synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2016, 6, e011113.	1.9	10
740	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016, 31, 1577-1581.	3.9	14
742	Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 697-702.	0.5	33
743	Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia. <i>Medicine (United States)</i> , 2016, 95, e5237.	1.0	3
744	Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients. <i>Neuroepidemiology</i> , 2016, 46, 261-267.	2.3	13
745	Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies. <i>Journal of Parkinson's Disease</i> , 2016, 6, 325-334.	2.8	7
746	The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation: A Study in 203 Consecutive Patients. <i>Sleep</i> , 2016, 39, 121-132.	1.1	177
747	Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2016, 39, 1543-1550.	1.1	20

#	ARTICLE	IF	CITATIONS
748	Orthostatic Circulatory Disorders: From Nosology to Nuts and Bolts. <i>American Journal of Hypertension</i> , 2016, 29, 1009-1019.	2.0	15
749	SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. <i>Journal of the Neurological Sciences</i> , 2016, 365, 96-100.	0.6	17
750	The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis. <i>Journal of the Neurological Sciences</i> , 2016, 363, 90-94.	0.6	9
751	No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population. <i>Neuroscience Letters</i> , 2016, 622, 113-117.	2.1	15
752	Altered bulbocavernosus reflex in patients with multiple system atrophy. <i>Neurological Research</i> , 2016, 38, 138-143.	1.3	3
753	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016, 86, 1242-1249.	1.1	89
754	Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. <i>Cogent Psychology</i> , 2016, 3, 1131476.	1.3	14
755	REM Sleep Behavior Disorder: a Prodromal Synucleinopathy. <i>Current Geriatrics Reports</i> , 2016, 5, 95-102.	1.1	3
756	Mechanisms and prevention of sudden death in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 1-6.	2.2	36
757	Laryngeal stridor in multiple system atrophy: Clinicopathological features and causal hypotheses. <i>Journal of the Neurological Sciences</i> , 2016, 361, 243-249.	0.6	37
758	Î±-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. <i>Acta Neuropathologica</i> , 2016, 132, 59-75.	7.7	58
759	Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 462-471.	0.5	63
760	Peripheral arterial endothelial dysfunction of neurodegenerative diseases. <i>Journal of the Neurological Sciences</i> , 2016, 366, 94-99.	0.6	9
761	Serum creatinine is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. <i>Neurological Research</i> , 2016, 38, 255-260.	1.3	2
762	Different loss of dopamine transporter according to subtype of multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 517-525.	6.4	34
763	Multiple system atrophy: pathogenic mechanisms and biomarkers. <i>Journal of Neural Transmission</i> , 2016, 123, 555-572.	2.8	55
764	The aetiology of Idiopathic Late Onset Cerebellar Ataxia (ILOCA): Clinical and imaging clues for a definitive diagnosis. <i>Journal of the Neurological Sciences</i> , 2016, 365, 156-157.	0.6	2
765	Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 107-111.	2.2	19

#	ARTICLE	IF	CITATIONS
766	DCTN1 p.K56R in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 56-61.	2.2	27
767	Association of the COQ2 V393A variant with risk of multiple system atrophy in East Asians: a case-control study and meta-analysis of the literature. <i>Neurological Sciences</i> , 2016, 37, 423-430.	1.9	44
768	Diagnostic value of blink reflex in multisystem atrophy, progressive supranuclear palsy and Parkinson disease. <i>Neurologia i Neurochirurgia Polska</i> , 2016, 50, 336-341.	1.2	7
769	Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension. <i>Hypertension</i> , 2016, 68, 418-426.	2.7	58
770	Mutational analysis of CHCHD2 in Chinese patients with multiple system atrophy and amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 368, 389-391.	0.6	8
771	Mutational analysis of COQ2 in patients with MSA in Italy. <i>Neurobiology of Aging</i> , 2016, 45, 213.e1-213.e2.	3.1	25
772	Hypnic jerks are an underestimated sleep motor phenomenon in patients with parkinsonism. A video-polysomnographic and neurophysiological study. <i>Sleep Medicine</i> , 2016, 26, 37-44.	1.6	6
773	Specific patterns of laryngeal electromyography during wakefulness are associated to sleep disordered breathing and nocturnal stridor in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 104-109.	2.2	14
774	Finger tapping analysis in patients with Parkinson's disease and atypical parkinsonism. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 49-55.	1.5	37
775	Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders. <i>Clinical Neuropsychologist</i> , 2016, 30, 849-900.	2.3	21
777	Review: The spectrum of clinical features seen with alpha synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 6-19.	3.2	67
778	Review: Multiple system atrophy: emerging targets for interventional therapies. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 20-32.	3.2	50
779	Cognitive impairments associated with morphological changes in cortical and subcortical structures in multiple system atrophy of the cerebellar type. <i>European Journal of Neurology</i> , 2016, 23, 92-100.	3.3	35
780	Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review. <i>Neuropathology</i> , 2016, 36, 64-76.	1.2	25
781	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2244-2254.	6.4	37
782	Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 36-41.	2.2	21
783	Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9593-9598.	7.1	89
784	Early stridor onset and stridor treatment predict survival in 136 patients with MSA. <i>Neurology</i> , 2016, 87, 1375-1383.	1.1	61

#	ARTICLE	IF	CITATIONS
785	Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 79-86.	2.2	27
786	Cerebrospinal β -synuclein in β -synuclein aggregation disorders: tau/ β -synuclein ratio as potential biomarker for dementia with Lewy bodies. <i>Journal of Neurology</i> , 2016, 263, 2271-2277.	3.6	37
787	Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 31-35.	2.2	5
788	Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. <i>Movement Disorders</i> , 2016, 31, 1506-1517.	3.9	120
789	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	5.2	388
790	Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic. <i>Neurology: Genetics</i> , 2016, 2, e121.	1.9	1
792	A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016, 87, 1591-1598.	1.1	139
793	Parkinsonism. <i>Seminars in Neurology</i> , 2016, 36, 330-334.	1.4	43
794	Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. <i>Neurology</i> , 2016, 87, 709-717.	1.1	45
795	Retinal thinning correlates with clinical severity in multiple system atrophy. <i>Journal of Neurology</i> , 2016, 263, 2039-2047.	3.6	14
796	Scan without evidence of dopaminergic deficit: A 10-year retrospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 53-58.	2.2	38
797	Does the Type of Multisystem Atrophy, Parkinsonism, or Cerebellar Ataxia Impact on the Nature of Sleep Disorders?. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 105.	4.2	2
798	Current Treatment of Multiple System Atrophy. <i>Current Treatment Options in Neurology</i> , 2016, 18, 51.	1.8	9
799	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016, 39, 405-412.	1.1	73
800	Post-mortem histopathology underlying β -amyloid PET imaging following flutemetamol F 18 injection. <i>Acta Neuropathologica Communications</i> , 2016, 4, 130.	5.2	76
801	MRI-based cerebellar volume measurements correlate with the International Cooperative Ataxia Rating Scale score in patients with spinocerebellar degeneration or multiple system atrophy. <i>Cerebellum and Ataxias</i> , 2016, 3, 14.	1.9	18
802	Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	3
803	Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage. <i>European Journal of Pain</i> , 2016, 20, 1223-1228.	2.8	15

#	ARTICLE	IF	CITATIONS
805	Parkinsonism-Plus Syndromes. , 2016, , 181-198.		1
806	Multiple System Atrophy Mistaken for Autoimmune Cerebellar Degeneration. American Journal of Medicine, 2016, 129, e183-e184.	1.5	1
807	Subtotal arytenoidectomy for the treatment of laryngeal stridor in multiple system atrophy: phonatory and swallowing results. Brazilian Journal of Otorhinolaryngology, 2016, 82, 116-120.	1.0	8
808	Argyrophilic Grain Disease Presenting as Excited Catatonia: A Case Report. Psychosomatics, 2016, 57, 431-438.	2.5	3
809	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
810	New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 554-561.	1.9	48
811	Supine hypertension in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
812	Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology, 2016, 86, 829-835.	1.1	170
813	CHCHD2 gene mutations in familial and sporadic Parkinson's disease. Neurobiology of Aging, 2016, 38, 217.e9-217.e13.	3.1	56
814	Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathology and Applied Neurobiology, 2016, 42, 95-106.	3.2	29
815	α-Synuclein strains and the variable pathologies of synucleinopathies. Journal of Neurochemistry, 2016, 139, 256-274.	3.9	72
816	Subgroup differences in "brain-type" transferrin and ±-synuclein in Parkinson's disease and multiple system atrophy. Journal of Biochemistry, 2016, 160, 87-91.	1.7	7
817	Medullary Hot-Cross Bun Sign in Multiple System Atrophy-Cerebellar. Journal of Medical Imaging and Radiation Sciences, 2016, 47, 113-115.	0.3	1
818	Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions. Molecular Imaging and Biology, 2016, 18, 302-312.	2.6	33
819	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. Journal of Neural Transmission, 2016, 123, 371-377.	2.8	9
820	Neurodegenerative Disorders. , 2016, , .		11
821	FBXO7 mutations in Parkinson's disease and multiple system atrophy. Neurobiology of Aging, 2016, 40, 192.e1-192.e5.	3.1	43
822	Autoimmune atypical parkinsonism " A group of treatable parkinsonism. Journal of the Neurological Sciences, 2016, 362, 40-46.	0.6	31

#	ARTICLE	IF	CITATIONS
823	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. <i>Neuroscience</i> , 2016, 322, 234-250.	2.3	24
824	Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 47-54.	2.2	62
825	Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 69-75.	2.2	47
826	Free-water imaging in Parkinson's disease and atypical parkinsonism. <i>Brain</i> , 2016, 139, 495-508.	7.6	165
827	Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 250-256.	3.6	14
828	Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. <i>Neurobiology of Aging</i> , 2016, 37, 74-81.	3.1	65
829	Significance of combined use of MRI and perfusion SPECT for evaluation of multiple system atrophy, cerebellar type. <i>Acta Radiologica</i> , 2016, 57, 742-749.	1.1	5
830	The Diagnosis and Natural History of Multiple System Atrophy, Cerebellar Type. <i>Cerebellum</i> , 2016, 15, 663-679.	2.5	34
831	Characteristic diffusion tensor tractography in multiple system atrophy with predominant cerebellar ataxia and cortical cerebellar atrophy. <i>Journal of Neurology</i> , 2016, 263, 61-67.	3.6	9
832	Multiple system atrophy-mimicking conditions: Diagnostic challenges. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S12-S15.	2.2	28
833	Is multiple system atrophy with cerebellar ataxia (MSA-C) like spinocerebellar ataxia and multiple system atrophy with parkinsonism (MSA-P) like Parkinson's disease? A saccade study on pathophysiology. <i>Clinical Neurophysiology</i> , 2016, 127, 1491-1502.	1.5	22
834	Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 60-66.	5.0	83
835	Association analysis of the GRN rs5848 and MAPT rs242557 polymorphisms in Parkinson's disease and multiple system atrophy: a large-scale population-based study and meta-analysis. <i>International Journal of Neuroscience</i> , 2016, 126, 947-954.	1.6	6
836	A neurophysiological examination of basal ganglia and cerebellum. <i>Clinical Neurophysiology</i> , 2016, 127, 1007-1008.	1.5	0
837	Comparison of Different Symptom Assessment Scales for Multiple System Atrophy. <i>Cerebellum</i> , 2016, 15, 190-200.	2.5	12
838	Orthostatic Hypotension and Orthostatic Intolerance. , 2016, , 1965-1984.e3.		0
839	MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 443-444.	1.9	23
840	Familial dysautonomia: History, genotype, phenotype and translational research. <i>Progress in Neurobiology</i> , 2017, 152, 131-148.	5.7	87

#	ARTICLE	IF	CITATIONS
841	Dentate nucleus iron deposition is a potential biomarker for tremorâ€dominant Parkinson's disease. <i>NMR in Biomedicine</i> , 2017, 30, e3554.	2.8	42
842	Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 683-693.	4.3	51
843	Role of Magnetic Resonance Imaging in the Diagnosis of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 12-20.	1.5	17
844	Natural history of pure autonomic failure: A <sc>U</sc>nited <sc>S</sc>tates prospective cohort. <i>Annals of Neurology</i> , 2017, 81, 287-297.	5.3	229
845	The many faces of autonomic failure in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 368-370.	3.9	0
846	Using â€swallow-tailâ€ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinsonâ€s disease: A susceptibility-weighted imaging study. <i>European Radiology</i> , 2017, 27, 3174-3180.	4.5	44
848	Transforming growth factor-Î²1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases. <i>Journal of Clinical Neuroscience</i> , 2017, 35, 47-49.	1.5	13
849	Impact of sleep apnea syndrome on survival in patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 92-95.	2.2	7
850	Pathology of Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a028035.	5.5	865
851	Serum uric acid levels in Parkinson's disease and related disorders. <i>Brain and Behavior</i> , 2017, 7, e00598.	2.2	34
852	Manual MRI morphometry in Parkinsonian syndromes. <i>Movement Disorders</i> , 2017, 32, 778-782.	3.9	67
853	Expansion of the classification of FTLT-DTP: distinct pathology associated with rapidly progressive frontotemporal degeneration. <i>Acta Neuropathologica</i> , 2017, 134, 65-78.	7.7	163
854	Onset of bladder and motor symptoms in multiple system atrophy: differences according to phenotype. <i>Clinical Autonomic Research</i> , 2017, 27, 103-106.	2.5	6
855	The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2017, 7, 331-346.	2.8	68
856	Pure autonomic failure. <i>Neurology</i> , 2017, 88, 1129-1136.	1.1	90
857	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71.	2.2	34
858	Pathologic correlates of supranuclear gaze palsy with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 68-71.	2.2	27
859	Evaluation of an optimized [¹⁸ F]fluoroâ€deoxyâ€glucose positron emission tomography voxelâ€wise method to early support differential diagnosis in atypical Parkinsonian disorders. <i>European Journal of Neurology</i> , 2017, 24, 687.	3.3	40

#	ARTICLE	IF	CITATIONS
860	Î±-synuclein astroglipathy: A possible specific feature in Î±-synucleinopathy. <i>Neuropathology</i> , 2017, 37, 379-381.	1.2	5
861	Differentiation of atypical Parkinson syndromes. <i>Journal of Neural Transmission</i> , 2017, 124, 997-1004.	2.8	30
862	Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 402-411.	1.9	109
863	Anhidrosis in multiple system atrophy involves pre- and postganglionic sudomotor dysfunction. <i>Movement Disorders</i> , 2017, 32, 397-404.	3.9	48
864	Combined use of dopamine transporter imaging (DAT-SPECT) and 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 375, 80-85.	0.6	32
865	Frontotemporal lobar degeneration-τDP with α multiple system atrophy phenocopy syndrome™. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 533-536.	3.2	4
866	Palliative Care Discussions in Multiple System Atrophy: A Retrospective Review. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 276-282.	0.5	13
867	Multiple System Atrophy. , 2017, , 183-192.		2
868	Animal Models of Movement Disorders. , 2017, , 11-21.		0
869	Clinical Features and Differential Diagnosis of Parkinson™s Disease. , 2017, , 103-115.		5
870	Serum uric acid level is linked to the disease progression rate in male patients with multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2017, 158, 15-19.	1.4	6
871	Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	1.1	40
872	Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases. <i>Neurological Sciences</i> , 2017, 38, 1187-1191.	1.9	16
873	Patterns of Eye Movement Impairment Correlate with Regional Brain Atrophy in Neurodegenerative Parkinsonism. <i>Neurodegenerative Diseases</i> , 2017, 17, 117-126.	1.4	22
875	Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2017, 377, 65-71.	0.6	11
876	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017, 38, 537-545.	1.1	12
877	Advances in the Clinical Differential Diagnosis of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 79-127.	2.0	4
878	The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. <i>Nuclear Medicine Communications</i> , 2017, 38, 487-492.	1.1	20

#	ARTICLE	IF	CITATIONS
879	Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia. <i>Neuropathology</i> , 2017, 37, 431-440.	1.2	10
880	Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 191-197.	1.5	24
881	Changes in the cell population in brain white matter in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 1074-1082.	3.9	40
882	Can postural abnormality really respond to levodopa in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2017, 377, 179-184.	0.6	22
883	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. <i>JAMA Neurology</i> , 2017, 74, 839.	9.0	68
884	Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches. <i>Seminars in Neurology</i> , 2017, 37, 215-227.	1.4	30
885	Transcranial sonography in idiopathic <sc>REM</sc> sleep behavior disorder and multiple system atrophy. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 238-246.	1.8	9
886	Hypersomnia in Neurodegenerative Diseases. <i>Sleep Medicine Clinics</i> , 2017, 12, 443-460.	2.6	15
887	Sleep, Breathing, and Neurologic Disorders. , 2017, , 787-890.		6
888	Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies. <i>Molecular Neurodegeneration</i> , 2017, 12, 44.	10.8	48
889	Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. <i>Clinical Nuclear Medicine</i> , 2017, 42, e80-e87.	1.3	31
890	Serum Klotho, vitamin D, and homocysteine in combination predict the outcomes of Chinese patients with multiple system atrophy. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 657-666.	3.9	24
891	Freezing of gait is an early clinical feature of progressive supranuclear palsy. <i>Neurology and Clinical Neuroscience</i> , 2017, 5, 86-90.	0.4	9
892	Wavelet analysis of the Valsalva maneuver: Methodology validation and application to pathological subjects. <i>Biomedical Signal Processing and Control</i> , 2017, 35, 79-86.	5.7	0
893	Orthostatic hypotension: A review. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S55-S67.	0.5	72
894	The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. <i>Journal of Neuroimmunology</i> , 2017, 309, 82-87.	2.3	4
895	Usefulness of combining 123I-FP-CIT-SPECT striatal asymmetry index and cardiac 123I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms. <i>Journal of the Neurological Sciences</i> , 2017, 377, 174-178.	0.6	18
896	Redefinition of Atypical Parkinsonian Syndromes. <i>Neurology International Open</i> , 2017, 01, E2-E7.	0.4	0

#	ARTICLE	IF	CITATIONS
897	Lack of benefit of acetyl- dl -leucine in patients with multiple system atrophy of the cerebellar type. Journal of the Neurological Sciences, 2017, 379, 12-13.	0.6	3
898	Combined Diffusion Tensor Imaging and Apparent Transverse Relaxation Rate Differentiate Parkinson Disease and Atypical Parkinsonism. American Journal of Neuroradiology, 2017, 38, 966-972.	2.4	32
899	Detecting the Cognitive Prodrome of Dementia with Lewy Bodies: A Prospective Study of REM Sleep Behavior Disorder. Sleep, 2017, 40, .	1.1	60
900	Multiple System Atrophy - State of the Art. Current Neurology and Neuroscience Reports, 2017, 17, 41.	4.2	27
901	The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurological Research, 2017, 39, 675-684.	1.3	38
902	Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain, 2017, 140, 1420-1436.	7.6	80
903	Diagnostic Value of Isolated Mentalis Versus Mentalis Plus Upper Limb Electromyography in Idiopathic REM Sleep Behavior Disorder Patients Eventually Developing a Neurodegenerative Syndrome. Sleep, 2017, 40, .	1.1	38
904	Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory process. Journal of Neuroinflammation, 2017, 14, 38.	7.2	58
905	Parkinson's Disease: Cognitive Impairment. Focus (American Psychiatric Publishing), 2017, 15, 42-54.	0.8	12
906	Treatment of Spinocerebellar Ataxia with Mesenchymal Stem Cells: A Phase I/IIa Clinical Study. Cell Transplantation, 2017, 26, 503-512.	2.5	49
907	Asim K. Bag, Lázaro Luís Faria do Amaral. , 0, , 19-20.		0
908	Asim K. Bag, Lázaro Luís Faria do Amaral. , 0, , 21-24.		0
909	Multiple system atrophy: insights into a rare and debilitating movement disorder. Nature Reviews Neurology, 2017, 13, 232-243.	10.1	128
910	White matter and cortical changes in atypical parkinsonisms: A multimodal quantitative MR study. Parkinsonism and Related Disorders, 2017, 39, 44-51.	2.2	26
911	Natural course and potential prognostic factors for sleep-disordered breathing in multiple system atrophy. Sleep Medicine, 2017, 34, 13-17.	1.6	19
912	Usefulness of diffusion-tensor MRI in the diagnosis of Parkinson variant of multiple system atrophy and Parkinson's disease: a valuable tool to differentiate between them?. Clinical Radiology, 2017, 72, 610.e9-610.e15.	1.1	23
913	Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson's disease. Journal of Neural Transmission, 2017, 124, 965-972.	2.8	14
914	Analysis of Extrastriatal ¹²³ I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. Journal of Nuclear Medicine, 2017, 58, 1117-1123.	5.0	35

#	ARTICLE	IF	CITATIONS
915	Non-motor symptoms and the quality of life in multiple system atrophy with different subtypes. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 63-68.	2.2	46
916	¹⁸ F-MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population. <i>Journal of the Neurological Sciences</i> , 2017, 373, 48-51.	0.6	12
917	<i>Movement Disorders Rehabilitation.</i> , 2017, , .		1
918	¹⁸ F-AV1451 binds to putamen in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 171-173.	3.9	26
919	Distinct patterns of imprecise consonant articulation among Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Brain and Language</i> , 2017, 165, 1-9.	1.6	69
921	The value of the bulbocavernosus reflex and pudendal nerve somatosensory evoked potentials in distinguishing between multiple system atrophy and Parkinson's disease at an early stage. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 195-203.	2.1	8
922	Atypical parkinsonism: Critical appraisal of a cohort. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 36-42.	2.2	12
923	Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. <i>Nature Reviews Urology</i> , 2017, 14, 79-89.	3.8	63
924	The Neuropsychology (Broadly Conceived) of Multiple System Atrophy, Progressive Supranuclear Palsy, and Corticobasal Degeneration. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 861-875.	0.5	36
925	<i>Absolute Neurocritical Care Review.</i> , 2017, , .		0
926	CSF biomarkers β -amyloid, tau proteins and α -synuclein in the differential diagnosis of Parkinson-plus syndromes. <i>Journal of the Neurological Sciences</i> , 2017, 382, 91-95.	0.6	66
927	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
928	Non-motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei. <i>Journal of Neurology</i> , 2017, 264, 2249-2257.	3.6	16
929	Potential clinical utility of multiple system atrophy biomarkers. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1189-1208.	2.8	13
930	Parkinsonian Patients with Striatal Cribiform State Present Rapidly Progressive Axial Parkinsonism. <i>European Neurology</i> , 2017, 78, 119-124.	1.4	0
931	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	5.3	161
932	A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor. <i>Journal of the Neurological Sciences</i> , 2017, 382, 53-54.	0.6	3
933	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608

#	ARTICLE	IF	CITATIONS
934	Postvoid residual predicts the diagnosis of multiple system atrophy in Parkinsonian syndrome. <i>Journal of the Neurological Sciences</i> , 2017, 381, 230-234.	0.6	18
935	Comparing abnormalities of amplitude of low-frequency fluctuations in multiple system atrophy and idiopathic Parkinson's disease measured with resting-state fMRI. <i>Psychiatry Research - Neuroimaging</i> , 2017, 269, 73-81.	1.8	30
936	Quantitative susceptibility mapping differentiates between parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 51-57.	2.2	77
937	Vaccination strategies in tauopathies and synucleinopathies. <i>Journal of Neurochemistry</i> , 2017, 143, 467-488.	3.9	30
938	Parkinson's Disease and Its Effect on the Lower Urinary Tract. <i>Urologic Clinics of North America</i> , 2017, 44, 415-428.	1.8	23
940	The New Diagnostic Criteria for Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 55-78.	2.0	37
941	Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study. <i>Clinical Neurophysiology</i> , 2017, 128, 1978-1984.	1.5	10
942	Pre- and postganglionic vasomotor dysfunction causes distal limb coldness in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2017, 380, 191-195.	0.6	3
943	Regional microstructural damage and patterns of eye movement impairment: a DTI and video-oculography study in neurodegenerative parkinsonian syndromes. <i>Journal of Neurology</i> , 2017, 264, 1919-1928.	3.6	13
944	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
946	Case of possible multiple system atrophy with a characteristic imaging finding of open bladder neck during storage phase as an initial sign. <i>International Journal of Urology</i> , 2017, 24, 816-819.	1.0	3
947	Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. <i>Neurology</i> , 2017, 89, 1043-1049.	1.1	45
948	Combined Central and Peripheral Degenerative Vestibular Disorders: CANVAS, Idiopathic Cerebellar Ataxia with Bilateral Vestibulopathy (CABV) and Other Differential Diagnoses of the CABV Phenotype. <i>Current Otorhinolaryngology Reports</i> , 2017, 5, 167-174.	0.5	8
949	Serum microRNA expression profiling in patients with multiple system atrophy. <i>Molecular Medicine Reports</i> , 2018, 17, 852-860.	2.4	26
950	C9ORF72 Intermediate Repeat Expansion in a Patient With Psychiatric Disorders and Progressive Cerebellar Ataxia. <i>Neurologist</i> , 2017, 22, 245-246.	0.7	7
951	Nonmotor Features in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2017, 134, 1285-1301.	2.0	21
952	Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping. <i>Neuroradiology</i> , 2017, 59, 759-769.	2.2	36
953	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. <i>Advances in Neurobiology</i> , 2017, 15, 55-92.	1.8	2

#	ARTICLE	IF	CITATIONS
954	Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations. <i>Cerebellum</i> , 2017, 16, 664-672.	2.5	35
955	Stratification of disease progression in a broad spectrum of degenerative cerebellar ataxias with a clustering method using MRI-based atrophy rates of brain structures. <i>Cerebellum and Ataxias</i> , 2017, 4, 9.	1.9	6
956	Deciphering the causes of sporadic late-onset cerebellar ataxias: a prospective study with implications for diagnostic work. <i>Journal of Neurology</i> , 2017, 264, 1118-1126.	3.6	34
957	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. <i>Lancet Neurology</i> , The, 2017, 16, 789-796.	10.2	155
958	Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study. <i>Journal of Neuroinflammation</i> , 2017, 14, 89.	7.2	29
959	Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 824-828.	1.5	10
960	Distinguishing spinocerebellar ataxia with pure cerebellar manifestation from multiple system atrophy (MSA-C) through saccade profiles. <i>Clinical Neurophysiology</i> , 2017, 128, 31-43.	1.5	10
961	Synucleinopathies: common features and hippocampal manifestations. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1485-1501.	5.4	33
962	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 509-516.	1.5	35
963	Assisting the Diagnosis of Neurodegenerative Disorders Using Principal Component Analysis and TensorFlow. <i>Advances in Intelligent Systems and Computing</i> , 2017, , 43-52.	0.6	2
964	Profile of cognitive impairment and underlying pathology in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 405-413.	3.9	95
965	MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2017, 54, 7736-7745.	4.0	119
966	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	2.8	46
967	Molecular Imaging of Extrapyraxidal Movement Disorders. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 18-30.	4.6	4
968	Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia. <i>Brain Stimulation</i> , 2017, 10, 242-250.	1.6	102
969	Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism. <i>Journal of Neural Transmission</i> , 2017, 124, 209-216.	2.8	8
970	Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 315-329.	3.2	44
971	Nutritional Status and Changes in Body Weight in Patients with Multiple System Atrophy. <i>European Neurology</i> , 2017, 77, 41-44.	1.4	7

#	ARTICLE	IF	CITATIONS
972	Increased aneuploidy is not a universal feature across α -synucleinopathies. <i>Movement Disorders</i> , 2017, 32, 475-476.	3.9	5
973	The involvement of supratentorial white matter in multiple system atrophy: a diffusion tensor imaging tractography study. <i>Acta Neurologica Belgica</i> , 2017, 117, 213-220.	1.1	16
974	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 389-396.	1.5	4
975	Neuropathology of dementia. , 2016, , 94-122.		5
976	Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy. <i>Journal of Neurosciences in Rural Practice</i> , 2017, 08, 562-568.	0.8	7
978	Tonic Electromyogram Density in Multiple System Atrophy with Predominant Parkinsonism and Parkinson's Disease. <i>Chinese Medical Journal</i> , 2017, 130, 684-690.	2.3	11
979	Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders. <i>Frontiers in Pharmacology</i> , 2017, 8, 80.	3.5	36
980	Multiple System Atrophy. , 2017, , .		0
981	Altered Functional and Causal Connectivity of Cerebello-Cortical Circuits between Multiple System Atrophy (Parkinsonian Type) and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 266.	3.4	30
982	Distinct Parameters in the EEG of the PLP α -SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 10, 252.	2.0	14
983	The Retina in Multiple System Atrophy: Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2017, 8, 206.	2.4	30
984	Slowed Prosaccades and Increased Antisaccade Errors As a Potential Behavioral Biomarker of Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2017, 8, 261.	2.4	15
985	Divergent Thinking in Parkinsonism: A Case-Control Study. <i>Frontiers in Neurology</i> , 2017, 8, 534.	2.4	7
986	Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies. <i>Frontiers in Neurology</i> , 2017, 8, 710.	2.4	90
987	Multivariate Analysis of 18F-DMFP PET Data to Assist the Diagnosis of Parkinsonism. <i>Frontiers in Neuroinformatics</i> , 2017, 11, 23.	2.5	32
988	MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 329.	2.9	43
989	F-18 FP-CIT PET in Multiple System Atrophy of the Cerebellar Type: Additional Role in Treatment. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-7.	0.8	4
990	Emerging clinical issues and multivariate analyses in PET investigations. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 386-404.	0.7	9

#	ARTICLE	IF	CITATIONS
999	A (Familial) PSP Look-Alike: Perry Syndrome. , 0, , 24-25.		1
1055	The Utility of Post-Void Residual Volume versus Sphincter Electromyography to Distinguish between Multiple System Atrophy and Parkinson's Disease. PLoS ONE, 2017, 12, e0169405.	2.5	17
1056	Striatofrontal Deafferentiation in MSA-P: Evaluation with [18F]FDG Brain PET. PLoS ONE, 2017, 12, e0169928.	2.5	13
1057	The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism. PLoS ONE, 2017, 12, e0180744.	2.5	27
1058	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0189897.	2.5	44
1059	Genomic copy number variation analysis in multiple system atrophy. Molecular Brain, 2017, 10, 54.	2.6	6
1060	Validity and reliability of a pilot scale for assessment of multiple system atrophy symptoms. Cerebellum and Ataxias, 2017, 4, 11.	1.9	6
1061	Changes in the symptom frequency of rapid eye movement sleep behavior disorder according to disease duration. Sleep Science and Practice, 2017, 1, .	1.3	9
1062	Body mass index and severity of parkinsonism in multiple system atrophy. Neurology International, 2017, 9, .	2.8	2
1063	Cholesterol Homeostasis and the Pathogenesis of Multiple System Atrophy. , 2017, 07, .		1
1064	Multiple system atrophy: clinicopathological characteristics in Japanese patients. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2017, 93, 251-258.	3.8	22
1065	A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders. Internal Medicine, 2017, 56, 2871-2878.	0.7	12
1066	Severe panuveitis in neuro-Behçet's disease in Malaysia: a case series. International Medical Case Reports Journal, 2017, Volume 10, 35-40.	0.8	0
1067	Risk of unsuccessful noninvasive ventilation for acute respiratory failure in heterogeneous neuromuscular diseases: a retrospective study. Neurology International, 2017, 9, 6904.	2.8	2
1068	Rapid Eye Movement Sleep Parasomnias. , 2017, , 993-1001.e6.		3
1069	Olivopontocerebellar Atrophy. , 2017, , .		89
1070	Autonomic dysfunction in genetic forms of synucleinopathies. Movement Disorders, 2018, 33, 359-371.	3.9	17
1071	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Movement Disorders, 2018, 33, 600-608.	3.9	77

#	ARTICLE	IF	CITATIONS
1072	Integrated neurodegenerative disease autopsy diagnosis. <i>Acta Neuropathologica</i> , 2018, 135, 643-646.	7.7	12
1073	Analysis of (CAG) _n expansion in ATXN1, ATXN2 and ATXN3 in Chinese patients with multiple system atrophy. <i>Scientific Reports</i> , 2018, 8, 3889.	3.3	11
1074	Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study. <i>Basal Ganglia</i> , 2018, 12, 4-7.	0.3	2
1075	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 94-98.	2.2	23
1076	Genetic and functional characters of GRN p.T487I mutation in Taiwanese patients with atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 61-66.	2.2	7
1077	Sleep Abnormalities in Multiple System Atrophy. <i>Current Treatment Options in Neurology</i> , 2018, 20, 16.	1.8	15
1078	TDP ⁴³ pathology in multiple system atrophy: colocalization of TDP ⁴³ and α -synuclein in glial cytoplasmic inclusions. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 707-721.	3.2	43
1079	Predictors of camptocormia in patients with Parkinson's disease: A prospective study from southwest China. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 69-75.	2.2	14
1080	Predictors of cognitive impairment in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2018, 388, 128-132.	0.6	7
1081	Characteristics of Early Oropharyngeal Dysphagia in Patients with Multiple System Atrophy. <i>Neurodegenerative Diseases</i> , 2018, 18, 84-90.	1.4	25
1082	MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism. <i>American Journal of Neuroradiology</i> , 2018, 39, 1047-1051.	2.4	23
1083	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	2.2	49
1084	Midbrain meningioma causing subacute parkinsonism. <i>Neurology: Clinical Practice</i> , 2018, 8, 166-168.	1.6	0
1085	The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1253-1273.	2.6	47
1086	MEETING REPORTER. <i>Current Opinion in Neurology</i> , 2018, 31, 1-24.	3.6	0
1087	Patterns of dopamine transporter imaging in subtypes of multiple system atrophy. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 170-176.	2.1	28
1088	COQ2 variants in Parkinson's disease and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2018, 125, 937-944.	2.8	10
1089	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763.	0.8	61

#	ARTICLE	IF	CITATIONS
1090	Impact of sleep-related breathing disorder on motor and non-motor symptoms in multiple system atrophy. <i>Sleep and Breathing</i> , 2018, 22, 981-987.	1.7	5
1091	Dementia. <i>American Journal of Medicine</i> , 2018, 131, 1161-1169.	1.5	314
1092	Loss of Motor Neurons Innervating Cervical Muscles in Patients With Multiple System Atrophy and Dropped Head. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 317-324.	1.7	2
1093	Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. <i>Annals of Neurology</i> , 2018, 83, 522-531.	5.3	150
1094	A diagnostic decision tree for adult cerebellar ataxia based on pontine magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 2018, 387, 187-195.	0.6	13
1095	Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 42-47.	2.2	25
1096	Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy. <i>Neurourology and Urodynamics</i> , 2018, 37, 1724-1730.	1.5	15
1097	Multiple system atrophy and apolipoprotein E. <i>Movement Disorders</i> , 2018, 33, 647-650.	3.9	15
1098	Hyperconnective and hypoconnective cortical and subcortical functional networks in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 75-80.	2.2	23
1099	Parkinson disease with and without Dementia: A prevalence study and future projections. <i>Movement Disorders</i> , 2018, 33, 537-543.	3.9	63
1100	Multiple system atrophy: Building a global community – 30 years of advocacy efforts. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 39-42.	2.8	3
1102	Familial Parkinson's point mutation abolishes multiple system atrophy prion replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 409-414.	7.1	43
1103	Alpha-synucleinopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.8	50
1104	An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 9-16.	2.2	55
1105	Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease. <i>Neurophysiologie Clinique</i> , 2018, 48, 103-110.	2.2	17
1106	Association of <i>TNF-Î±</i> rs1799964 and <i>IL-1Î²</i> rs16944 polymorphisms with multiple system atrophy in Chinese Han population. <i>International Journal of Neuroscience</i> , 2018, 128, 761-764.	1.6	16
1107	Abnormal pain perception in patients with Multiple System Atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 28-33.	2.2	9
1108	MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 10-16.	2.2	14

#	ARTICLE	IF	CITATIONS
1109	Present and future of disease-modifying therapies in multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 31-38.	2.8	7
1110	Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment?. <i>Sleep Medicine</i> , 2018, 42, 53-60.	1.6	22
1111	First symptoms in multiple system atrophy. <i>Clinical Autonomic Research</i> , 2018, 28, 215-221.	2.5	53
1112	Tau Imaging in Parkinsonism: What Have We Learned So Far?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 118-130.	1.5	14
1113	Neuropathology of autonomic dysfunction in synucleinopathies. <i>Movement Disorders</i> , 2018, 33, 349-358.	3.9	144
1114	Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 146, 99-113.	1.8	5
1115	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 2.	5.2	50
1116	CSF biological antioxidant potentials may differentiate neurodegenerative diseases-A preliminary report. <i>Neurology and Clinical Neuroscience</i> , 2018, 6, 45-47.	0.4	2
1117	Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy. <i>Journal of Neurology</i> , 2018, 265, 1540-1547.	3.6	11
1118	Dilemma of multiple system atrophy and spinocerebellar ataxias. <i>Journal of Neurology</i> , 2018, 265, 2764-2772.	3.6	11
1119	Multiple system atrophy and CAG repeat length: A genetic screening of polyglutamine disease genes in Italian patients. <i>Neuroscience Letters</i> , 2018, 678, 37-42.	2.1	10
1120	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	4.5	88
1121	Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts. <i>Human Brain Mapping</i> , 2018, 39, 2842-2858.	3.6	32
1122	Idiopathic cerebellar ataxia (IDCA): Diagnostic criteria and clinical analyses of 63 Japanese patients. <i>Journal of the Neurological Sciences</i> , 2018, 384, 30-35.	0.6	10
1123	Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 574-580.	2.3	12
1124	Modulation of Cerebellar-Cortical Connections in Multiple System Atrophy Type C by Cerebellar Repetitive Transcranial Magnetic Stimulation. <i>Neuromodulation</i> , 2018, 21, 402-408.	0.8	15
1125	Î±-Synuclein: Multiple System Atrophy Prions. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a024588.	6.2	64
1126	Distinct Î±-Synuclein strains and implications for heterogeneity among Î±-Synucleinopathies. <i>Neurobiology of Disease</i> , 2018, 109, 209-218.	4.4	121

#	ARTICLE	IF	CITATIONS
1127	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harbor Perspectives in Biology, 2018, 10, a033118.	5.5	616
1128	Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein. Neuroscience Research, 2018, 128, 58-62.	1.9	15
1129	Feedback Facility-Assisted Balance Training in a Patient With Multiple System Atrophy: A Case Presentation. PM and R, 2018, 10, 555-559.	1.6	5
1130	Alpha-synuclein levels in patients with multiple system atrophy: a meta-analysis. International Journal of Neuroscience, 2018, 128, 477-486.	1.6	12
1131	Ocular features of multiple system atrophy. Journal of Clinical Neuroscience, 2018, 47, 234-239.	1.5	10
1132	Pathologies Responsible for the Development of the Neurogenic Bladder. , 2018, , 17-36.		0
1133	Translational therapies for multiple system atrophy: Bottlenecks and future directions. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 7-14.	2.8	11
1134	Multiple System Atrophy: An Oligodendroglioneuronal Synucleinopathy1. Journal of Alzheimer's Disease, 2018, 62, 1141-1179.	2.6	127
1135	3-Hz postural tremor in multiple system atrophy cerebellar type (MSA-C) a static posturography study. Neurological Sciences, 2018, 39, 71-77.	1.9	7
1136	MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathologica, 2018, 135, 49-63.	7.7	70
1137	Key themes and future prospects in translational multiple system atrophy research. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 43-45.	2.8	0
1138	Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 175-184.	1.9	94
1139	Combining olfactory test and motion analysis sensors in Parkinson's disease preclinical diagnosis: a pilot study. Acta Neurologica Scandinavica, 2018, 137, 204-211.	2.1	13
1140	The neuropathology of multiple system atrophy and its therapeutic implications. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 1-6.	2.8	33
1141	Evaluation of autonomic functions of patients with multiple system atrophy and Parkinson's disease by head-up tilt test. Journal of Neural Transmission, 2018, 125, 153-162.	2.8	6
1142	Neuropsychological and clinical heterogeneity of cognitive impairment in patients with multiple system atrophy. Clinical Neurology and Neurosurgery, 2018, 164, 121-126.	1.4	25
1143	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
1144	Multi-class parkinsonian disorders classification with quantitative MR markers and graph-based features using support vector machines. Parkinsonism and Related Disorders, 2018, 47, 64-70.	2.2	16

#	ARTICLE	IF	CITATIONS
1145	Does sympathetic dysfunction occur before denervation in pure autonomic failure?. <i>Clinical Science</i> , 2018, 132, 1-16.	4.3	6
1146	Neuroprotection afforded by circadian regulation of intracellular glutathione levels: A key role for miRNAs. <i>Free Radical Biology and Medicine</i> , 2018, 119, 17-33.	2.9	23
1147	Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. <i>Neurological Sciences</i> , 2018, 39, 359-364.	1.9	8
1148	123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy. <i>Clinical Nuclear Medicine</i> , 2018, 43, e33-e36.	1.3	14
1149	Symptomatic therapy of multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 26-30.	2.8	18
1150	Diagnosis of multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 15-25.	2.8	112
1151	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 16-23.	2.2	32
1152	Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. <i>Neuroscience Letters</i> , 2018, 664, 128-132.	2.1	9
1153	Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 15-21.	2.2	25
1154	A case of multiple system atrophy-parkinsonian type with stuttering- and palilalia-like dysfluencies and putaminal atrophy. <i>Journal of Fluency Disorders</i> , 2018, 57, 51-58.	1.7	2
1155	Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management. <i>Clinical Autonomic Research</i> , 2018, 28, 83-101.	2.5	46
1156	Depression and anxiety in multiple system atrophy. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 33-37.	2.1	26
1157	Multiple System Atrophy: Many Lessons from the Transcriptome. <i>Neuroscientist</i> , 2018, 24, 294-307.	3.5	7
1158	Atypical parkinsonian syndromes: a general neurologist's perspective. <i>European Journal of Neurology</i> , 2018, 25, 41-58.	3.3	46
1159	Brain morphological alteration and cognitive dysfunction in multiple system atrophy. <i>Quantitative Imaging in Medicine and Surgery</i> , 2018, 8, 1030-1038.	2.0	11
1160	Continuous glucose monitoring can disclose glucose fluctuation in advanced Parkinsonian syndromes. <i>Neurology International</i> , 2018, 10, 7921.	2.8	4
1161	At room temperature in water: efficient hydrogenation of furfural to furfuryl alcohol with a Pt/SiC catalyst. <i>RSC Advances</i> , 2018, 8, 37243-37253.	3.6	21
1162	Anomalous effect of the aging degree on the ionic permeability of silica shells. <i>RSC Advances</i> , 2018, 8, 38499-38505.	3.6	4

#	ARTICLE	IF	CITATIONS
1163	Linear Classification in Speech-Based Objective Differential Diagnosis of Parkinsonism. , 2018, , .		4
1164	A "hot crossed buns" sign, orthostatic syncope & gait ataxia point to probable multiple systems atrophy with dysarthria and slowed fluency suspicious for associated cognitive impairment. Cogent Medicine, 2018, 5, 1564530.	0.7	0
1165	Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2643-2656.	2.2	21
1166	Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease. Annals of Clinical and Translational Neurology, 2018, 5, 1394-1407.	3.7	39
1167	LRP10 in α -synucleinopathies. Lancet Neurology, The, 2018, 17, 1033-1034.	10.2	11
1168	Association study between multiple system atrophy and TREM2 p.R47H. Neurology: Genetics, 2018, 4, e257.	1.9	9
1169	The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis. Frontiers in Aging Neuroscience, 2018, 10, 326.	3.4	57
1170	Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. Journal of Neuroinflammation, 2018, 15, 305.	7.2	45
1171	Multiparametric MR imaging of Parkinsonisms at 3 tesla: Its role in the differentiation of idiopathic Parkinson's disease versus atypical Parkinsonian disorders. European Journal of Radiology, 2018, 109, 95-100.	2.6	24
1172	Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study. Frontiers in Neurology, 2018, 9, 1099.	2.4	4
1173	Abnormal functional connectivity of the amygdala is associated with depressive symptoms in patients with multiple system atrophy. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3133-3142.	2.2	12
1174	Role of myocardial 123I-mIBG innervation imaging in the diagnosis of neurodegenerative diseases. Clinical and Translational Imaging, 2018, 6, 449-458.	2.1	6
1175	Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology, 2018, 91, e1539-e1544.	1.1	25
1176	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	3.8	32
1177	Skin α -synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Scientific Reports, 2018, 8, 14246.	3.3	75
1178	Causes of Death in Chinese Patients with Multiple System Atrophy. , 2018, 9, 102.		27
1179	Elevated microRNA-520d-5p in the serum of patients with Parkinson's disease, possibly through regulation of cereloplasmin expression. Neuroscience Letters, 2018, 687, 88-93.	2.1	14
1180	Phenoconversion from Idiopathic Rapid Eye Movement Sleep Behavior Disorder to Lewy Body Disease. Movement Disorders Clinical Practice, 2018, 5, 506-511.	1.5	19

#	ARTICLE	IF	CITATIONS
1181	Clinical characteristics and quality of life in Chinese patients with multiple system atrophy. <i>Brain and Behavior</i> , 2018, 8, e01135.	2.2	15
1182	Functional MRI in Atypical Parkinsonisms. <i>International Review of Neurobiology</i> , 2018, 142, 149-173.	2.0	11
1183	High Resolution Manofluorographic Study in Patients With Multiple System Atrophy: Possible Early Detection of Upper Esophageal Sphincter and Proximal Esophageal Abnormality. <i>Frontiers in Medicine</i> , 2018, 5, 286.	2.6	12
1184	Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. <i>Stem Cell Reports</i> , 2018, 11, 1185-1198.	4.8	46
1185	The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. , 2018, 08, .		80
1186	Sympathetic and Parasympathetic Coactivation Induces Perturbed Heart Rate Dynamics in Patients with Paroxysmal Atrial Fibrillation. <i>Medical Science Monitor</i> , 2018, 24, 2164-2172.	1.1	12
1187	PET Molecular Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018, 142, 3-36.	2.0	8
1189	Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018, 265, 2602-2613.	3.6	80
1190	Diagnostic challenges in multiple system atrophy. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 179-184.	2.2	4
1191	Diagnostic challenges in rapidly progressive dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 761-772.	2.8	29
1192	Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders. <i>Journal of Palliative Medicine</i> , 2018, 21, 1507-1517.	1.1	18
1193	Using deep neural networks along with dimensionality reduction techniques to assist the diagnosis of neurodegenerative disorders. <i>Logic Journal of the IGPL</i> , 2018, 26, 618-628.	1.5	27
1194	Converging Patterns of α -Synuclein Pathology in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1005-1016.	1.7	26
1195	Subtle Esophageal Motility Alterations in Parkinsonian Syndromes: Synucleinopathies vs. Tauopathies. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 406-412.	1.5	13
1197	Young-onset multiple system atrophy: Clinical and pathological features. <i>Movement Disorders</i> , 2018, 33, 1099-1107.	3.9	30
1198	Eosinophilia in the muscle layer of the esophagus and the urinary bladder in a Multiple System Atrophy patient with dysphagia and dysuria. <i>Pathology International</i> , 2018, 68, 382-387.	1.3	1
1199	Comparison of MRI and ^{123}I -FP-CIT SPECT for the evaluation of MSA-P clinical severity. <i>Biomedical Reports</i> , 2018, 8, 523-528.	2.0	1
1200	Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [^{123}I] FP-CIT single-photon emission computed tomography (DaTscan). <i>Neurological Sciences</i> , 2018, 39, 1401-1407.	1.9	3

#	ARTICLE	IF	CITATIONS
1201	Reduced gray matter volume is correlated with frontal cognitive and behavioral impairments in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 390, 231-238.	0.6	11
1202	Corpus callosal involvement is correlated with cognitive impairment in multiple system atrophy. <i>Journal of Neurology</i> , 2018, 265, 2079-2087.	3.6	19
1203	Difference in severity of sleep apnea in patients with rapid eye movement sleep behavior disorder with or without parkinsonism. <i>Sleep Medicine</i> , 2018, 49, 99-104.	1.6	4
1204	Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy. <i>Neuropathology</i> , 2018, 38, 361-371.	1.2	4
1205	Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy. <i>Journal of Neurology</i> , 2018, 265, 2033-2039.	3.6	3
1206	Analysis of the TMEM230 gene in patients with multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2018, 392, 128-129.	0.6	2
1207	The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy. <i>Translational Neurodegeneration</i> , 2018, 7, 15.	8.0	12
1208	Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. <i>CNS Drugs</i> , 2018, 32, 827-837.	5.9	16
1209	Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. <i>BMC Neurology</i> , 2018, 18, 69.	1.8	7
1210	Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy. <i>Neurobiology of Disease</i> , 2018, 118, 155-160.	4.4	5
1211	Very old onset parkinsonism: A clinical-pathological study. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 39-43.	2.2	8
1212	Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 817-822.	2.0	2
1214	Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 123.	3.4	43
1215	Functional Variant rs3135500 in NOD2 Increases the Risk of Multiple System Atrophy in a Chinese Population. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 150.	3.4	9
1216	Effects of Multi-Session Repetitive Transcranial Magnetic Stimulation on Motor Control and Spontaneous Brain Activity in Multiple System Atrophy: A Pilot Study. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 90.	2.0	13
1217	The Bulbocavernosus Reflex in the Differential Diagnosis of Multiple System Atrophy with Predominant Parkinsonism and Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 697.	2.4	6
1218	Extensive Delayed Brain Atrophy after Resuscitation in a Patient with Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2018, 8, 754.	2.4	0
1219	Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2018, 9, 265.	2.4	32

#	ARTICLE	IF	CITATIONS
1220	MSA Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 17.	2.8	9
1221	Neuroimaging in Atypical Parkinsonian Disorders. <i>Neurographics</i> , 2018, 8, 154-166.	0.2	1
1222	Nocturnal Hypertension in Multiple System Atrophy May Cause Posterior Reversible Encephalopathy Syndrome. <i>Internal Medicine</i> , 2018, 57, 3187-3191.	0.7	2
1223	The Etiologies of Chronic Progressive Cerebellar Ataxia in a Korean Population. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
1238	The natural history of idiopathic autonomic failure. <i>Neurology</i> , 2018, 91, e1245-e1254.	1.1	29
1239	Immune-mediated ataxias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 313-332.	1.8	38
1240	Sporadic adult-onset ataxia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 217-225.	1.8	23
1241	The neuropathology of the adult cerebellum. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 154, 129-149.	1.8	48
1242	Analysis of GWAS-linked variants in multiple system atrophy. <i>Neurobiology of Aging</i> , 2018, 67, 201.e1-201.e4.	3.1	16
1243	Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 567-574.	2.5	7
1244	Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. <i>Clinical Autonomic Research</i> , 2019, 29, 627-631.	2.5	40
1245	The utility of the combined use of ¹²³ I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes. <i>Acta Radiologica</i> , 2019, 60, 230-238.	1.1	16
1246	Abnormalities of white and grey matter in early multiple system atrophy: comparison of parkinsonian and cerebellar variants. <i>European Radiology</i> , 2019, 29, 716-724.	4.5	32
1247	Minimal change multiple system atrophy with limbic-predominant α -synuclein pathology. <i>Acta Neuropathologica</i> , 2019, 137, 167-169.	7.7	11
1249	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	2.2	16
1250	Analysis of on-surface and in-air movement in handwriting of subjects with Parkinson's disease and atypical parkinsonism. <i>Biomedizinische Technik</i> , 2019, 64, 187-194.	0.8	7
1251	A 57-Year-Old Woman With Progressive Left Hand Clumsiness and Falls. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 656-660.	1.5	4
1252	Fecal and Blood Microbial 16s rRNA Gene Alterations in Chinese Patients with Multiple System Atrophy and Its Subtypes. <i>Journal of Parkinson's Disease</i> , 2019, 9, 711-721.	2.8	17
1253	Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116421.	0.6	9
1254	Characterization of Cerebellar Atrophy and Resting State Functional Connectivity Patterns in Sporadic Adult-Onset Ataxia of Unknown Etiology (SAOA). <i>Cerebellum</i> , 2019, 18, 873-881.	2.5	7
1255	Efficient RT-QuIC seeding activity for α -synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. <i>Translational Neurodegeneration</i> , 2019, 8, 24.	8.0	106
1256	Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease. <i>BMC Neurology</i> , 2019, 19, 194.	1.8	10

#	ARTICLE	IF	CITATIONS
1257	Can infections trigger alpha-synucleinopathies?. Progress in Molecular Biology and Translational Science, 2019, 168, 299-322.	1.7	55
1258	Sleep as a Therapeutic Target in the Aging Brain. Neurotherapeutics, 2019, 16, 554-568.	4.4	35
1259	Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease. Scientific Reports, 2019, 9, 11111.	3.3	3
1260	Urodynamic study for distinguishing multiple system atrophy from Parkinson disease. Neurology, 2019, 93, e946-e953.	1.1	16
1261	Towards Disease-specific Speech Markers for Differential Diagnosis in Parkinsonism. , 2019, , .		5
1262	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. Journal of Neural Transmission, 2019, 126, 1437-1445.	2.8	25
1263	Current radiotracers to image neurodegenerative diseases. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 17.	3.9	28
1264	Young-onset multiple system atrophy: Its rarity and heterogeneity. Movement Disorders, 2019, 34, 1085-1086.	3.9	0
1265	Is 1H-MR spectroscopy useful as a diagnostic aid in MSA-C?. Cerebellum and Ataxias, 2019, 6, 7.	1.9	3
1266	Clinical neurophysiology of multiple system atrophy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 161, 423-428.	1.8	1
1267	Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathologica Communications, 2019, 7, 113.	5.2	56
1268	Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. Expert Opinion on Drug Discovery, 2019, 14, 969-982.	5.0	4
1269	Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors. Frontiers in Neurology, 2019, 10, 621.	2.4	25
1270	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain, 2019, 142, 2813-2827.	7.6	121
1271	Isolated rapid eye movement sleep behavior disorder and cyclic alternating pattern: is sleep microstructure a predictive parameter of neurodegeneration?. Sleep, 2019, 42, .	1.1	27
1272	Earlier age of onset in multiple system atrophy with smoking and heavy alcohol use. Parkinsonism and Related Disorders, 2019, 66, 212-215.	2.2	5
1273	Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism and Related Disorders, 2019, 66, 94-99.	2.2	11
1274	The microbiome in autonomic medicine and other updates in recent autonomic research. Clinical Autonomic Research, 2019, 29, 361-362.	2.5	3

#	ARTICLE	IF	CITATIONS
1275	The "Hot Cross Bun" Sign Is Not Always Multiple System Atrophy: Etiologies of 11 Cases. <i>Journal of Movement Disorders</i> , 2019, 12, 27-30.	1.3	22
1276	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
1277	Pisa Syndrome in Chinese Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 651.	2.4	6
1278	Deep learning to differentiate parkinsonian disorders separately using single midsagittal MR imaging: a proof of concept study. <i>European Radiology</i> , 2019, 29, 6891-6899.	4.5	51
1279	Glial α -synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. <i>Glia</i> , 2019, 67, 1933-1957.	4.9	27
1280	Alterations of the Gut Microbiota in Multiple System Atrophy Patients. <i>Frontiers in Neuroscience</i> , 2019, 13, 1102.	2.8	42
1281	Distinct Autoimmune Anti- α -Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2253.	4.8	27
1282	Quantitative Validation of a Visual Rating Scale for Defining High-Iron Putamen in Patients With Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2019, 10, 1014.	2.4	8
1283	Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 40-45.	2.2	13
1284	Atomic Fe hetero-layered coordination between g-C ₃ N ₄ and graphene nanomeshes enhances the ORR electrocatalytic performance of zinc-air batteries. <i>Journal of Materials Chemistry A</i> , 2019, 7, 1451-1458.	10.3	70
1285	Differentiating early Parkinson's disease and multiple system atrophy with parkinsonism by saccade velocity profiles. <i>Clinical Neurophysiology</i> , 2019, 130, 2203-2215.	1.5	11
1286	Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 155-177.	1.8	16
1287	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	3.9	19
1288	Quantifying iron deposition in the cerebellar subtype of multiple system atrophy and spinocerebellar ataxia type 6 by quantitative susceptibility mapping. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116525.	0.6	16
1289	Conjugal cerebellar type of multiple system atrophy: Person-to-person transmission?. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 68-70.	2.2	5
1290	Prion-like propagation of α -synuclein in neurodegenerative diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 323-348.	1.7	18
1291	REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion. <i>Neurology</i> , 2019, 93, e1171-e1179.	1.1	45
1292	Differentiation of multiple system atrophy from Parkinson's disease by structural connectivity derived from probabilistic tractography. <i>Scientific Reports</i> , 2019, 9, 16488.	3.3	25

#	ARTICLE	IF	CITATIONS
1293	MicroRNAs Dysregulation and Metabolism in Multiple System Atrophy. <i>Frontiers in Neuroscience</i> , 2019, 13, 1103.	2.8	11
1294	Multiple System Atrophy: Recent Developments and Future Perspectives. <i>Movement Disorders</i> , 2019, 34, 1629-1642.	3.9	65
1295	Association of innervation-adjusted alpha-synuclein in arrector pili muscles with cardiac noradrenergic deficiency in autonomic synucleinopathies. <i>Clinical Autonomic Research</i> , 2019, 29, 587-593.	2.5	8
1296	Multiple System Atrophy: Phenotypic spectrum approach coupled with brain 18-FDG PET. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 3-9.	2.2	19
1297	Acoustic Tracking of Pitch, Modal, and Subharmonic Vibrations of Vocal Folds in Parkinson's Disease and Parkinsonism. <i>IEEE Access</i> , 2019, 7, 150339-150354.	4.2	23
1298	α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2120-2126.	3.7	87
1299	Similarities and differences in cerebellar grey matter volume and disrupted functional connectivity in idiopathic Parkinson's disease and multiple system atrophy. <i>Neuropsychologia</i> , 2019, 124, 125-132.	1.6	10
1300	Spatial Patterns of Decreased Cerebral Blood Flow and Functional Connectivity in Multiple System Atrophy (Cerebellar-Type): A Combined Arterial Spin Labeling Perfusion and Resting State Functional Magnetic Resonance Imaging Study. <i>Frontiers in Neuroscience</i> , 2019, 13, 777.	2.8	17
1301	Blood NfL. <i>Neurology</i> , 2019, 93, e1104-e1111.	1.1	144
1302	The art of making a clinical diagnosis of multiple system atrophy. <i>Brain</i> , 2019, 142, 2555-2557.	7.6	2
1303	Spinal cord α-synuclein deposition associated with myoclonus in patients with MSA-C. <i>Neurology</i> , 2019, 93, 302-309.	1.1	11
1304	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	2.8	15
1305	Considerations before initiating therapy in Parkinsonism: basing on the quality of life. <i>Journal of Neurology</i> , 2019, 266, 3119-3125.	3.6	1
1306	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	2.7	49
1307	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. <i>The Lancet Digital Health</i> , 2019, 1, e222-e231.	12.3	73
1308	Silver staining (Campbell-Switzer) of neuronal α-synuclein assemblies induced by multiple system atrophy and Parkinson's disease brain extracts in transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 148.	5.2	28
1309	Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. <i>PLoS ONE</i> , 2019, 14, e0223113.	2.5	9
1310	Shrinkage of the myenteric neurons of the small intestine in patients with multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 221, 102583.	2.8	3

#	ARTICLE	IF	CITATIONS
1311	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 249.	3.4	30
1312	A case of multiple system atrophy. <i>Journal of International Medical Research</i> , 2019, 47, 5839-5843.	1.0	1
1313	Sensitivity and specificity of cardiac 123I-MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116409.	0.6	10
1314	Stridor in multiple system atrophy. <i>Neurology</i> , 2019, 93, 630-639.	1.1	86
1315	Electromyography activity level in rapid eye movement sleep predicts neurodegenerative diseases in idiopathic rapid eye movement sleep behavior disorder: a 5-year longitudinal study. <i>Sleep Medicine</i> , 2019, 56, 128-134.	1.6	27
1316	Altered Functional Connectivity of Cerebello-Cortical Circuit in Multiple System Atrophy (Cerebellar-Type). <i>Frontiers in Neuroscience</i> , 2018, 12, 996.	2.8	20
1317	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. <i>Frontiers in Neurology</i> , 2019, 10, 5.	2.4	25
1318	Self-reported urinary impairment identifies "fast progressors" in terms of neuronal loss in multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 217, 1-6.	2.8	2
1319	End of life planning in parkinsonian diseases. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 73-78.	2.2	8
1320	Differentiation Between Multiple System Atrophy and Other Spinocerebellar Degenerations Using Diffusion Kurtosis Imaging. <i>Academic Radiology</i> , 2019, 26, e333-e339.	2.5	6
1321	Quantitative Research of 11C-CFT and 18F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software. <i>Frontiers in Neuroscience</i> , 2019, 13, 299.	2.8	15
1322	Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings. <i>EJNMMI Research</i> , 2019, 9, 7.	2.5	13
1323	Sex and gender influence symptom manifestation and survival in multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 219, 49-52.	2.8	18
1324	Treatment of Multiple System Atrophy. <i>Current Clinical Neurology</i> , 2019, , 141-145.	0.2	0
1325	Clinical spectrum of glutamic acid decarboxylase antibodies in a Taiwanese population. <i>European Journal of Neurology</i> , 2019, 26, 1384-1390.	3.3	6
1326	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update". Hypokinetic-rigid movement disorders. <i>Journal of Neural Transmission</i> , 2019, 126, 933-995.	2.8	28
1327	A comparison of the prevalence of orthostatic hypotension between older patients with Alzheimer's Disease, Lewy body dementia, and without dementia. <i>Experimental Gerontology</i> , 2019, 124, 110628.	2.8	30
1328	Simultaneous tonic and phasic REM sleep without atonia best predicts early phenocconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	1.1	31

#	ARTICLE	IF	CITATIONS
1329	One line: A method for differential diagnosis of parkinsonian syndromes. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 229-235.	2.1	9
1330	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.8	16
1331	Treatment of psychiatric disturbances in hypokinetic movement disorders. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 965-981.	2.8	8
1332	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 3-12.	2.2	26
1333	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1117-1123.	1.9	61
1334	Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. <i>Neurology</i> , 2019, 93, e77-e87.	1.1	62
1335	Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2019, 402, 100-106.	0.6	5
1336	A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. <i>NeuroImage: Clinical</i> , 2019, 23, 101858.	2.7	15
1337	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. <i>Brain Stimulation</i> , 2019, 12, 1290-1297.	1.6	23
1338	Longitudinal study of a cohort of MSA-C patients in South Italy: survival and clinical features. <i>Neurological Sciences</i> , 2019, 40, 2105-2109.	1.9	11
1339	Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. <i>Clinical Autonomic Research</i> , 2019, 29, 385-395.	2.5	2
1340	L-dopa response pattern in a rat model of mild striatonigral degeneration. <i>PLoS ONE</i> , 2019, 14, e0218130.	2.5	0
1341	Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. <i>Brain</i> , 2019, 142, 2051-2067.	7.6	215
1342	Erectile Dysfunction Preceding Clinically Diagnosed α -Synucleinopathies: A Case-Control Study in Olmsted County. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	1.1	7
1343	Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 147-156.	2.1	15
1344	Nigrosome 1 imaging: technical considerations and clinical applications. <i>British Journal of Radiology</i> , 2019, 92, 20180842.	2.2	29
1345	Alterations in Cognition-Related Cerebello-Cerebral Networks in Multiple System Atrophy. <i>Cerebellum</i> , 2019, 18, 770-780.	2.5	18
1346	Prevalence and clinicoradiological features of spinocerebellar ataxia type 34 in a Japanese ataxia cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 238-242.	2.2	23

#	ARTICLE	IF	CITATIONS
1347	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2019, 126, 925-932.	2.8	11
1348	Exploring the frequency and clinical background of the "zebra sign" in amyotrophic lateral sclerosis and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2019, 401, 90-94.	0.6	5
1349	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. <i>Mayo Clinic Proceedings</i> , 2019, 94, 892-905.	3.0	112
1350	Pupillary dysfunction of multiple system atrophy: Dynamic pupillometric findings and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 234-237.	2.2	6
1351	The Shaking Palsy of the Larynx" Potential Biomarker for Multiple System Atrophy: A Pilot Study and Literature Review. <i>Frontiers in Neurology</i> , 2019, 10, 241.	2.4	22
1352	Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease. <i>Molecular Brain</i> , 2019, 12, 49.	2.6	50
1353	Assessment of cognitive profile as a prodromal marker of the evolution of rapid eye movement sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	1.1	22
1354	Altered functional connectivity of dentate nucleus in parkinsonian and cerebellar variants of multiple system atrophy. <i>Brain Imaging and Behavior</i> , 2019, 13, 1733-1745.	2.1	17
1355	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. <i>Scientific Reports</i> , 2019, 9, 6079.	3.3	18
1356	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 226-234.	2.2	4
1357	The educational programs for extrapyramidal disease and spinocerebellar degeneration patients and their families. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 61-64.	0.4	1
1358	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
1359	Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. <i>Journal of Neurology</i> , 2019, 266, 1771-1781.	3.6	35
1360	The severity of motor dysfunctions and urinary dysfunction is not correlated in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2019, 400, 25-29.	0.6	4
1362	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. <i>Neurology</i> , 2019, 92, e1479-e1486.	1.1	100
1363	Does outpatient palliative care improve patient-centered outcomes in Parkinson's disease: Rationale, design, and implementation of a pragmatic comparative effectiveness trial. <i>Contemporary Clinical Trials</i> , 2019, 79, 28-36.	1.8	26
1364	Tandem gait abnormality in Parkinson disease: Prevalence and implication as a predictor of fall risk. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 83-87.	2.2	6
1365	Speculating the timing of iron deposition in the putamen in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 106-110.	2.2	6

#	ARTICLE	IF	CITATIONS
1366	A mouse model of adult-onset multiple system atrophy. <i>Neurobiology of Disease</i> , 2019, 127, 339-349.	4.4	14
1367	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	3.9	36
1368	Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. <i>Journal of Neurology</i> , 2019, 266, 1394-1404.	3.6	29
1369	Frequency and factors related to drooling in Chinese patients with multiple system atrophy: a cross-sectional study. <i>Clinical Autonomic Research</i> , 2019, 29, 595-601.	2.5	6
1370	The aggregation state of α -synuclein deposits in dermal nerve fibers of patients with Parkinson's disease resembles that in the brain. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 66-72.	2.2	24
1371	Cardiac 123I-MIBG Scintigraphy in Neurodegenerative Parkinson Syndromes: Performance and Pitfalls in Clinical Practice. <i>Frontiers in Neurology</i> , 2019, 10, 152.	2.4	23
1372	Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI. <i>NeuroImage: Clinical</i> , 2019, 22, 101748.	2.7	114
1373	Multiple system atrophy mimicked by multi-organ pathology. <i>Practical Neurology</i> , 2019, 19, 350-351.	1.1	1
1374	Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1757-1763.	5.0	29
1375	Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2019, 56, 7003-7021.	4.0	22
1376	Differential diagnosis of multiple system atrophy with predominant parkinsonism and Parkinson's disease using neural networks. <i>Journal of the Neurological Sciences</i> , 2019, 401, 19-26.	0.6	19
1377	Prevalence of and factors associated with postural deformities in Chinese patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 324-327.	2.2	5
1379	Multiple System Atrophy. , 2019, , 549-562.		0
1380	Differences in the intra-cerebellar connections and graph theoretical measures between Parkinson's disease and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2019, 400, 129-134.	0.6	9
1381	Does peripheral inflammation contribute to multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 340-341.	2.2	7
1382	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	2.4	30
1383	Do multiple system atrophy and Parkinson's disease show distinct patterns of volumetric alterations across hippocampal subfields? An exploratory study. <i>European Radiology</i> , 2019, 29, 4948-4956.	4.5	17
1384	Assessment of APOE in atypical parkinsonism syndromes. <i>Neurobiology of Disease</i> , 2019, 127, 142-146.	4.4	21

#	ARTICLE	IF	CITATIONS
1385	Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. <i>Acta Neuropathologica</i> , 2019, 137, 455-466.	7.7	45
1386	Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 564-568.	3.9	41
1387	Detecting frontotemporal dementia syndromes using MRI biomarkers. <i>NeuroImage: Clinical</i> , 2019, 22, 101711.	2.7	35
1388	Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 156-161.	2.2	9
1389	Abnormal α -synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. <i>European Journal of Neurology</i> , 2019, 26, 1245-1251.	3.3	38
1390	Circadian rhythms of cardiovascular autonomic function: Physiology and clinical implications in neurodegenerative diseases. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 217, 91-101.	2.8	29
1391	Multimodal MRI evaluation of parkinsonian limbic pathologies. <i>Neurobiology of Aging</i> , 2019, 76, 194-200.	3.1	12
1392	Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 199-203.	2.2	18
1393	Frontal lobe function, behavioral changes and quality of life in patients with multiple system atrophy. <i>Restorative Neurology and Neuroscience</i> , 2019, 37, 11-19.	0.7	8
1394	A Comparison of Pain between Parkinson's Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey. <i>Pain Research and Management</i> , 2019, 2019, 1-6.	1.8	6
1395	Blood pressure circadian rhythm alterations in alpha-synucleinopathies. <i>Journal of Neurology</i> , 2019, 266, 1141-1152.	3.6	25
1396	Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. <i>NeuroImage: Clinical</i> , 2019, 22, 101720.	2.7	34
1397	Early distinction of Parkinson's variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	3.9	21
1398	Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 395-404.	2.6	33
1399	Occurrence of Stridor During Sleep in a Patient With Spinocerebellar Ataxia Type 17. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 153-155.	2.6	6
1400	A COMMUNICATION AID SYSTEM BY FEATURE EXTRACTION OF ELECTROOCULOGRAPHIC SIGNALS. <i>Biomedical Engineering - Applications, Basis and Communications</i> , 2019, 31, 1950048.	0.6	2
1401	Epigallocatechin gallate in multiple system atrophy (PROMESA). <i>Annals of Translational Medicine</i> , 2019, 7, S278-S278.	1.7	0
1402	Multiple system atrophy and myoclonus. <i>Neurology</i> , 2019, 93, 287-288.	1.1	0

#	ARTICLE	IF	CITATIONS
1403	Development of a Non-Contact Nurse Call System by Image Processing of Eye Movement. Transactions of the Institute of Systems Control and Information Engineers, 2019, 32, 16-23.	0.1	1
1404	Various Motor and Non-Motor Symptoms in Early Multiple System Atrophy. Neurodegenerative Diseases, 2019, 19, 238-243.	1.4	14
1405	Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism. Mayo Clinic Proceedings, 2019, 94, 1825-1831.	3.0	4
1406	Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism and Related Disorders, 2019, 67, 27-33.	2.2	21
1407	Enfermedades cerebelosas. Medicine, 2019, 12, 4527-4536.	0.0	0
1408	A patient clinically diagnosed as multiple system atrophy harboring LRRK2 p.G2019S. Clinical Parkinsonism & Related Disorders, 2019, 1, 100-101.	0.9	2
1409	Recognizing and treating atypical Parkinson disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 301-320.	1.8	10
1410	How to approach a patient with parkinsonism â€“ red flags for atypical parkinsonism. International Review of Neurobiology, 2019, 149, 1-34.	2.0	4
1411	Classification of atypical parkinsonism per pathology versus phenotype. International Review of Neurobiology, 2019, 149, 37-47.	2.0	10
1412	Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192.	2.0	74
1413	Genetic mimics of the non-genetic atypical parkinsonian disorders â€“ the â€˜atypicalâ€™ atypical. International Review of Neurobiology, 2019, 149, 327-351.	2.0	8
1414	Differential value of brain magnetic resonance imaging in multiple system atrophy cerebellar phenotype and spinocerebellar ataxias. Scientific Reports, 2019, 9, 17329.	3.3	19
1415	Is ¹²³ I-MIBG Scintigraphy Beneficial or Excessive for the Diagnosis of Parkinsonâ€™s Disease in the Early Phase?. Neurodegenerative Diseases, 2019, 19, 88-95.	1.4	4
1416	Neuroimaging in Vascular Parkinsonism. Current Neurology and Neuroscience Reports, 2019, 19, 102.	4.2	12
1417	Diffusion Tensor Magnetic Resonance Imaging for Differentiating Multiple System Atrophy Cerebellar Type and Spinocerebellar Ataxia Type 3. Brain Sciences, 2019, 9, 354.	2.3	13
1418	Ocular motor manifestations of movement disorders. Current Opinion in Ophthalmology, 2019, 30, 443-448.	2.9	5
1419	Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (United States), 2019, 98, e16603.	1.0	6
1420	A 3D Deep Residual Convolutional Neural Network for Differential Diagnosis of Parkinsonian Syndromes on ¹⁸ F-FDG PET Images. , 2019, 2019, 3531-3534.		14

#	ARTICLE	IF	CITATIONS
1421	<p>Differential Diagnosis Of Multiple-System Atrophy With Parkinsonâ€™s Disease By External Anal- And Urethral-Sphincter Electromyography</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3061-3067.	2.2	5
1422	Anesthesia in Patients With Multiple-System Atrophy: A Narrative Review and Practice Guidance. A&A Practice, 2019, 12, 176-179.	0.4	3
1423	Quantitative autonomic function test in differentiation of multiple system atrophy from idiopathic Parkinson disease. Chinese Medical Journal, 2019, 132, 1919-1924.	2.3	3
1424	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
1425	Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes. Clinical Nuclear Medicine, 2019, 44, 282-288.	1.3	22
1426	Comparison of gait parameters between drug-naïve patients diagnosed with multiple system atrophy with predominant parkinsonism and Parkinson's disease. Parkinsonism and Related Disorders, 2019, 60, 87-91.	2.2	7
1427	REM Sleep Behavior Disorder Associated with Parkinsonâ€™s Disease and Multiple System Atrophy. , 2019, , 53-65.		2
1428	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. Parkinsonism and Related Disorders, 2019, 59, 93-100.	2.2	29
1429	Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. Movement Disorders, 2019, 34, 396-405.	3.9	252
1430	What Is Behind Cerebellar Vertigo and Dizziness?. Cerebellum, 2019, 18, 320-332.	2.5	52
1431	The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement Disorders, 2019, 34, 246-254.	3.9	46
1432	Network Imaging in Parkinsonian and Other Movement Disorders: Network Dysfunction and Clinical Correlates. International Review of Neurobiology, 2019, 144, 143-184.	2.0	6
1433	Quantifying apraxia and ophthalmokinetic abnormalities in patients with atypical Parkinsonism: A new way to differential diagnosis?. Parkinsonism and Related Disorders, 2019, 61, 39-44.	2.2	2
1434	MIBG myocardial scintigraphy in progressive supranuclear palsy. Journal of the Neurological Sciences, 2019, 396, 3-7.	0.6	4
1435	Oligodendroglial Î±-synucleinopathy-driven neuroinflammation in multiple system atrophy. Brain Pathology, 2019, 29, 380-396.	4.1	50
1436	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Molecular Neurobiology, 2019, 56, 5067-5074.	4.0	7
1437	Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases. Parkinsonism and Related Disorders, 2019, 61, 82-87.	2.2	81
1438	An update on advances in magnetic resonance imaging of multiple system atrophy. Journal of Neurology, 2019, 266, 1036-1045.	3.6	47

#	ARTICLE	IF	CITATIONS
1439	Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker?. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 132-137.	2.2	16
1440	Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 74-81.	2.2	8
1441	MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. <i>Neurological Research</i> , 2019, 41, 110-117.	1.3	13
1442	Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. <i>Hypertension</i> , 2019, 73, 235-241.	2.7	25
1443	Altered structural connectivity of the motor subnetwork in multiple system atrophy with cerebellar features. <i>European Radiology</i> , 2019, 29, 2783-2791.	4.5	8
1444	Parkinson's Disease. <i>Medical Clinics of North America</i> , 2019, 103, 337-350.	2.5	269
1445	Stridor-related gray matter alterations in multiple system atrophy: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 226-230.	2.2	6
1446	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 82-92.	2.2	22
1447	Prevalence of pain in atypical parkinsonism: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2019, 266, 2093-2102.	3.6	12
1448	Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 105-110.	2.2	11
1449	Available and future treatments for atypical parkinsonism. A systematic review. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 159-174.	3.9	22
1451	The Diagnosis of Parkinson's Disease: Current Clinical Practice and Future Trends. , 2019, , 103-116.		1
1452	Progress in the treatment of Parkinson-Plus syndromes. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 101-110.	2.2	6
1453	Effects of anodal tDCS on motor and cognitive function in a patient with multiple system atrophy. <i>Disability and Rehabilitation</i> , 2020, 42, 887-891.	1.8	7
1454	Parkinsonism and dysautonomia: Multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 146-149.	2.2	1
1455	Progression of Oropharyngeal Dysphagia in Patients with Multiple System Atrophy. <i>Dysphagia</i> , 2020, 35, 24-31.	1.8	18
1456	Parkinsonism and dysautonomia: Multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 150-151.	2.2	1
1457	Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant. <i>Journal of Neurology</i> , 2020, 267, 87-94.	3.6	24

#	ARTICLE	IF	CITATIONS
1458	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	6.4	61
1459	Relationship of substantia nigra hyperechogenicity to risk of Lewy body disease in idiopathic REM sleep behavior disorder patients: a longitudinal study. <i>Sleep Medicine</i> , 2020, 68, 31-34.	1.6	10
1460	Noninvasive and quantitative evaluation of movement disorder disability using an infrared depth sensor. <i>Journal of Clinical Neuroscience</i> , 2020, 71, 135-140.	1.5	6
1461	Falls in Synucleinopathies. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 30-43.	0.5	7
1462	Vocal Fold "Paralysis": An Early Sign in Multiple System Atrophy. <i>Journal of Voice</i> , 2020, 34, 940-944.	1.5	4
1463	Cerebrospinal fluid levels of alpha-synuclein, amyloid β^2 , tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. <i>Neuroscience Letters</i> , 2020, 715, 134564.	2.1	8
1464	Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study. <i>Neuroepidemiology</i> , 2020, 54, 58-63.	2.3	4
1465	A diagnostic ceiling for exome sequencing in cerebellar ataxia and related neurological disorders. <i>Human Mutation</i> , 2020, 41, 487-501.	2.5	58
1466	Thirty Years of Multiple System Atrophy (1989-2019): Are We Better at Diagnosing It Than Previously?. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 175-176.	1.5	1
1467	Serum adiponectin levels between patients with Parkinson's disease and those with PSP. <i>Neurological Sciences</i> , 2020, 41, 1125-1131.	1.9	5
1468	Cerebellar Dizziness and Vertigo: Etiologies, Diagnostic Assessment, and Treatment. <i>Seminars in Neurology</i> , 2020, 40, 087-096.	1.4	17
1469	Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116627.	0.6	6
1470	Vocal cord electromyographic correlates of stridor in multiple system atrophy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 31-35.	2.2	6
1471	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377.	9.0	94
1472	Evolution of neuropsychological profile in motor subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 67-73.	2.2	23
1473	Longitudinal study of striatal aromatic l-amino acid decarboxylase activity in patients with idiopathic rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2020, 68, 50-56.	1.6	8
1474	Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2020, 10, 123-130.	2.8	14
1475	Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 2, 20-24.	0.9	1

#	ARTICLE	IF	CITATIONS
1476	Evolving concepts on bradykinesia. <i>Brain</i> , 2020, 143, 727-750.	7.6	120
1477	Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord?. <i>Journal of Neurology</i> , 2020, 267, 659-664.	3.6	28
1478	Clinical features of multiple system atrophy with or without rapid eye movement behavior disorder: a cross-sectional study in southwest China. <i>Clinical Autonomic Research</i> , 2020, 30, 239-245.	2.5	3
1479	Pathological changes in the cerebellum of patients with multiple system atrophy and Parkinson's disease—a stereological study. <i>Brain Pathology</i> , 2020, 30, 576-588.	4.1	10
1480	Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 522-545.	3.2	72
1481	Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. <i>Cells</i> , 2020, 9, 2.	4.1	15
1482	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. <i>Journal of Neurology</i> , 2020, 267, 1097-1102.	3.6	5
1483	Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using α -Synuclein and External Anal Sphincter Electromyography. <i>Frontiers in Neurology</i> , 2020, 11, 1043.	2.4	10
1484	Contribution of Five Functional Loci of Dopamine Metabolism-Related Genes to Parkinson's Disease and Multiple System Atrophy in a Chinese Population. <i>Frontiers in Neuroscience</i> , 2020, 14, 889.	2.8	3
1485	Serum TNF- α and neurodegeneration in isolated REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 1-7.	2.2	7
1486	Comparison of 123I-MIBG scintigraphy and phosphorylated α -synuclein skin deposits in synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 48-53.	2.2	22
1487	Cell-free amplification of prions: Where do we stand?. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 175, 325-358.	1.7	7
1488	Sex differences in movement disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 175, 275-282.	1.8	7
1489	Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	20
1490	Relationship between tongue pressure and functional oral intake scale diet type in patients with neurological and neuromuscular disorders. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106196.	1.4	7
1491	Transplantation of Adipose-Derived Stem Cells Alleviates Striatal Degeneration in a Transgenic Mouse Model for Multiple System Atrophy. <i>Cell Transplantation</i> , 2020, 29, 096368972096018.	2.5	1
1492	Mean Apparent Propagator MRI Is Better Than Conventional Diffusion Tensor Imaging for the Evaluation of Parkinson's Disease: A Prospective Pilot Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 563595.	3.4	26
1493	Clarification of undiagnosed ataxia using whole-exome sequencing with clinical implications. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 58-64.	2.2	12

#	ARTICLE	IF	CITATIONS
1494	Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. <i>Scientific Reports</i> , 2020, 10, 15761.	3.3	21
1496	Restâ€Activity Pattern Alterations in Idiopathic REM Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2020, 88, 817-829.	5.3	19
1497	<scp>MicroRNA</scp> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. <i>Movement Disorders</i> , 2020, 35, 1873-1879.	3.9	15
1498	Intrafamilial phenotypic variation in spinocerebellar ataxia type 23. <i>Cerebellum and Ataxias</i> , 2020, 7, 7.	1.9	2
1499	Sacral Reflex Characteristics of Patients with Multiple System Atrophy. <i>Parkinson's Disease</i> , 2020, 2020, 1-7.	1.1	1
1500	Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 38-43.	2.2	10
1501	MR imaging and spectroscopy in degenerative ataxias: toward multimodal, multisite, multistage monitoring of neurodegeneration. <i>Current Opinion in Neurology</i> , 2020, 33, 451-461.	3.6	13
1502	Neurovestibular Dysfunction and Falls in Parkinson's Disease and Atypical Parkinsonism: A Prospective 1 Year Follow-Up Study. <i>Frontiers in Neurology</i> , 2020, 11, 580285.	2.4	13
1503	Association of mitochondrial genomic background with risk of Multiple System Atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 200-204.	2.2	4
1504	Validation of the new index of baroreflex function to identify neurogenic orthostatic hypotension. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2020, 229, 102744.	2.8	10
1505	Morphology and signal changes of the lentiform nucleus based on susceptibility weighted imaging in parkinsonism-predominant multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 194-199.	2.2	5
1506	Cognitive Profile and Its Evolution in a Cohort of Multiple System Atrophy Patients. <i>Frontiers in Neurology</i> , 2020, 11, 537360.	2.4	14
1507	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , 2020, 20, 432.	1.8	15
1508	MRI-Based Radiomics of Basal Nuclei in Differentiating Idiopathic Parkinsonâ€™s Disease From Parkinsonian Variants of Multiple System Atrophy: A Susceptibility-Weighted Imaging Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 587250.	3.4	19
1509	Unsupervised clustering of dopamine transporter <scp>PET</scp> imaging discovers heterogeneity of parkinsonism. <i>Human Brain Mapping</i> , 2020, 41, 4744-4752.	3.6	9
1510	Defining and predicting transdiagnostic categories of neurodegenerative disease. <i>Nature Biomedical Engineering</i> , 2020, 4, 787-800.	22.5	22
1511	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
1512	Current Management and Emerging Therapies in Multiple System Atrophy. <i>Neurotherapeutics</i> , 2020, 17, 1582-1602.	4.4	11

#	ARTICLE	IF	CITATIONS
1513	Orofacial dystonia and associated bulbar symptoms in multiple system atrophy: A blinded video analysis. <i>Journal of the Neurological Sciences</i> , 2020, 417, 116992.	0.6	6
1514	Cerebrospinal Fluid Biomarkers in Parkinson's Disease: A Critical Overview of the Literature and Meta-Analyses. <i>Brain Sciences</i> , 2020, 10, 466.	2.3	26
1515	The specific pattern of retinal nerve fiber layer thinning in Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2021, 268, 4023-4032.	3.6	18
1516	Elevated Percentage of CD3+ T-Cells and CD4+/CD8+ Ratios in Multiple System Atrophy Patients. <i>Frontiers in Neurology</i> , 2020, 11, 658.	2.4	13
1517	Bilateral middle cerebellar peduncle lesions: Neuroimaging features and differential diagnoses. <i>Brain and Behavior</i> , 2020, 10, e01778.	2.2	12
1518	Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?. <i>Movement Disorders</i> , 2020, 35, 2174-2183.	3.9	26
1519	Plasma immune markers in an idiopathic REM sleep behavior disorder cohort. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 145-150.	2.2	22
1520	Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. <i>Acta Neuropathologica Communications</i> , 2020, 8, 117.	5.2	43
1521	Difference in cardiovascular response during orthostatic stress in Parkinson's disease and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 1377-1386.	2.8	1
1522	Differential value of external anal- and urethral-sphincter electromyography in multiple system atrophy cerebellar type and spinocerebellar ataxias. <i>Journal of Clinical Neuroscience</i> , 2020, 80, 16-22.	1.5	3
1523	Early decrease in intermediate monocytes in peripheral blood is characteristic of multiple system atrophy-cerebellar type. <i>Journal of Neuroimmunology</i> , 2020, 349, 577395.	2.3	5
1524	Cortical hypometabolism associated with cognitive impairment of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 151-156.	2.2	9
1525	The Use of FDG PET Parametric Imaging in the Diagnosis of Olivopontocerebellar Atrophy. <i>Clinical Nuclear Medicine</i> , 2020, 45, e419-e421.	1.3	3
1526	Changes of Amide Proton Transfer Imaging in Multiple System Atrophy Parkinsonism Type. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 572421.	3.4	2
1527	Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies. <i>Clinical Medicine Insights: Cardiology</i> , 2020, 14, 117954682095341.	1.8	8
1528	Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy. <i>Brain and Behavior</i> , 2020, 10, e01827.	2.2	20
1529	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 21.	5.3	17
1530	Commentary: Discriminating α -synuclein strains in parkinson's disease and multiple system atrophy. <i>Frontiers in Neuroscience</i> , 2020, 14, 802.	2.8	1

#	ARTICLE	IF	CITATIONS
1531	Cut metagenomics-derived genes as potential biomarkers of Parkinson's disease. <i>Brain</i> , 2020, 143, 2474-2489.	7.6	72
1532	Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 18-25.	2.2	12
1533	Inflammatory cytokine levels in multiple system atrophy. <i>Medicine (United States)</i> , 2020, 99, e21509.	1.0	0
1534	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
1535	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in Synucleinopathies. <i>Movement Disorders</i> , 2020, 35, 2333-2338.	3.9	8
1536	Assessment of ¹⁸ F-FI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
1537	Biallelic Intronic AAGGG Expansion of RFC1 is Related to Multiple System Atrophy. <i>Annals of Neurology</i> , 2020, 88, 1132-1143.	5.3	41
1538	A Phase 1 Randomized Trial of Specific Active Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1957-1965.	3.9	53
1539	Autonomic Dysfunction in the Synucleinopathies. <i>Seminars in Neurology</i> , 2020, 40, 492-501.	1.4	17
1540	Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	45
1541	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. <i>Npj Parkinson's Disease</i> , 2020, 6, 39.	5.3	8
1542	Resting Heart Rate Variability Is Associated With Subsequent Orthostatic Hypotension: Comparison Between Healthy Older People and Patients With Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 567984.	2.4	7
1543	Quantification of Blood Caffeine Levels in Patients With Parkinson's Disease and Multiple System Atrophy by Caffeine ELISA. <i>Frontiers in Neurology</i> , 2020, 11, 580127.	2.4	7
1544	Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2450-2460.	3.7	16
1545	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	2.4	65
1546	Corticospinal Tract Impairment of Patients With Parkinson's Disease: Triple Stimulation Technique Findings. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 588085.	3.4	5
1547	Iron deposition in Parkinsonisms: A Quantitative Susceptibility Mapping study in the deep grey matter. <i>European Journal of Radiology</i> , 2020, 133, 109394.	2.6	15
1549	Reduced dopamine transporter binding predicts early transition to Lewy body disease in Japanese patients with idiopathic rapid eye movement sleep behavior disorder. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116821.	0.6	13

#	ARTICLE	IF	CITATIONS
1550	Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. <i>Neurology: Clinical Practice</i> , 2020, 10, 7-14.	1.6	15
1551	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β -amyloid ₄₂ , total-tau, phospho-tau and α -synuclein in the differential diagnosis of neurodegenerative dementia. <i>Journal of Neurology</i> , 2020, 267, 2567-2581.	3.6	6
1552	Neuropathological findings in multiple system atrophy with cognitive impairment. <i>Journal of Neural Transmission</i> , 2020, 127, 1031-1039.	2.8	13
1553	Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation. <i>Clinical Autonomic Research</i> , 2020, 30, 255-263.	2.5	10
1554	Cerebrovascular pathology and misdiagnosis of multiple system atrophy: An autopsy study. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 34-40.	2.2	8
1555	Propagation of Pathological α -Synuclein from the Urogenital Tract to the Brain Initiates MSA-like Syndrome. <i>IScience</i> , 2020, 23, 101166.	4.1	18
1556	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020, 143, 1780-1797.	7.6	66
1557	Evidence of distinct α -synuclein strains underlying disease heterogeneity. <i>Acta Neuropathologica</i> , 2021, 142, 73-86.	7.7	56
1558	An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention. <i>Journal of Neurology</i> , 2020, 267, 2754-2770.	3.6	25
1559	Is There a Difference in Autonomic Dysfunction Between Multiple System Atrophy Subtypes?. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 405-412.	1.5	8
1560	loflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	3.6	12
1561	Sleep-Induced Glottis Closure in Multiple System Atrophy Evaluated by Four-Dimensional Computed Tomography. <i>Frontiers in Medicine</i> , 2020, 7, 132.	2.6	6
1562	The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 97-104.	2.2	38
1563	Infections or Sepsis Preceding Clinically Diagnosed α -Synucleinopathies : A Case-Control Study. <i>Movement Disorders</i> , 2020, 35, 1684-1689.	3.9	3
1564	Cerebellar Atrophy in Multiple System Atrophy (Cerebellar Type) and Its Implication for Network Connectivity. <i>Cerebellum</i> , 2020, 19, 636-644.	2.5	5
1565	Asymmetry index of Blink Reflex Recovery Cycle differentiates Parkinson's disease from atypical Parkinsonian syndromes. <i>Journal of Neurology</i> , 2020, 267, 1859-1863.	3.6	6
1566	Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 901-902.	3.9	0
1567	Which Autonomic Features Distinguish Multiple System Atrophy and When. <i>Movement Disorders</i> , 2020, 35, 902-903.	3.9	0

#	ARTICLE	IF	CITATIONS
1568	The importance of brain banking for dementia practice: the first experience of Turkey. <i>Cell and Tissue Banking</i> , 2020, 21, 367-375.	1.1	5
1569	Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. <i>Neurological Sciences</i> , 2020, 41, 3633-3641.	1.9	0
1570	Parkinson's disease or atypical parkinsonism? The importance of acoustic voice analysis in differential diagnosis of speech disorders. <i>Brain and Behavior</i> , 2020, 10, e01700.	2.2	17
1571	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1171-1184.	2.8	6
1572	Appropriate assessment method of 123I-MIBG myocardial scintigraphy for the diagnosis of Lewy body diseases and idiopathic REM sleep behavior disorder. <i>Journal of Neurology</i> , 2020, 267, 3248-3257.	3.6	5
1573	Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116927.	0.6	8
1574	Association Between Vitamins and Amyotrophic Lateral Sclerosis: A Center-Based Survey in Mainland China. <i>Frontiers in Neurology</i> , 2020, 11, 488.	2.4	20
1575	<scp>Alpha-Synuclein</scp> Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. <i>Annals of Neurology</i> , 2020, 88, 503-512.	5.3	78
1576	Predicting phenoconversion in pure autonomic failure. <i>Neurology</i> , 2020, 95, e889-e897.	1.1	36
1577	Skin Biopsy May Help to Distinguish Multiple System Atrophy's Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. <i>Movement Disorders</i> , 2020, 35, 1649-1657.	3.9	50
1578	A New Statistical Framework for Corpus Callosum Sub-Region Characterization Based on LBP Texture in Patients With Parkinsonian Disorders: A Pilot Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 477.	2.8	5
1579	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 355-356.	2.5	6
1580	Effects of gender on cognitive and behavioral manifestations in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 925-934.	2.8	10
1581	Dysphagia Affecting Quality of Life in Cerebellar Ataxia—a Large Survey. <i>Cerebellum</i> , 2020, 19, 437-445.	2.5	21
1582	Dysarthria enhancement mechanism under external clear speech instruction in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 905-914.	2.8	7
1583	Epigenetic modulation of ARL1 and increased HLA expression in brains of multiple system atrophy patients. <i>Acta Neuropathologica Communications</i> , 2020, 8, 29.	5.2	19
1584	Central auditory processing in parkinsonian disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 111-132.	6.1	12
1585	Immunotherapies in Huntington's disease and α -Synucleinopathies. <i>Frontiers in Immunology</i> , 2020, 11, 337.	4.8	23

#	ARTICLE	IF	CITATIONS
1586	Relationship between cardiac parasympathetic dysfunction and the anteroposterior diameter of the medulla oblongata in multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 231-238.	2.5	7
1587	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. <i>Clinica Chimica Acta</i> , 2020, 506, 55-66.	1.1	2
1588	Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder. <i>Clinical Autonomic Research</i> , 2020, 30, 207-213.	2.5	23
1589	No biallelic intronic AAGGG repeat expansion in RFC1 was found in patients with late-onset ataxia and MSA. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 1-2.	2.2	29
1590	Phenoconversion from rapid eye movement sleep behaviour disorder to multiple system atrophy is predicted by abnormal dopamine transporter imaging combined with normal ¹²³ I- β -metaiodobenzylguanidine myocardial scintigraphy: a case report. <i>Psychogeriatrics</i> , 2020, 20, 807-809.	1.2	1
1591	Diagnosing multiple system atrophy at the prodromal stage. <i>Clinical Autonomic Research</i> , 2020, 30, 197-205.	2.5	17
1592	Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2021, 268, 2703-2712.	3.6	23
1593	Neurogenic lower urinary tract dysfunction predicts prognosis in patients with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 247-254.	2.5	11
1594	<i>In vivo</i> signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder. <i>European Journal of Neurology</i> , 2020, 27, 1285-1295.	3.3	17
1595	Non-Invasive Cerebellar Stimulation in Neurodegenerative Ataxia: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1948.	4.1	39
1596	Urate is closely linked to white matter integrity in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1029-1039.	3.7	4
1597	Transcriptomic differences in MSA clinical variants. <i>Scientific Reports</i> , 2020, 10, 10310.	3.3	7
1598	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	3.6	17
1599	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020, 88, 643-645.	5.3	27
1600	Design and Operation of the Lombardy Parkinson's Disease Network. <i>Frontiers in Neurology</i> , 2020, 11, 573.	2.4	3
1601	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 107-109.	2.2	3
1602	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 57-63.	2.2	18
1603	Is Ross Syndrome a New Type of Synucleinopathy? A Brief Research Report. <i>Frontiers in Neuroscience</i> , 2020, 14, 635.	2.8	4

#	ARTICLE	IF	CITATIONS
1604	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105924.	1.4	3
1605	Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes. <i>Clinical Neurophysiology</i> , 2020, 131, 2200-2208.	1.5	4
1606	Positron emission computed tomography/single photon emission computed tomography in Parkinson disease. <i>Chinese Medical Journal</i> , 2020, 133, 1448-1455.	2.3	6
1607	The Characteristics of Tremor Motion Help Identify Parkinson's Disease and Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2020, 11, 540.	2.4	4
1609	Changes in clinical features of multiple system atrophy in Japan. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100054.	0.9	0
1610	Traumatic brain injury preceding clinically diagnosed α -synucleinopathies. <i>Neurology</i> , 2020, 94, e764-e773.	1.1	10
1611	<scp>Laterâ€œOnset</scp> Multiple System Atrophy: A Multicenter Asian Study. <i>Movement Disorders</i> , 2020, 35, 1692-1693.	3.9	13
1612	A comparison of auditory and vestibular dysfunction in Parkinson's disease and Multiple System Atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 51-57.	2.2	20
1613	Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study. <i>Journal of Neurology</i> , 2020, 267, 855-859.	3.6	3
1614	Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions. <i>Translational Neurodegeneration</i> , 2020, 9, 7.	8.0	39
1615	Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. <i>Neuroscience Letters</i> , 2020, 722, 134826.	2.1	4
1616	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	3.1	42
1617	The discriminative capacity of CSF β -amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116756.	0.6	14
1618	Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 49-55.	2.2	12
1619	Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. <i>Neurobiology of Disease</i> , 2020, 139, 104813.	4.4	49
1620	Characterizing vocal tremor in progressive neurological diseases via automated acoustic analyses. <i>Clinical Neurophysiology</i> , 2020, 131, 1155-1165.	1.5	18
1621	Heightened risk of early vocal fold motion impairment onset and dysphagia in the parkinsonian variant of multiple system atrophy: a comparative study. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100037.	0.9	1
1622	Generation and Characterization of Novel Monoclonal Antibodies Targeting α 62/sequestosome-1 Across Human Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 407-418.	1.7	8

#	ARTICLE	IF	CITATIONS
1623	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	3.7	31
1624	Spiral drawing: Quantitative analysis and artificial-intelligence-based diagnosis using a smartphone. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116723.	0.6	12
1625	Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 307-317.	3.7	22
1626	MSA: From basic mechanisms to experimental therapeutics. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 94-104.	2.2	13
1627	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α -synucleinopathy. <i>Journal of Neuroinflammation</i> , 2020, 17, 35.	7.2	11
1628	Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 254-262.	1.9	22
1629	Prominent White Matter Involvement in Multiple System Atrophy of Cerebellar Type. <i>Movement Disorders</i> , 2020, 35, 816-824.	3.9	15
1630	Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria. <i>Journal of Neurology</i> , 2020, 267, 1269-1277.	3.6	23
1631	Urodynamic and gait analyses in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116676.	0.6	3
1632	Prevalence and characterisation of vocal fold motion impairment (VFMI) in patients with Multiple system atrophy compared with Parkinson's disease. <i>Revue Neurologique</i> , 2020, 176, 608-613.	1.5	5
1633	Vertical pons hyperintensity and hot cross bun sign in cerebellar-type multiple system atrophy and spinocerebellar ataxia type 3. <i>BMC Neurology</i> , 2020, 20, 157.	1.8	12
1634	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	6.2	96
1635	The structural differences between patient-derived α -synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020, 139, 977-1000.	7.7	149
1636	Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1388-1395.	3.9	15
1637	Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. <i>Movement Disorders</i> , 2020, 35, 1438-1447.	3.9	8
1638	Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. <i>Neurology</i> , 2020, 94, e1828-e1834.	1.1	33
1639	Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 720-729.	1.9	148
1640	Repeat expansion scanning of the <i>NOTCH2NL</i> gene in patients with multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 517-526.	3.7	67

#	ARTICLE	IF	CITATIONS
1641	Theory of Mind in multiple system atrophy: comparison with Parkinson's disease and healthy subjects. <i>Journal of Neural Transmission</i> , 2020, 127, 915-923.	2.8	4
1642	The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population. <i>Neurological Sciences</i> , 2020, 41, 2531-2537.	1.9	6
1643	Sympathetic outflow to skin predicts central autonomic dysfunction in multiple system atrophy. <i>Neurological Sciences</i> , 2020, 41, 2241-2248.	1.9	5
1644	Impact of depressive symptoms on self-perceived severity of autonomic dysfunction in multiple system atrophy: relevance for patient-reported outcomes in clinical trials. <i>Clinical Autonomic Research</i> , 2020, 30, 215-221.	2.5	11
1645	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	2.2	15
1646	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. <i>Brain Pathology</i> , 2020, 30, 766-778.	4.1	19
1647	Multiple system atrophy: the nature of the beast revisited. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 3-4.	1.9	6
1648	Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2775.	4.1	17
1649	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns based approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2901-2910.	6.4	23
1650	Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. <i>Acta Neuropathologica</i> , 2020, 140, 49-62.	7.7	218
1651	Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. <i>Nature Genetics</i> , 2020, 52, 482-493.	21.4	216
1652	<i>RFC1</i> Intronic Repeat Expansions Absent in Pathologically Confirmed Multiple Systems Atrophy. <i>Movement Disorders</i> , 2020, 35, 1277-1279.	3.9	26
1653	Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. <i>Acta Neuropathologica Communications</i> , 2020, 8, 39.	5.2	28
1654	Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival. <i>Movement Disorders</i> , 2020, 35, 1462-1466.	3.9	5
1655	Multiple system atrophy mimicry in MRI: Watch out for paraneoplastic rhombencephalitis. <i>Journal of Clinical Neuroscience</i> , 2020, 76, 238-240.	1.5	6
1656	Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1163-1172.	3.9	12
1657	Possible "Premotor" Multiple System Atrophy-Cerebellar Form. <i>European Neurology</i> , 2020, 83, 80-86.	1.4	8
1658	DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB. <i>Neurobiology of Aging</i> , 2020, 93, 143.e5-143.e7.	3.1	3

#	ARTICLE	IF	CITATIONS
1659	The clinical application of nigrosome 1 detection on high-resolution susceptibility-weighted imaging in the evaluation of suspected Parkinsonism: The real-world performance and pitfalls. PLoS ONE, 2020, 15, e0231010.	2.5	3
1660	The Dysfunctional Autonomic Function and "Dysfunctional" Fatigue in Drug Naïve Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 605-612.	2.8	7
1661	Assessment and Rating of Motor Cerebellar Ataxias With the Kinect v2 Depth Sensor: Extending Our Appraisal. Frontiers in Neurology, 2020, 11, 179.	2.4	14
1662	Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism. Acta Radiologica, 2021, 62, 234-242.	1.1	9
1663	Esophageal Dysmotility is Common in Patients With Multiple System Atrophy. Laryngoscope, 2021, 131, 832-838.	2.0	2
1664	3-Hz Postural Tremor in MSA-C and SCA: Revisiting an Old but Underestimated Cerebellar Sign by Posturography. Cerebellum, 2021, 20, 246-253.	2.5	2
1665	Accuracy of death certificates for recording parkinsonian syndromes and associated dementia. Journal of Neurology, 2021, 268, 140-146.	3.6	9
1666	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. American Journal of Geriatric Psychiatry, 2021, 29, 375-383.	1.2	36
1667	No genetic evidence for the involvement of GGC repeat expansions of the NOTCH2NLC gene in Chinese patients with multiple system atrophy. Neurobiology of Aging, 2021, 97, 144.e5-144.e7.	3.1	5
1668	Low Prevalence of NOTCH2NLC GGC Repeat Expansion in White Patients with Movement Disorders. Movement Disorders, 2021, 36, 251-255.	3.9	23
1669	Diagnostic usefulness of putaminal abnormality on diffusion- and susceptibility-weighted imaging: two illustrative cases of multiple system atrophy-parkinsonian type. Neurological Sciences, 2021, 42, 1211-1213.	1.9	0
1670	Brain $5\text{-HT}_1\text{A}$ Receptor Binding in Multiple System Atrophy: An [^{18}F]MPPF PET Study. Movement Disorders, 2021, 36, 246-251.	3.9	15
1671	Cricopharyngeal bar on videofluoroscopy: high specificity for inclusion body myositis. Journal of Neurology, 2021, 268, 1016-1024.	3.6	9
1672	Broad white matter impairment in multiple system atrophy. Human Brain Mapping, 2021, 42, 357-366.	3.6	16
1673	Magnetic resonance imaging abnormalities as a marker of multiple system atrophy in isolated rapid eye movement sleep behavior disorder. Sleep, 2021, 44, .	1.1	9
1674	Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism. Movement Disorders, 2021, 36, 1-10.	3.9	49
1675	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	3.9	26
1676	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. European Radiology, 2021, 31, 4277-4284.	4.5	8

#	ARTICLE	IF	CITATIONS
1677	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 87-91.	2.2	16
1678	Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies. <i>European Journal of Neurology</i> , 2021, 28, 1210-1217.	3.3	9
1679	Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. <i>Neurobiology of Disease</i> , 2021, 148, 105184.	4.4	14
1680	Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 895-904.	3.9	31
1681	Atypical parkinsonian syndromes in a North African tertiary referral center. <i>Brain and Behavior</i> , 2021, 11, e01924.	2.2	5
1682	Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA) Trial. <i>Journal of Neurology</i> , 2021, 367, 1000-1006.	4.7	14
1683	The Profile and Evolution of Neuropsychiatric Symptoms in Multiple System Atrophy: Self- and Caregiver Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 124-131.	1.8	4
1684	Hypomethylation of SNCA in Idiopathic REM Sleep Behavior Disorder Associated With Phenoconversion. <i>Movement Disorders</i> , 2021, 36, 955-962.	3.9	4
1685	Mini-Review: The MSA transcriptome. <i>Neuroscience Letters</i> , 2021, 743, 135586.	2.1	6
1686	Quantitative Measurement of Cerebrospinal Fluid Amyloid- β^2 Species by Mass Spectrometry. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 573-584.	2.6	13
1687	Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 683-691.	2.6	6
1688	Identification of a pre-possible multiple system atrophy phase. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 313-317.	2.1	4
1689	Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting. <i>Movement Disorders</i> , 2021, 36, 460-470.	3.9	27
1690	Signs of early cellular dysfunction in multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 268-282.	3.2	16
1691	Conventional Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Disorders: A Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 217-223.	1.5	7
1692	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 241-245.	3.9	15
1693	Multiple System Atrophy. , 2021, , 1-29.		0
1694	Multiple System Atrophy. , 2021, , 261-271.		0

#	ARTICLE	IF	CITATIONS
1696	Hot cross bun sign: A case report of multiple system atrophy presenting predominantly as respiratory insufficiency. <i>Indian Journal of Respiratory Care</i> , 2021, 10, 148.	0.1	0
1697	Comprehensive functional evaluation of the spectrum of multi-system atrophy with ¹⁸ F-FDG PET/CT and ^{99m} Tc TRODAT-1 SPECT: 5 Year's experience from a tertiary care center. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 490.	0.5	3
1698	A Questionnaire-Based Study on Clinical REM Sleep Behavior Disorder and Subtypes in Multiple System Atrophy. <i>European Neurology</i> , 2021, 84, 368-374.	1.4	2
1699	Interrelationships between Survival, Sex, and Blood Pressure in Patients with Multiple System Atrophy. <i>Neuroepidemiology</i> , 2021, 55, 56-61.	2.3	3
1700	A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1833-1841.	6.4	15
1701	Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2021, 31, 117-125.	2.5	10
1702	Urinary dysfunction in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, , 209-249.	0.1	0
1703	Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 183, 175-196.	1.8	4
1704	The utility of susceptibility-weighted imaging in the diagnosis of multiple system atrophy, cerebellar type. <i>Journal of Medical Sciences (Taiwan)</i> , 2021, .	0.2	0
1705	Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease. <i>Neurology</i> , 2021, 96, e1369-e1382.	1.1	93
1706	Alpha-Synucleinopathies. , 2021, , 387-410.		0
1707	Management of Motor Symptoms in Dementia Disorders. , 2021, , 201-227.		1
1708	Pre-mutations in the FMR1 gene in Serbian patients with undetermined tremor, ataxia and parkinsonism. <i>Neurological Research</i> , 2021, 43, 321-326.	1.3	1
1709	Parkinsonian Dementias. , 2021, , 91-117.		0
1710	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 211-222.	1.8	3
1711	Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease. <i>Nature Medicine</i> , 2021, 27, 411-418.	30.7	160
1712	Hot cross bun is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. <i>Npj Parkinson's Disease</i> , 2021, 7, 15.	5.3	20
1713	Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features. <i>Internal Medicine</i> , 2021, 60, 367-372.	0.7	8

#	ARTICLE	IF	CITATIONS
1714	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.	6.2	12
1715	Sighs during sleep in multiple system atrophy. <i>Sleep Medicine</i> , 2021, 78, 75-80.	1.6	5
1716	Bullous Pemphigoid Associated with Multiple System Atrophy: Case Series. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 445-448.	1.5	2
1717	The hypointense substantia nigra sign. A novel MRI marker of progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117286.	0.6	1
1718	Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. <i>Clinical Neurophysiology</i> , 2021, 132, 666-682.	1.5	88
1719	Gastrointestinal dysfunction in movement disorders. <i>Neurological Sciences</i> , 2021, 42, 1355-1365.	1.9	11
1720	Variability of FP-CIT PET Patterns Associated With Clinical Features of Multiple System Atrophy. <i>Neurology</i> , 2021, 96, e1663-e1671.	1.1	6
1721	Comparison of 6-[18F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism. <i>EJNMMI Research</i> , 2021, 11, 16.	2.5	3
1722	RFC1-related ataxia is a mimic of early multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 444-446.	1.9	25
1723	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinson's Disease. <i>Biomedicines</i> , 2021, 9, 230.	3.2	12
1724	Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 years. <i>BMJ Open</i> , 2021, 11, e045100.	1.9	10
1725	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 647783.	2.8	17
1726	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.	7.6	2
1727	Morphological Changes in Cortical and Subcortical Structures in Multiple System Atrophy Patients With Mild Cognitive Impairment. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 649051.	2.0	10
1728	A study on the characteristics of cognitive function in patients with multiple system atrophy in China. <i>Scientific Reports</i> , 2021, 11, 4995.	3.3	8
1729	Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease. <i>Current Radiopharmaceuticals</i> , 2021, 14, 64-69.	0.8	5
1730	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism: Similarities and Differences. <i>Cells</i> , 2021, 10, 656.	4.1	25
1731	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	3.6	12

#	ARTICLE	IF	CITATIONS
1732	Cardiac ¹⁸ F- ¹⁸ F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 582-586.	1.5	15
1734	Sympathetic and sensory nerve fiber function in multiple system atrophy and idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 3435-3443.	3.6	8
1736	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	7.3	27
1737	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. <i>Drugs and Aging</i> , 2021, 38, 355-373.	2.7	8
1738	Biallelic RFC1-expansion in a French multicentric sporadic ataxia cohort. <i>Journal of Neurology</i> , 2021, 268, 3337-3343.	3.6	24
1739	Pathological laughter and crying in multiple system atrophy with different subtypes: Frequency and related factors. <i>Journal of Affective Disorders</i> , 2021, 283, 60-65.	4.1	1
1740	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811.	3.3	11
1741	Pharmacokinetics and pharmacodynamics of amprelosetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension. <i>Clinical Autonomic Research</i> , 2021, 31, 395-403.	2.5	5
1742	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	3.9	22
1743	Can novel non-invasive autonomic tests help discriminate between pure autonomic failure and multiple system atrophy?. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 231, 102773.	2.8	3
1744	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 82-90.	2.2	2
1745	My Treatment Approach to Multiple System Atrophy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 708-719.	3.0	12
1746	Local Passive Heat for the Treatment of Hypertension in Autonomic Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e018979.	3.7	18
1747	Case of Parkinsonism That Never Had a Good Response to Levodopa. , 2021, , 101-104.		0
1748	Elevated cerebral blood flow in patients with pure autonomic failure. <i>Clinical Autonomic Research</i> , 2021, 31, 405-414.	2.5	3
1749	Measurement and Correction of Stooped Posture during Gait Using Wearable Sensors in Patients with Parkinsonism: A Preliminary Study. <i>Sensors</i> , 2021, 21, 2379.	3.8	1
1751	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	1.5	7
1752	Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions. <i>Neuroradiology Journal</i> , 2021, 34, 263-288.	1.2	4

#	ARTICLE	IF	CITATIONS
1753	In Vivo Diagnosis of Synucleinopathies. <i>Neurology</i> , 2021, 96, e2513-e2524.	1.1	63
1754	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. <i>Movement Disorders</i> , 2021, 36, 1704-1711.	3.9	18
1755	Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort. <i>Journal of Parkinson's Disease</i> , 2021, 11, 811-819.	2.8	3
1756	High prevalence of serum anti-NH2-terminal of α -synuclein antibodies in patients with multiple system atrophy and corticobasal syndrome. <i>Journal of Neurology</i> , 2021, 268, 4291-4295.	3.6	6
1757	Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [¹¹ C]raclopride PET uptake and MRI grey matter morphometry. <i>Journal of Neural Engineering</i> , 2021, 18, 046037.	3.5	15
1758	The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 57-58.	2.2	1
1759	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86.	6.2	19
1760	Human alpha-synuclein overexpressing MBP29 mice mimic functional and structural hallmarks of the cerebellar subtype of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 68.	5.2	9
1761	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 8936.	3.3	24
1762	Early atypical signs and insula hypometabolism predict survival in multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 881-889.	1.9	12
1763	Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson's disease and multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3469-3481.	6.4	24
1764	Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3522-3529.	6.4	9
1765	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. <i>Brain</i> , 2021, 144, 1138-1151.	7.6	24
1766	Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 648531.	3.4	4
1767	Molecular Imaging of Neurodegenerative Parkinsonism. <i>PET Clinics</i> , 2021, 16, 261-272.	3.0	0
1768	Functional Connectome in Parkinson's Disease and Parkinsonism. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 24.	4.2	14
1769	Validation of α -Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes. <i>Movement Disorders</i> , 2021, 36, 2663-2669.	3.9	62
1770	Potential Fluid Biomarkers and a Prediction Model for Better Recognition Between Multiple System Atrophy-Cerebellar Type and Spinocerebellar Ataxia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 644699.	3.4	1

#	ARTICLE	IF	CITATIONS
1771	Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. <i>Journal of Parkinson's Disease</i> , 2021, 11, 685-694.	2.8	10
1772	Quantitative Cellular Changes in the Thalamus of Patients with Multiple System Atrophy. <i>Neuroscience</i> , 2021, 459, 142-152.	2.3	3
1773	The Utilization of Consensus Techniques in Education and Research in Medical Professions. <i>Journal of Prosthetics and Orthotics</i> , 2021, 33, 175-183.	0.4	2
1774	Cerebral Metabolism Related to Cognitive Impairments in Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2021, 12, 652059.	2.4	4
1775	Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors. <i>BMC Neurology</i> , 2021, 21, 181.	1.8	2
1776	A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117366.	0.6	3
1777	Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure. <i>Annals of Neurology</i> , 2021, 89, 1212-1220.	5.3	51
1778	The differential diagnostic value of a battery of oculomotor evaluation in Parkinson's Disease and Multiple System Atrophy. <i>Brain and Behavior</i> , 2021, 11, e02184.	2.2	13
1779	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132.	2.2	22
1780	Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis. <i>Behavioural Neurology</i> , 2021, 2021, 1-9.	2.1	4
1782	Radiomics on routine T1-weighted MRI can delineate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. <i>European Radiology</i> , 2021, 31, 8218-8227.	4.5	15
1783	Robust α -synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 80.	5.2	11
1784	Of Criteria and Men: Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach. <i>Brain Sciences</i> , 2021, 11, 695.	2.3	2
1785	The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Aggregates. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2021, 80, 514-529.	1.7	11
1786	Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases. <i>Neurologia</i> , 2021, , .	0.7	5
1787	Coronavirus disease 2019-associated worsening and improvement of ataxia and gait in a patient with multiple system atrophy. <i>Geriatrics and Gerontology International</i> , 2021, 21, 591-593.	1.5	0
1788	Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia. <i>Brain</i> , 2021, 144, 2310-2321.	7.6	38
1789	α -Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. <i>Acta Neuropathologica</i> , 2021, 142, 495-511.	7.7	80

#	ARTICLE	IF	CITATIONS
1790	Adult-onset Alexander disease mimicking multiple system atrophy predominant cerebellar ataxia. <i>Journal of Clinical Neuroscience</i> , 2021, 87, 150-152.	1.5	0
1791	¹²³ I-Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 717-724.	1.5	3
1792	Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 2075-2095.	3.3	22
1793	Clinical Utility of ¹⁸ F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2314-2323.	3.9	41
1794	Bereitschaftspotential in Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2021, 12, 608322.	2.4	0
1795	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	7.6	65
1796	Management of balance problems in an elderly with multiple system atrophy with predominant cerebellar ataxia (MSA-C) and sick sinus syndrome. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 208-210.	0.5	0
1797	The Role of Imaging Studies in Favor of Possible Cerebellar Multiple System Atrophy. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e603-e604.	1.3	0
1798	Quantitative Evaluation of Cerebellar Function in Multiple System Atrophy with Transcranial Magnetic Stimulation. <i>Cerebellum</i> , 2022, 21, 219-224.	2.5	3
1799	Rapid Eye Movement Sleep Behavior Disorder-like Symptoms Due to Arousal Responses Associated with Severe Obstructive Sleep Apnea-hypopnea. <i>Internal Medicine</i> , 2021, 60, 1775-1778.	0.7	0
1800	Premotor antidepressants use differs according to Parkinson's disease subtype: A cohort study. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 137-141.	2.2	0
1801	Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 628710.	2.4	3
1802	A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [18F]PM-PBB3 tau PET. <i>Journal of the Neurological Sciences</i> , 2021, 425, 117440.	0.6	9
1803	Phosphorylated α -synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis. <i>Neuroscience Letters</i> , 2021, 756, 135964.	2.1	9
1804	REM Sleep Behaviour Disorder in Multiple System Atrophy: From Prodromal to Progression of Disease. <i>Frontiers in Neurology</i> , 2021, 12, 677213.	2.4	14
1805	Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein. <i>Genes</i> , 2021, 12, 948.	2.4	10
1806	Neurodegenerative disorders affecting the autonomic nervous system: Pure autonomic failure and multiple system atrophy. <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.4	0
1807	Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 75-81.	2.2	11

#	ARTICLE	IF	CITATIONS
1808	Cerebrospinal fluid and plasma distribution of anti- α -synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 98-104.	2.2	13
1809	Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study. <i>Brain Sciences</i> , 2021, 11, 879.	2.3	1
1810	Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy. <i>Neurobiology of Disease</i> , 2021, 153, 105332.	4.4	17
1811	Fatigue prevalence and associated factors in patients with multiple system atrophy. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 553-558.	2.1	4
1812	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. <i>Journal of Neural Transmission</i> , 2021, 128, 1481-1494.	2.8	6
1813	The language profile in multiple system atrophy: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 1195-1203.	2.8	4
1815	The hot cross bun sign in corticobasal degeneration. <i>Neuropathology</i> , 2021, 41, 376-380.	1.2	4
1816	Very late-onset Friedreich's ataxia with rapid course mimicking as possible multiple system atrophy cerebellar type. <i>BMJ Case Reports</i> , 2021, 14, e242073.	0.5	1
1817	Reduction in Pulse Pressure during Standing Can Distinguish Neurogenic Orthostatic Hypotension. <i>Diagnostics</i> , 2021, 11, 1331.	2.6	0
1818	Systematic video-analysis of motor events during REM sleep in idiopathic REM sleep behavior disorder, follow-up and DAT-SPECT. <i>Sleep Medicine</i> , 2021, 83, 132-144.	1.6	9
1819	Diagnostic performance of T2* gradient echo, susceptibility-weighted imaging, and quantitative susceptibility mapping for patients with multiple system atrophy's parkinsonian type: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 308-318.	4.5	6
1820	Retina thickness in atypical parkinsonism: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2022, 269, 1272-1281.	3.6	4
1821	CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes. <i>Neurology: Clinical Practice</i> , 2021, 11, e867-e875.	1.6	2
1822	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. <i>European Neurology</i> , 2021, 84, 435-443.	1.4	5
1823	Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. <i>Scientific Reports</i> , 2021, 11, 14992.	3.3	14
1824	Imaging features associated with idiopathic normal pressure hydrocephalus have high specificity even when comparing with vascular dementia and atypical parkinsonism. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 35.	5.0	18
1825	Lower urinary tract dysfunction in Parkinsonian syndromes. <i>Neurological Sciences</i> , 2021, 42, 4045-4054.	1.9	6
1826	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1052-1060.	1.5	6

#	ARTICLE	IF	CITATIONS
1827	Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 632891.	3.4	14
1828	Transcranial sonography in differential diagnosis of Parkinson disease and other movement disorders. <i>Chinese Medical Journal</i> , 2021, 134, 1726-1731.	2.3	4
1829	Multiple system atrophy variant with severe hippocampal pathology. <i>Brain Pathology</i> , 2022, 32, e13002.	4.1	18
1830	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	2.8	4
1831	Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension. <i>Hypertension</i> , 2021, 78, 525-531.	2.7	9
1832	Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C. <i>BMC Neurology</i> , 2021, 21, 328.	1.8	5
1833	Novel Therapies for Parkinsonian Syndromes—Recent Progress and Future Perspectives. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 720220.	2.9	6
1834	Faster Region-Based Convolutional Neural Network in the Classification of Different Parkinsonism Patterns of the Striatum on Maximum Intensity Projection Images of [18F]FP-CIT Positron Emission Tomography. <i>Diagnostics</i> , 2021, 11, 1557.	2.6	5
1835	Neurophysiological evaluation of visual function in iRBD: potential role in stratifying RBD conversion risk. <i>Sleep Medicine</i> , 2021, 84, 26-31.	1.6	0
1836	Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: a pilot study. <i>Metabolic Brain Disease</i> , 2022, 37, 209-217.	2.9	11
1837	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 155-161.	2.2	12
1838	Disease-, region- and cell type specific diversity of α -synuclein carboxy terminal truncations in synucleinopathies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 146.	5.2	10
1839	Early recognition and diagnosis of multiple system atrophy: best practice and emerging concepts. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 993-1004.	2.8	6
1840	Differentiation of Cerebellum-Type and Parkinson-Type of Multiple System Atrophy by Using Multimodal MRI Parameters. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 687649.	3.4	1
1841	Association Between Globular Glial Tauopathies and Frontotemporal Dementia—Expanding the Spectrum of Gliocentric Disorders. <i>JAMA Neurology</i> , 2021, 78, 1004.	9.0	16
1842	Development of parkinsonism after long-standing cervical dystonia — A cohort. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117477.	0.6	10
1843	Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1167-1176.	2.8	14
1844	Nocturnal stridor in multiple system atrophy: Video-polysomnography and clinical features. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 48-53.	2.2	1

#	ARTICLE	IF	CITATIONS
1845	Reply to: "Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?" Movement Disorders, 2021, 36, 2000-2001.	3.9	0
1846	Postganglionic Sudomotor Dysfunction and Brain Glucose Hypometabolism in Patients with Multiple System Atrophy. Journal of Parkinson's Disease, 2021, 11, 1247-1256.	2.8	2
1848	Long-term MRI changes in a patient with Kelch-like protein 11-associated paraneoplastic neurological syndrome. European Journal of Neurology, 2021, 28, 4261-4266.	3.3	9
1849	Prevalence of Fragile X-Associated Tremor/Ataxia Syndrome in Patients with Cerebellar Ataxia in Japan. Cerebellum, 2022, 21, 851-860.	2.5	11
1850	Pathologic characterization of canine multiple system degeneration in the Ibizan hound. Veterinary Pathology, 2021, , 030098582110430.	1.7	1
1851	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. Journal of Neuroscience Research, 2021, 99, 2922-2931.	2.9	1
1852	Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy. Journal of Cellular and Molecular Medicine, 2021, 25, 9634-9646.	3.6	9
1853	Is Multiple System Atrophy a Prion-like Disorder?. International Journal of Molecular Sciences, 2021, 22, 10093.	4.1	12
1854	Measuring anxiety in Lewy Body Disease " which scale to choose?. Clinical Parkinsonism & Related Disorders, 2021, 5, 100110.	0.9	0
1855	Individual voxel-based morphometry adjusting covariates in multiple system atrophy. Parkinsonism and Related Disorders, 2021, 90, 114-119.	2.2	4
1856	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. Clinical Autonomic Research, 2021, 31, 713-717.	2.5	10
1857	Seizure prevalence in neurodegenerative diseases" a study of autopsy proven cases. European Journal of Neurology, 2022, 29, 12-18.	3.3	6
1858	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. Frontiers in Neurology, 2021, 12, 711358.	2.4	7
1859	The evaluation of the swallow tail sign in patients with parkinsonism and gait disorders. Journal of the Neurological Sciences, 2021, 428, 117581.	0.6	3
1860	Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies. Frontiers in Aging Neuroscience, 2021, 13, 717930.	3.4	10
1861	Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study. BioMedical Engineering OnLine, 2021, 20, 90.	2.7	5
1862	Serum Cystatin C as a Potential Predictor of the Severity of Multiple System Atrophy With Predominant Cerebellar Ataxia: A Case-Control Study in Chinese Population. Frontiers in Neuroscience, 2021, 15, 663980.	2.8	2
1864	Elderly-Onset Multiple System Atrophy with Lewy Body Pathology: A Case Report. Case Reports in Neurology, 2021, 13, 613-619.	0.7	0

#	ARTICLE	IF	CITATIONS
1865	Differentiating neurodegenerative parkinsonian syndromes using vestibular evoked myogenic potentials and balance assessment. <i>Clinical Neurophysiology</i> , 2021, 132, 2808-2819.	1.5	2
1866	Differentiation of multiple system atrophy subtypes by gray matter atrophy. <i>Journal of Neuroimaging</i> , 2021, , .	2.0	4
1867	Development of α -Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α -Synucleinopathies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 703984.	3.4	12
1868	Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2207-2208.	3.9	0
1869	Do patients with multiple system atrophy have decreased nocturnal urinary concentration?. <i>Clinical Autonomic Research</i> , 2021, 31, 787-790.	2.5	1
1870	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. <i>Clinical Neurophysiology</i> , 2021, 132, 2568-2607.	1.5	85
1871	COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117623.	0.6	17
1872	Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. <i>Neurobiology of Disease</i> , 2021, 159, 105509.	4.4	8
1873	Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients. <i>ENeurologicalSci</i> , 2021, 25, 100369.	1.3	5
1874	Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy. <i>Brain Sciences</i> , 2021, 11, 141.	2.3	3
1875	Epidemiology of atypical parkinsonian syndromes. <i>Tzu Chi Medical Journal</i> , 2022, 34, 169.	1.1	5
1876	Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 171-180.	0.4	5
1877	Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 493-509.	2.0	6
1878	Cerebrospinal Fluid α -Synuclein Species in Cognitive and Movements Disorders. <i>Brain Sciences</i> , 2021, 11, 119.	2.3	14
1879	Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test. <i>Neurology India</i> , 2021, 69, 430.	0.4	0
1880	The Value of Sacral Reflex and Sympathetic Skin Reflex in the Diagnosis of Multiple System Atrophy P-Type. <i>Parkinson's Disease</i> , 2021, 2021, 1-6.	1.1	0
1881	Matching of the postmortem hypothalamus from patients and controls. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 179, 141-156.	1.8	5
1884	Letter on "Natural history of pure autonomic failure: A United States prospective cohort". <i>Annals of Neurology</i> , 2017, 81, 910-910.	5.3	2

#	ARTICLE	IF	CITATIONS
1885	Clinical Neurological Phenotype of FXTAS. , 2010, , 1-16.		2
1886	Neurodegenerative Aspects of Multiple System Atrophy. , 2014, , 2157-2180.		5
1887	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods in Molecular Biology, 2018, 1750, 139-155.	0.9	12
1888	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
1889	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease?. , 2017, , 15-36.		1
1890	The Role of Astrocytes in Parkinsonâ€™s Disease. , 2014, , 127-144.		3
1891	Neuropsychiatric Manifestations in Atypical Parkinsonian Syndromes. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 141-170.	0.3	1
1892	Clinical Neurological Phenotype of FXTAS. , 2016, , 1-24.		3
1893	Atypical Parkinsonism. , 2017, , 141-169.		1
1894	PET and SPECT Imaging in Parkinsonian Syndromes. , 2014, , 619-638.		1
1896	Aetiopathogenesis. , 2014, , 57-81.		3
1899	Neuropathology of Ataxias. , 2013, , 2327-2347.		4
1900	Multiple System Atrophy. , 2012, , 453-457.		2
1901	Neuropathology of Movement Disorders. , 2011, , 871-898.		2
1902	Relevance of non-specific MRI features in multiple system atrophy. Clinical Neurology and Neurosurgery, 2017, 159, 29-33.	1.4	15
1903	Association of orthostatic blood pressure with the symptoms of orthostatic hypotension and cognitive impairment in patients with multiple system atrophy. Journal of Clinical Neuroscience, 2020, 75, 40-44.	1.5	5
1904	Reproducible metabolic topographies associated with multiple system atrophy: Network and regional analyses in Chinese and American patient cohorts. NeuroImage: Clinical, 2020, 28, 102416.	2.7	12
1906	Increased alpha-synuclein tear fluid levels in patients with Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 8507.	3.3	24

#	ARTICLE	IF	CITATIONS
1907	Neuroimaging in Dementia. <i>Seminars in Neurology</i> , 2017, 37, 510-537.	1.4	69
1908	Multiple System Atrophy (MSA). , 2013, , 129-138.		1
1909	Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity. <i>Chinese Medical Journal</i> , 2021, 134, 690-698.	2.3	8
1912	Diagnostic challenges in movement disorders: Sensory Ataxia Neuropathy Dysarthria and Ophthalmoplegia (SANDO) syndrome. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013010343-bcr2013010343.	0.5	9
1913	Impairment of brainstem implicit learning paradigms differentiates multiple system atrophy (MSA) from idiopathic Parkinson syndrome. <i>BMJ Open</i> , 2013, 3, e003098.	1.9	4
1914	Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-12.	1.1	9
1915	A Review of Neuroimaging in Rare Neurodegenerative Diseases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 544-556.	1.5	10
1916	Multiple system atrophy pathology is associated with primary Sjögren's syndrome. <i>JCI Insight</i> , 2020, 5, .	5.0	3
1917	Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-ioflupane SPECT: an investigation of parkinsonian syndromes. <i>EJNMMI Research</i> , 2019, 9, 85.	2.5	3
1918	Lewy Body Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 435-463.	0.8	104
1919	Ataxia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 1208-1226.	0.8	52
1920	Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 919-935.	0.8	12
1921	Sweating Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 116-137.	0.8	7
1922	Autonomic History, Examination, and Laboratory Evaluation. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 25-43.	0.8	6
1923	Synucleinopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 72-92.	0.8	13
1925	Cohort Study in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2021, 11, e407-e413.	1.6	9
1926	Elevated serum growth differentiation factor 15 in multiple system atrophy patients: A case control study. <i>World Journal of Clinical Cases</i> , 2020, 8, 2473-2483.	0.8	3
1927	Differences between Spinocerebellar Ataxias and Multiple System Atrophy-Cerebellar Type on Proton Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2012, 7, e47925.	2.5	43

#	ARTICLE	IF	CITATIONS
1928	Differences in Dopaminergic Modulation to Motor Cortical Plasticity between Parkinson's Disease and Multiple System Atrophy. PLoS ONE, 2013, 8, e62515.	2.5	21
1929	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	2.5	407
1930	Abnormal Pulmonary Function and Respiratory Muscle Strength Findings in Chinese Patients with Parkinson's Disease and Multiple System Atrophy—Comparison with Normal Elderly. PLoS ONE, 2014, 9, e116123.	2.5	51
1931	Quantitative Evaluation of Human Cerebellum-Dependent Motor Learning through Prism Adaptation of Hand-Reaching Movement. PLoS ONE, 2015, 10, e0119376.	2.5	31
1932	The Global Cognition, Frontal Lobe Dysfunction and Behavior Changes in Chinese Patients with Multiple System Atrophy. PLoS ONE, 2015, 10, e0139773.	2.5	28
1933	Neuroprotective Effect of a DJ-1 Based Peptide in a Toxin Induced Mouse Model of Multiple System Atrophy. PLoS ONE, 2016, 11, e0148170.	2.5	16
1934	Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders. PLoS ONE, 2016, 11, e0149278.	2.5	25
1935	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. PLoS ONE, 2016, 11, e0157755.	2.5	35
1936	Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes. PLoS ONE, 2016, 11, e0165869.	2.5	26
1937	Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. PLoS ONE, 2017, 12, e0172145.	2.5	21
1938	Different subregional metabolism patterns in patients with cerebellar ataxia by 18F-fluorodeoxyglucose positron emission tomography. PLoS ONE, 2017, 12, e0173275.	2.5	13
1939	Kinetics of α -synuclein prions preceding neuropathological inclusions in multiple system atrophy. PLoS Pathogens, 2020, 16, e1008222.	4.7	21
1940	Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease?. Prague Medical Report, 2018, 119, 85-96.	0.8	9
1941	Autonomic Dysfunctions in Parkinsonian Disorders. Journal of Movement Disorders, 2009, 2, 72-77.	1.3	7
1942	Cognitive Impairments in Multiple System Atrophy of the Cerebellar Type. Journal of Movement Disorders, 2011, 4, 41-45.	1.3	14
1943	A Case of Multiple System Atrophy-Cerebellar Type Preceded by Dementia. Journal of Movement Disorders, 2012, 5, 48-52.	1.3	2
1944	Genetic Screening for Spinocerebellar Ataxia Genes in a Japanese Single-Hospital Cohort. Journal of Movement Disorders, 2017, 10, 116-122.	1.3	6
1945	Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis. Journal of Movement Disorders, 2018, 11, 107-120.	1.3	28

#	ARTICLE	IF	CITATIONS
1946	Cognition, Olfaction and Uric Acid in Early de novo Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2018, 11, 139-144.	1.3	6
1947	Increased Signal in the Superior Cerebellar Peduncle of Patients with Progressive Supranuclear Palsy. <i>Journal of Movement Disorders</i> , 2019, 12, 166-171.	1.3	3
1948	Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study. <i>Journal of Movement Disorders</i> , 2019, 12, 177-183.	1.3	6
1949	Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes. <i>Journal of Movement Disorders</i> , 2020, 13, 39-46.	1.3	16
1950	Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia. <i>Journal of Movement Disorders</i> , 2020, 13, 20-26.	1.3	18
1951	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. <i>Reviews in the Neurosciences</i> , 2020, 31, 723-742.	2.9	30
1952	The Differential Diagnosis of Parkinson's Disease. , 0, , 109-128.		20
1953	Abnormal static and dynamic functional connectivity of resting-state fMRI in multiple system atrophy. <i>Aging</i> , 2020, 12, 16341-16356.	3.1	7
1954	Repetitive transcranial magnetic stimulation of the cerebellum improves ataxia and cerebello-fronto plasticity in multiple system atrophy: a randomized, double-blind, sham-controlled and TMS-EEG study. <i>Aging</i> , 2020, 12, 20611-20622.	3.1	29
1955	Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. <i>Oncotarget</i> , 2016, 7, 54215-54227.	1.8	30
1956	Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation. <i>Oncotarget</i> , 2015, 6, 13278-13294.	1.8	6
1957	Increased cerebellar activation after repetitive transcranial magnetic stimulation over the primary motor cortex in patients with multiple system atrophy. <i>Annals of Translational Medicine</i> , 2016, 4, 103-103.	1.7	18
1958	The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question "are polyphenols a viable therapeutic option against proteinopathies?". <i>Annals of Translational Medicine</i> , 2020, 8, 719-719.	1.7	7
1959	Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias. <i>Current Neuropharmacology</i> , 2018, 17, 21-32.	2.9	4
1960	Usefulness of 5 Minutes 123I-mIBG Scan in Parkinson's Disease and Heart Failure. <i>Current Radiopharmaceuticals</i> , 2020, 13, 120-129.	0.8	5
1961	A Case Report of a Multiple System Atrophy-C Patient Treated by Korean Medicine. <i>The Journal of Internal Korean Medicine</i> , 2018, 39, 1042-1051.	0.3	4
1962	Neuropsychological aspects. , 2013, , 144-170.		2
1963	Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 747-754.	0.9	27

#	ARTICLE	IF	CITATIONS
1964	The Utility of the Combined Use of ¹²³ I-FP-CIT and ¹²³ I-MIBG Myocardial Scintigraphy in Differentiating Parkinson's Disease from Other Parkinsonian Syndromes. <i>Yonago Acta Medica</i> , 2018, 61, 117-127.	0.7	3

1965	Don't forget non-Alzheimer dementias. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 243-254.	1.3	6
------	--	-----	---

1966	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		
------	---	--	--

#	ARTICLE	IF	CITATIONS
1982	Eye of the tiger sign with an unexpected pathological diagnosis. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 98-103.	1.5	0
1983	Vascular Risk Factors and Cognition in Multiple System Atrophy. <i>Frontiers in Neuroscience</i> , 2021, 15, 749949.	2.8	3
1984	Video Representation of Dopamine-Responsive Multiple System Atrophy Cerebellar Type. <i>American Journal of Case Reports</i> , 2021, 22, e933995.	0.8	3
1985	Neurofilament light chain and α -synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. <i>Npj Parkinson's Disease</i> , 2021, 7, 93.	5.3	45
1986	A historical review of multiple system atrophy with a critical appraisal of cellular and animal models. <i>Journal of Neural Transmission</i> , 2021, 128, 1507-1527.	2.8	9
1987	Parkinsonism and dysautonomia with anti-CV2/CRMP5 associated paraneoplastic neurological syndromes mimicking multiple system atrophy: a case report. <i>BMC Neurology</i> , 2021, 21, 408.	1.8	5
1988	Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Neurodegenerative Diseases</i> , 2021, 21, 30-35.	1.4	9
1989	Female sexual dysfunction in multiple system atrophy: does it matter?. <i>Clinical Autonomic Research</i> , 2021, 31, 649-650.	2.5	1
1990	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
1991	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 6-19.	1.5	21
1992	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 53-58.	2.2	6
1993	“Sinal da Cruz”. <i>Revista Neurociencias</i> , 2010, 18, 60-62.	0.0	0
1996	Visual Hallucinations in Neurodegenerative Disorders. , 2010, , 51-64.		0
1997	Multiple System Atrophy, Orthostatic Hypotension, and Autonomic Dysfunction and Cognition. , 2010, , 57-66.		0
1998	Autonomic Dysfunction. , 2010, , 103-112.		0
1999	Olivopontocerebellar Atrophy. , 2010, , 324-330.		0
2000	Multiple System Atrophy. , 2010, , 227-229.		0
2001	A Case of Multiple System Atrophy Successfully Treated with Hachimijiugan. <i>Kampo Medicine</i> , 2011, 62, 565-569.	0.1	0

#	ARTICLE	IF	CITATIONS
2002	Critères diagnostiques. , 2011, , 111-117.		0
2003	Sueño, respiración y trastornos neurológicos. , 2011, , 436-498.		0
2004	Bewegungsstörungen. , 2011, , 955-1054.		0
2006	A semi-quantitative evaluation of substantia nigra hyperechogenicity in Parkinson's disease and Parkinsonian syndrome using the Gray Scale Median ultrasound analysis. Neurosonology, 2012, 25, 7-12.	0.0	0
2007	Cardiovascular Manifestations of Autonomic Disorders. , 2012, , 1949-1961.		5
2008	Multiple System Atrophy. Current Clinical Neurology, 2012, , 30-31.	0.2	0
2010	Systematrophien. , 2012, , 223-249.		0
2012	Role of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Parkinsonian Disorders. , 0, ,		0
2015	Neuropathology of parkinsonism. , 2013, , 239-257.		0
2016	Atrophie multisystémique (MSA). , 2013, , 167-171.		0
2017	Idiopathic Late Onset Cerebellar Ataxia (ILOCA), and Cerebellar plus Syndrome. , 2013, , 2143-2150.		0
2019	Clinical Presentation. , 2014, , 97-119.		0
2021	Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy. World Journal of Neurology, 2014, 4, 1.	0.6	0
2022	Patients with Parkinsonism and Sleep Problems. , 2015, , 579-583.		0
2023	Comparative Study of Diagnostic Significance of Urethral Sphincter Electromyography and External Anal Sphincter Electromyography in Patients with Multiple System Atrophy. Journal of Neurology & Neurophysiology, 2015, 06, .	0.1	0
2024	Extrapyramidal Diseases: Atypical Parkinsonisms. , 2015, , 369-374.		0
2025	Sleep in Neurodegenerative Diseases. , 2015, , 271-283.		3
2027	Unprovoked Saddle Pulmonary Embolism in a Patient with Shy-Drager syndrome. Are They Related?. Journal of Case Reports, 2015, 5, 166-169.	0.1	0

#	ARTICLE	IF	CITATIONS
2028	Multiple System Atrophy Manifested by Bilateral Vocal Cord Palsy as an Initial Sign. Korean Journal of Critical Care Medicine, 2015, 30, 123-127.	0.1	0
2029	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
2030	Ataxien. Springer-Lehrbuch, 2016, , 625-643.	0.0	0
2031	Parkinsonism with little response to levodopa. , 2016, , 207-214.		0
2032	Shy-Drager Syndromeã†. , 2017, , .		0
2034	Exam 5 Questions. , 2017, , 189-233.		0
2035	Myoclonus and Startle Syndromes. , 2017, , 315-325.		0
2036	Coincidence of corticobasal syndrome and cerebellar form of multiple system atrophy. Neurologie Pro Praxi, 2017, 18, 134-136.	0.1	0
2037	OBSOLETE: Orthostatic Hypotension and Vasovagal Syncope. , 2018, , .		1
2039	Multiple Systematrophie. Springer Reference Medizin, 2018, , 1-6.	0.0	0
2040	Structural MRI in Neurodegenerative Non-Alzheimerâ€™s Dementia. Neuromethods, 2018, , 241-265.	0.3	0
2042	Olivopontocerebellar Atrophy. Degeneration and inflammation. HERALD of North-Western State Medical University Named After I I Mechnikov, 2018, 10, 81-85.	0.2	0
2044	Clinics in diagnostic imaging (191). Singapore Medical Journal, 2018, 59, 550-554.	0.6	0
2045	Parkinsonian and cerebellar phenotypes of probable MSA: An insight in to prognostic factors based on autonomic functions. Annals of Indian Academy of Neurology, 2020, 23, 289.	0.5	0
2046	Multiple System Atrophy, Orthostatic Hypotension, and Autonomic Dysfunction and Cognition. , 2019, , 87-96.		0
2050	Alpha-Synucleinopathies. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 274-297.	0.1	2
2051	Parkinsonism and Related Disorders. , 0, , .		0
2054	Neuropathology of Ataxias. , 2020, , 1-23.		0

#	ARTICLE	IF	CITATIONS
2056	Recurrent laryngospasm as the only presenting feature of multiple system atrophy. <i>Neurological Sciences</i> , 2020, 41, 2629-2630.	1.9	1
2057	A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 6.	2.0	3
2058	Frontline of Non-genetic Cerebellar Ataxia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1138-1144.	0.0	0
2059	Estudio de registro de pacientes con desórdenes del movimiento con autoprescripción de formas no estandarizadas de cannabis. Experiencia de un centro especializado en movimientos anormales de Buenos Aires. <i>Neurología Argentina</i> , 2020, 12, 165-171.	0.3	0
2060	Comparison of Neuropathological Characteristics between Multiple System Atrophy Cerebellar Type and Parkinsonian Type. <i>Journal of the Korean Neurological Association</i> , 2020, 38, 194-203.	0.1	0
2061	White matter and nigral alterations in multiple system atrophy-parkinsonian type. <i>Npj Parkinson's Disease</i> , 2021, 7, 96.	5.3	10
2062	Pareidolia in Parkinson's Disease and Multiple System Atrophy. <i>Parkinson's Disease</i> , 2021, 2021, 1-6.	1.1	3
2063	Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 421-426.	3.9	30
2064	Multiple Systematrophie. <i>Springer Reference Medizin</i> , 2020, , 1325-1330.	0.0	0
2065	Newly Diagnosed Amyotrophic Lateral Sclerosis in a Patient with Multiple-System Atrophy. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
2075	Drugs in the Treatment of Dystonia, Multisystem Atrophy, and Non-Parkinson Tremor. , 2020, , 1-16.		1
2076	Synuclein in neurodegeneration. <i>Advances in Clinical Chemistry</i> , 2021, 103, 97-134.	3.7	10
2078	A Patient with Spinocerebellar Ataxia 2 Presenting with Multiple System Atrophy. <i>Journal of the Korean Neurological Association</i> , 2020, 38, 33-36.	0.1	0
2080	Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy. <i>Scientific Reports</i> , 2021, 11, 21683.	3.3	9
2081	Multiple System Atrophy (MSA) Caregiversâ€™ Experience: A Mixed Methods Study. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-30.	0.5	1
2083	Cardiovagal Baroreflex Sensitivity in Parkinson's Disease and Multiple-System Atrophy. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
2099	The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways. <i>Journal of Biomedical Science</i> , 2021, 28, 78.	7.0	45
2100	Profiling of Differentially Expressed MicroRNAs in Saliva of Parkinson's Disease Patients. <i>Frontiers in Neurology</i> , 2021, 12, 738530.	2.4	14
2102	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 107.	5.3	11
2103	An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 40-44.	2.2	9
2104	Association Analysis of WNT3, HLA-DRB5 and IL1R2 Polymorphisms in Chinese Patients With Parkinson's Disease and Multiple System Atrophy. <i>Frontiers in Genetics</i> , 2021, 12, 765833.	2.3	5
2105	PET-CT in brain disorders: The South African context. <i>South African Journal of Radiology</i> , 2021, 25, 2201.	0.3	1
2106	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 348-359.	2.1	5
2107	Head-impulse tests aid in differentiation of multiple system atrophy from Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 2972-2979.	3.6	5
2108	Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease. <i>Movement Disorders</i> , 2021, , .	3.9	6
2109	Frequency of FMR1 Premutation Alleles in Patients with Undiagnosed Cerebellar Ataxia and Multiple System Atrophy in the Japanese Population. <i>Cerebellum</i> , 2021, , 1.	2.5	3
2110	The role of cardiovascular autonomic failure in the differential diagnosis of α -synucleinopathies. <i>Neurological Sciences</i> , 2022, 43, 187-198.	1.9	5
2111	Idiopathic Late Onset Cerebellar Ataxia (ILOCA), and Cerebellar Plus Syndrome. , 2022, , 2433-2440.		0
2112	Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 690013.	2.8	8
2113	Neuropathology of Ataxias. , 2022, , 2615-2637.		0
2114	Randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults. <i>Neurology and Clinical Neuroscience</i> , 2022, 10, 14-24.	0.4	5
2115	Multiple System Atrophy (MSA). , 2022, , 2409-2432.		0
2116	Efficacy of Human Umbilical Cord Blood-Mononuclear Cell Transplantation for MSA Treatment and Its Effects on Changes in T-Cell Subsets in Peripheral Blood and Inflammatory Factors. <i>Disease Markers</i> , 2021, 2021, 1-7.	1.3	1
2118	A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
2119	Risk Factors for Phenoconversion in <sc>Rapid Eye Movement</sc> Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2022, 91, 404-416.	5.3	27
2120	Multiple system atrophy and C9orf72 hexanucleotide repeat expansions in a cohort of Italian patients. <i>Neurobiology of Aging</i> , 2022, 112, 12-15.	3.1	3
2121	Fatigue in Patients With Multiple System Atrophy. <i>Neurology</i> , 2022, 98, .	1.1	5
2122	A Case Report of Non-Motor Symptoms Evaluated Using the Non-Motor Symptom Scale in a Patient with Secondary Parkinsonism Presumed to be Probable Lewy Body Dementia and Improved with Combined Treatment with Herbal Medicine and Acupuncture. <i>The Journal of Internal Korean Medicine</i> , 2021, 42, 833-845.	0.3	0
2123	Sleep-related hypoventilation and hypercapnia in multiple system atrophy detected by polysomnography with transcutaneous carbon dioxide monitoring. <i>Sleep and Breathing</i> , 2022, 26, 1779-1789.	1.7	3
2124	Passive Immunization in Alpha-Synuclein Preclinical Animal Models. <i>Biomolecules</i> , 2022, 12, 168.	4.0	13
2125	High-Frequency Repetitive Transcranial Magnetic Stimulation Over the Left Dorsolateral Prefrontal Cortex Shortly Alleviates Fatigue in Patients With Multiple System Atrophy: A Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 755352.	2.4	0
2126	Impact of tracheostomy invasive ventilation on survival in Japanese patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, , .	2.2	7
2127	Homerâ€™s Antibody Disease: A Potentially Treatable MSAâ€™s Mimic. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 178-182.	1.5	10
2128	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. <i>Journal of Neurochemistry</i> , 2023, 164, 346-363.	3.9	10
2129	High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy. <i>Npj Parkinson's Disease</i> , 2022, 8, 11.	5.3	15
2130	Therapeutics in the Pipeline Targeting <i>Î±</i>-Synuclein for Parkinson's Disease. <i>Pharmacological Reviews</i> , 2022, 74, 207-237.	16.0	39
2131	<sc>mTOR</sc> Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Doubleâ€™Blind, Placeboâ€™Controlled Futility Trial and 1â€™Year Biomarker Longitudinal Analysis. <i>Movement Disorders</i> , 2022, 37, 778-789.	3.9	16
2132	Quantitative susceptibility mapping reveals alterations of dentate nuclei in common types of degenerative cerebellar ataxias. <i>Brain Communications</i> , 2022, 4, fcab306.	3.3	15
2133	Cognition in Patients With Multiple System Atrophy (MSA) and Its Neuroimaging Correlation: A Prospective Case-Control Study. <i>Cureus</i> , 2022, 14, e21717.	0.5	1
2134	Role of Apolipoprotein E in the Clinical Profile of Atypical Parkinsonian Syndromes. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 36-43.	1.3	3
2135	Postganglionic Sudomotor Assessment in Early Stage of Multiple System Atrophy and Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.1	8
2136	Excessive Daytime Sleepiness Is Associated With Non-motor Symptoms of Multiple System Atrophy: A Cross-Sectional Study in China. <i>Frontiers in Neurology</i> , 2021, 12, 798771.	2.4	4

#	ARTICLE	IF	CITATIONS
2137	Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2022, 59, 2277-2287.	4.0	7
2138	A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism. <i>European Radiology</i> , 2022, 32, 3597-3608.	4.5	7
2139	Infectious Agents as Potential Drivers of α -Synucleinopathies. <i>Movement Disorders</i> , 2022, 37, 464-477.	3.9	7
2140	Diagnostic utility of GDF15 in neurodegenerative diseases: A systematic review and meta-analysis. <i>Brain and Behavior</i> , 2022, 12, e2502.	2.2	7
2141	Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy. <i>European Journal of Neurology</i> , 2021, , .	3.3	6
2142	Etiology and course of cerebellar ataxia: A study from Eastern India. <i>Medical Journal of Dr D Y Patil Vidyapeeth</i> , 2023, 16, 591.	0.1	0
2143	Data-driven subtype classification of patients with early-stage multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 92-97.	2.2	2
2144	The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT). <i>Diagnostics</i> , 2022, 12, 385.	2.6	11
2145	Computer-Aided Classification Framework of Parkinsonian Disorders Using 11C-CFT PET Imaging. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 792951.	3.4	6
2146	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. <i>NeuroImage: Clinical</i> , 2022, 33, 102958.	2.7	3
2147	Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalami, and frontomesial white matter. <i>Cerebral Cortex</i> , 2022, 32, 5628-5636.	2.9	6
2148	Consequences of variability in α -synuclein fibril structure on strain biology. <i>Acta Neuropathologica</i> , 2022, 143, 311-330.	7.7	15
2149	Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. <i>Translational Neurodegeneration</i> , 2022, 11, 7.	8.0	42
2150	Different α -synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	40
2151	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	2.5	7
2152	Ataxia in a Movement Disorders Outpatient Clinic: a Single-Center Experience in Turkey. <i>Cerebellum</i> , 2022, , 1.	2.5	1
2153	<i>GIPC1</i> CGG Repeat Expansion Is Associated with Movement Disorders. <i>Annals of Neurology</i> , 2022, 91, 704-715.	5.3	18
2154	The Frontal and Cerebellar Metabolism Related to Cognitive Dysfunction in Multiple System Atrophy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 788166.	3.4	5

#	ARTICLE	IF	CITATIONS
2155	Fluid markers of synapse degeneration in synucleinopathies. <i>Journal of Neural Transmission</i> , 2022, 129, 187-206.	2.8	4
2156	â€œPhalanx signâ€ helps to discriminate MSA-C from idiopathic late onset cerebellar ataxia. <i>Journal of Neurology</i> , 2022, 269, 3900-3903.	3.6	1
2157	Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy. <i>Movement Disorders</i> , 2022, , .	3.9	4
2158	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. <i>Brain</i> , 2022, 145, 584-595.	7.6	65
2159	Advanced brain aging in multiple system atrophy compared to Parkinsonâ€™s disease. <i>NeuroImage: Clinical</i> , 2022, 34, 102997.	2.7	7
2160	Does essential tremor increase risk of cognitive impairment and dementia? Yes. <i>International Review of Neurobiology</i> , 2022, , 195-231.	2.0	9
2163	Diagnostic accuracy of quantitative susceptibility mapping in multiple system atrophy: The impact of echo time and the potential of histogram analysis. <i>NeuroImage: Clinical</i> , 2022, 34, 102989.	2.7	7
2164	Phosphorylated Î±-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. <i>Brain</i> , 2023, 146, 1065-1074.	7.6	18
2166	Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases. <i>BMC Neurology</i> , 2022, 22, 67.	1.8	1
2167	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. <i>Scientific Reports</i> , 2022, 12, 2763.	3.3	8
2168	Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis. <i>Journal of Neural Transmission</i> , 2022, 129, 301-309.	2.8	6
2169	A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Neuroscience</i> , 2022, 16, 805953.	2.8	13
2170	Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders. <i>Movement Disorders</i> , 2022, 37, 1235-1244.	3.9	4
2171	Sensitivity to Change and Patientâ€™Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Dataâ€™Driven Analysis. <i>Movement Disorders</i> , 2022, 37, 1425-1431.	3.9	8
2172	Diagnostic Value of Salivary Realâ€™Time Quakingâ€™Induced Conversion in Parkinson's Disease and Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1059-1063.	3.9	31
2173	Three-Dimensional Digital Reconstruction of the Cerebellar Cortex: Lobule Thickness, Surface Area Measurements, and Layer Architecture. <i>Cerebellum</i> , 2023, 22, 249-260.	2.5	9
2174	Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD. <i>Nature and Science of Sleep</i> , 2022, Volume 14, 407-418.	2.7	10
2175	Relationships of Nutritional Factors and Agrochemical Exposure with Parkinsonâ€™s Disease in the Province of Brescia, Italy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3309.	2.6	4

#	ARTICLE	IF	CITATIONS
2176	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 848991.	3.4	4
2177	Differential diagnosis of parkinsonism based on deep metabolic imaging indices. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263029.	5.0	9
2178	Large-scale network dysfunction in Î±-Synucleinopathy: A meta-analysis of resting-state functional connectivity. <i>EBioMedicine</i> , 2022, 77, 103915.	6.1	14
2179	Evaluation of Brain SPECT with 99mTc-TRODAT-1 in the Differential Diagnosis of Parkinsonism. <i>Parkinson's Disease</i> , 2022, 2022, 1-10.	1.1	1
2180	Oculomotor and Visual-Vestibular Disturbances in Parkinsonâ€™s Disease. , 2022, , 115-129.		1
2181	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. <i>Brain Communications</i> , 2022, 4, fcac040.	3.3	8
2182	Clinical and pathological characteristics of later onset multiple system atrophy. <i>Journal of Neurology</i> , 2022, 269, 4310-4321.	3.6	8
2183	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 121-127.	2.2	2
2184	Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout. <i>Methods</i> , 2022, 203, 142-151.	3.8	6
2185	Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. <i>Movement Disorders</i> , 2022, 37, 1245-1255.	3.9	8
2186	Lower urinary tract dysfunction in uncommon neurological diseases: A report of the neurourology promotion committee of the International Continence Society. , 2022, 1, 100022.		3
2187	Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010573.	4.8	25
2188	Î±-Synuclein Radiotracer Development and <i>In Vivo</i> Imaging: Recent Advancements and New Perspectives. <i>Movement Disorders</i> , 2022, 37, 936-948.	3.9	24
2189	Automated Differentiation of Atypical Parkinsonian Syndromes Using Brain Iron Patterns in Susceptibility Weighted Imaging. <i>Diagnostics</i> , 2022, 12, 637.	2.6	2
2190	Pain in atypical parkinsonism, vascular parkinsonism, and Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2022, 43, 4797-4802.	1.9	2
2191	Oral appliance therapy for obstructive sleep apnea in multiple system atrophy with floppy epiglottis: a case series of three patients. <i>Sleep and Breathing</i> , 2022, , 1.	1.7	0
2192	Heterogeneity of Multiple System Atrophy: An Update. <i>Biomedicines</i> , 2022, 10, 599.	3.2	13
2193	Toward Automated Articulation Rate Analysis via Connected Speech in Dysarthrias. <i>Journal of Speech, Language, and Hearing Research</i> , 2022, 65, 1386-1401.	1.6	3

#	ARTICLE	IF	CITATIONS
2194	Freezing of Gait in Multiple System Atrophy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 833287.	3.4	2
2195	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 851788.	3.4	7
2196	Normative Data for Brainstem Structures, the Midbrain-to-Pons Ratio, and the Magnetic Resonance Parkinsonism Index. <i>American Journal of Neuroradiology</i> , 2022, 43, 707-714.	2.4	3
2197	An atypical clinical course of a 71-year-old man with right arm weakness and ataxia. <i>Parkinsonism and Related Disorders</i> , 2022, 105, 154-156.	2.2	1
2198	Tracheostomy is associated with increased survival in Multiple System Atrophy patients with stridor. <i>European Journal of Neurology</i> , 2022, 29, 2232-2240.	3.3	5
2199	Synuclein-One study: skin biopsy detection of phosphorylated α -synuclein for diagnosis of synucleinopathies. <i>Biomarkers in Medicine</i> , 2022, 16, 499-509.	1.4	8
2200	Utility of 18F FDG-PET in Parkinsonism in an African population. <i>ENeurologicalSci</i> , 2022, 27, 100399.	1.3	1
2201	Neurodegenerative Traits Detected via 3D CNNs Trained with Simulated Brain MRI: Prediction Supported by Visualization of Discriminant Voxels. , 2021, , .		0
2202	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. <i>Molecular Neurodegeneration</i> , 2021, 16, 82.	10.8	28
2203	Therapeutic Application of rTMS in Atypical Parkinsonian Disorders. <i>Behavioural Neurology</i> , 2021, 2021, 1-12.	2.1	0
2204	Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13488.	4.1	18
2205	Multiscale Entropy of Resting-State Functional Magnetic Resonance Imaging Differentiates Progressive Supranuclear Palsy and Multiple System Atrophy. <i>Life</i> , 2021, 11, 1411.	2.4	0
2206	Neuropathology and molecular diagnosis of Synucleinopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 83.	10.8	101
2207	Progression of Nigrostriatal Denervation in Cerebellar Multiple System Atrophy. <i>Neurology</i> , 2022, 98, 232-236.	1.1	6
2208	The Cold Hand Sign in Multiple System Atrophy: Frequency-Associated Factors and Its Impact on Survival. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 767211.	3.4	4
2209	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	3.9	14
2210	Effects of Non-invasive Brain Stimulation on Multiple System Atrophy: A Systematic Review. <i>Frontiers in Neuroscience</i> , 2021, 15, 771090.	2.8	5
2211	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinson's Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. <i>Cells</i> , 2022, 11, 87.	4.1	5

#	ARTICLE	IF	CITATIONS
2212	Overactive Bladder Symptoms Within Nervous System: A Focus on Etiology. <i>Frontiers in Physiology</i> , 2021, 12, 747144.	2.8	3
2213	Cognition and driving ability in isolated and symptomatic REM sleep behavior disorder. <i>Sleep</i> , 2022, 45, .	1.1	1
2215	Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 119.	5.3	19
2216	Remembering John Q Trojanowski, in his own words: A life dedicated to discovering building blocks and using them to build bridges of knowledge, collaboration, and discovery. <i>Npj Parkinson's Disease</i> , 2022, 8, 43.	5.3	1
2217	Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder. <i>Neurology</i> , 2022, 98, .	1.1	14
2219	Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.1	11
2220	Altered voxel-level whole-brain functional connectivity in multiple system atrophy patients with depression symptoms. <i>BMC Psychiatry</i> , 2022, 22, 279.	2.6	4
2221	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. <i>PLoS ONE</i> , 2022, 17, e0267024.	2.5	1
2222	Clinical diagnosis sensitivity of neuropathologically established multiple system atrophy in Japan. <i>Journal of Neurology</i> , 2022, 269, 5162-5164.	3.6	2
2223	Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test. <i>Npj Parkinson's Disease</i> , 2022, 8, 42.	5.3	5
2224	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
2225	RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α -Synuclein. <i>Biomolecules</i> , 2022, 12, 576.	4.0	7
2226	Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 32-37.	2.2	3
2231	Multiple system atrophy. , 0, , 27-57.		0
2232	Clinical aspects of movement disorders. , 0, , 29-50.		0
2233	Synucleinopathies. , 2014, , 149-175.		0
2273	Oligoclonal Bands in Multiple System Atrophy: Case Report and Proposed Mechanisms of Immunogenicity. <i>Frontiers in Neuroscience</i> , 2022, 16, 852939.	2.8	1
2275	Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2022, 34, 103022.	2.7	12

#	ARTICLE	IF	CITATIONS
2276	Translocator Protein (18 kDa) Polymorphism (rs6971) in the Korean Population. <i>Dementia and Neurocognitive Disorders</i> , 2022, 21, 71.	1.4	3
2277	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1369-1387.	2.8	10
2278	Tracheostomy invasive ventilation for stridor in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 105-106.	2.2	0
2279	Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α -synuclein transgenic mice. <i>Acta Neuropathologica</i> , 2022, 143, 663-685.	7.7	12
2280	Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. <i>Brain</i> , 2022, 145, 2755-2768.	7.6	8
2281	Eye tracking identifies biomarkers in α -synucleinopathies versus progressive supranuclear palsy. <i>Journal of Neurology</i> , 2022, 269, 4920-4938.	3.6	6
2282	Atypical Parkinsonism: Methamphetamine may play a role. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05808.	0.5	2
2283	Is MRPI 2.0 More Useful than MRPI and M/P Ratio in Differential Diagnosis of PSP-P with Other Atypical Parkinsonisms?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2701.	2.4	7
2284	Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor/neuropsychiatric subtypes. <i>Neuroscience Letters</i> , 2022, 781, 136675.	2.1	12
2285	Ultrastructural and biochemical classification of pathogenic tau, α -synuclein and TDP-43. <i>Acta Neuropathologica</i> , 2022, 143, 613-640.	7.7	22
2286	Marked response to levodopa in a patient with multiple system atrophy presenting with orthostatic hypotension: should reduced DAT uptake on DaTSCAN be a criterion for response to levodopa?. <i>Neurological Sciences</i> , 2022, , .	1.9	0
2287	Pharyngolaryngeal semiology and prognostic factors in multiple system atrophy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 4473-4483.	1.6	1
2288	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. <i>EBioMedicine</i> , 2022, 80, 104021.	6.1	26
2289	A review of diagnostic imaging approaches to assessing Parkinson's disease. <i>Brain Disorders</i> , 2022, 6, 100037.	1.7	0
2290	Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. <i>Physica Medica</i> , 2022, 98, 131-138.	0.7	9
2291	Female Urinary Retention Progressing to Possible Multiple System Atrophy-cerebellar Form after 12 Years. <i>Internal Medicine</i> , 2022, 61, 3599-3604.	0.7	3
2292	Criteria-unfulfilled multiple system atrophy at an initial stage exhibits laterality of middle cerebellar peduncles. <i>Journal of the Neurological Sciences</i> , 2022, , 120281.	0.6	0
2293	Methylation of MAPT Gene in Neurodegenerative Synucleinopathies. <i>Russian Journal of Genetics</i> , 2022, 58, 576-584.	0.6	0

#	ARTICLE	IF	CITATIONS
2294	Combined CSF α -SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 33-41.	2.2	12
2295	Symptomatic Care in Multiple System Atrophy: State of the Art. <i>Cerebellum</i> , 2023, 22, 433-446.	2.5	7
2296	The Indirect Impact of COVID-19 on Major Clinical Outcomes of People With Parkinson's Disease or Parkinsonism: A Cohort Study. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	4
2297	Cognitive profile in idiopathic autonomic failure: relation with white matter hyperintensities and neurofilament levels. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 864-876.	3.7	4
2298	Clinicopathological correlates of pyramidal signs in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2022, , .	3.7	2
2299	Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2798-2811.	6.4	15
2300	Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
2314	Factors associated with mortality in early stages of parkinsonism. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	4
2315	Detection and differentiation of ataxic and hypokinetic dysarthria in cerebellar ataxia and parkinsonian disorders via wave splitting and integrating neural networks. <i>PLoS ONE</i> , 2022, 17, e0268337.	2.5	7
2316	Age and Gender Differences in Cardiovascular Autonomic Failure in the Transgenic PLP-syn Mouse, a Model of Multiple System Atrophy. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
2317	Late-onset MSA differs from younger-onset MSA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 583.1-583.	1.9	0
2318	Diffusion tensor imaging for the differential diagnosis of Parkinsonism by machine learning. <i>Biomedical Journal</i> , 2023, 46, 100541.	3.1	4
2319	Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. <i>Neurobiology of Disease</i> , 2022, 170, 105780.	4.4	17
2321	Troubles cognitifs et psycho-comportementaux dans la Maladie de Parkinson idiopathique et les syndromes parkinsoniens atypiques. , 2022, , 277-290.		0
2322	Outils d'imagerie dans les maladies neurodégénératives. , 2022, , 73-85.		0
2323	Syndromes parkinsoniens. , 2022, , 227-237.		0
2324	Maladies apparentées à la maladie de Parkinson idiopathique. , 2022, , 253-265.		0
2325	A Wearable Multi-sensor System for Classification of Multiple System Atrophy and Parkinson's Disease. , 2022, , .		0
2326	Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1776-1778.	3.9	0
2327	A novel diagnostic approach for patients with adult-onset dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1039-1048.	1.9	3
2329	Improving the Accuracy of Diagnosis for Multiple-System Atrophy Using Deep Learning-Based Method. <i>Biology</i> , 2022, 11, 951.	2.8	1
2330	Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1921-1935.	2.8	7
2331	Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. <i>European Journal of Neurology</i> , 2022, 29, 2944-2955.	3.3	4
2332	<sc><i>COQ2</i></sc> and <sc><i>SNCA</i></sc> polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition. <i>European Journal of Neurology</i> , 2022, 29, 2956-2966.	3.3	2
2333	Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	8

#	ARTICLE	IF	CITATIONS
2334	Cognitive Syndromes Associated With Movement Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 726-749.	0.8	0
2335	Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease. Molecular Neurobiology, 2022, 59, 1-9.	4.0	4
2336	Resting-State Brain Network Analysis Methods and Applications. , 0, , .		0
2337	Quantitative assessment of oculomotor function by videonystagmography in multiple system atrophy. Clinical Neurophysiology, 2022, 141, 15-23.	1.5	1
2338	Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson's Disease Using Quantitative Indices of 18F-FP-CIT PET/CT. Diagnostics, 2022, 12, 1402.	2.6	4
2339	Performance of α -Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	5.2	31
2340	FDG PET in the differential diagnosis of degenerative parkinsonian disorders: usefulness of voxel-based analysis in clinical practice. Neurological Sciences, 0, , .	1.9	2
2341	Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168.	5.6	15
2342	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. Parkinsonism and Related Disorders, 2022, 101, 9-14.	2.2	2
2344	Odor identification predicts the transition of patients with isolated <sc>RBD</sc> : A retrospective study. Annals of Clinical and Translational Neurology, 0, , .	3.7	2
2345	A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism. Neuropathology, 0, , .	1.2	1
2346	Risk of <sc>SARS-CoV-2</sc> infection, hospitalization, and death for <sc>COVID-19</sc> in people with Parkinson disease or parkinsonism over a 15-month period: A cohort study. European Journal of Neurology, 2022, 29, 3205-3217.	3.3	7
2347	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia. Brain Communications, 2022, 4, .	3.3	3
2348	Diagnosing Premotor Multiple System Atrophy. Neurology, 2022, 99, .	1.1	4
2349	Parkinson's Progression Markers Initiative brain autopsy program. Parkinsonism and Related Disorders, 2022, 101, 62-65.	2.2	2
2350	Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2022, 101, 43-48.	2.2	5
2351	Adult Onset Sporadic Cerebellar Ataxia in Singapore: Diagnostic Outcomes of Paraneoplastic Antibody Testing and Early Clinical Features of Paraneoplastic Cerebellar Degeneration. Annals of the Academy of Medicine, Singapore, 2017, 46, 118-120.	0.4	0
2352	Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy. Frontiers in Neurology, 0, 13, .	2.4	3

#	ARTICLE	IF	CITATIONS
2353	Evaluation of the visual system with visual evoked potential and optical coherence tomography in patients with idiopathic Parkinson's disease and with multiple system atrophy. <i>Documenta Ophthalmologica</i> , 2022, 145, 99-112.	2.2	2
2354	Semiautomated Algorithm for the Diagnosis of Multiple System Atrophy With Predominant Parkinsonism. <i>Journal of Movement Disorders</i> , 0, , .	1.3	0
2355	Neurocognitive health of older adults experiencing homelessness in Oakland, California. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
2356	Intermediate and Expanded <i>HTT</i> Alleles and the Risk for Synucleinopathies. <i>Movement Disorders</i> , 2022, 37, 1841-1849.	3.9	5
2357	Neuropathology and emerging biomarkers in corticobasal syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 919-929.	1.9	27
2358	Neurofilament light levels predict clinical progression and death in multiple system atrophy. <i>Brain</i> , 2022, 145, 4398-4408.	7.6	17
2359	¹⁸ F-Florbetapir Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy – Parkinsonian Subtype. <i>Movement Disorders</i> , 2022, 37, 1915-1923.	3.9	10
2360	Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study. <i>Journal of Neurology</i> , 2022, 269, 6354-6365.	3.6	11
2361	Combined functional and structural imaging of brain white matter reveals stage-dependent impairment in multiple system atrophy of cerebellar type. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	4
2362	Common Variants Near <i>ZIC1</i> and <i>ZIC4</i> in Autopsy-Confirmed Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 2110-2121.	3.9	6
2363	Differentiation of Parkinson's disease and Parkinsonism predominant multiple system atrophy in early stage by morphometrics in susceptibility weighted imaging. <i>Frontiers in Human Neuroscience</i> , 0, 16, .	2.0	0
2364	Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	5
2365	Magnetic Resonance T1w/T2w Ratio in the Putamen and Cerebellum as a Marker of Cognitive Impairment in MSA: a Longitudinal Study. <i>Cerebellum</i> , 0, , .	2.5	1
2366	Analysis of sleep, daytime sleepiness, and autonomic function in multiple system atrophy and Parkinson disease: a prospective study. <i>Journal of Clinical Sleep Medicine</i> , 2023, 19, 63-71.	2.6	4
2367	Multiple system atrophy. <i>Nature Reviews Disease Primers</i> , 2022, 8, .	30.5	59
2368	A Review on the Clinical Diagnosis of Multiple System Atrophy. <i>Cerebellum</i> , 2023, 22, 825-839.	2.5	6
2369	A Mouse Model of Multiple System Atrophy: Bench to Bedside. <i>Neurotherapeutics</i> , 2023, 20, 117-126.	4.4	3
2370	Multiple System Atrophy. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
2371	Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2211-2222.	2.8	8
2372	The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis. <i>Neuropsychology Review</i> , 0, , .	4.9	0
2373	Alterations of brain activity in multiple system atrophy patients with freezing of gait: A resting-state fMRI study. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	1
2374	Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders. <i>Biomolecules</i> , 2022, 12, 1099.	4.0	3
2375	<scp>HOMER</scp> Antibodies Were Not Detected in Two German Cohorts of Patients with Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 2165-2166.	3.9	1
2376	Macroscopic diagnostic clue for parkinsonism. <i>Neuropathology</i> , 2022, 42, 394-419.	1.2	3
2377	Prevalence and associated factors of frailty and sarcopenia in multiple system atrophy and progressive supranuclear palsy: a cross-sectional study. <i>Neurological Sciences</i> , 0, , .	1.9	1
2378	Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2099-2109.	3.9	3
2379	COVID-19 pandemic and the international classification of functioning in multiple system atrophy: a cross-sectional, nationwide survey in Japan. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
2380	Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 30-35.	2.2	4
2381	Diagnosis of orthostatic hypotension in older people. , 2022, 1, 45-52.		0
2382	Montreal Cognitive Assessment predicts the short-term risk of Lewy body disease in isolated <scp>REM</scp> sleep behavior disorder with reduced <scp>MIBG</scp> scintigraphy. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	2
2383	Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinson's Disease. <i>Cerebellum</i> , 2024, 23, 22-30.	2.5	0
2384	Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, 103, 56-59.	2.2	2
2385	Hemoglobin-binding α -synuclein levels in erythrocytes are elevated in patients with multiple system atrophy. <i>Neuroscience Letters</i> , 2022, 789, 136868.	2.1	2
2386	Imaging biomarkers for early multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, 103, 60-68.	2.2	2
2387	Progressive autonomic failure. , 2022, , 297-337.		0
2388	Urinary Dysfunction in Multiple System Atrophy. , 2022, , 1-20.		0

#	ARTICLE	IF	CITATIONS
2389	Effect of aspiration prevention surgery in three patients with multiple system atrophy who have been hospitalized for aspiration pneumonia. <i>Clinical Neurology</i> , 2022, 62, 621-626.	0.1	0
2390	Autophagy in Lewy body diseases and multiple system atrophy. , 2022, , 227-244.		0
2391	Pervasive and diffuse muscle activity during REM sleep and non-REM sleep characterises multiple system atrophy in comparison with Parkinson's disease. <i>Journal of Sleep Research</i> , 0, , .	3.2	1
2392	High-Contrast Imaging of α -Synuclein Pathologies in Living Patients with Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 2159-2161.	3.9	8
2393	Multiple system atrophy prions transmit neurological disease to mice expressing wild-type human α -synuclein. <i>Acta Neuropathologica</i> , 2022, 144, 677-690.	7.7	7
2394	Autonomic dysfunction in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2023, 270, 109-129.	3.6	4
2395	A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2015-2027.	2.8	4
2396	Diffusion Magnetic Resonance Imaging Microstructural Abnormalities in Multiple System Atrophy: A Comprehensive Review. <i>Movement Disorders</i> , 2022, 37, 1963-1984.	3.9	5
2397	Prevalence of axial postural abnormalities and their subtypes in Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2023, 270, 139-151.	3.6	6
2398	Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 419-432.	2.6	3
2399	Neurophysiological differentiation of upper motor neuron damage in neurodegenerative disorders. <i>Clinical Neurophysiology Practice</i> , 2022, 7, 273-278.	1.4	1
2400	Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects. <i>Cerebellum</i> , 2023, 22, 1098-1108.	2.5	3
2401	Clinical Features and Neuroimaging Findings of Neuropil Antibody-Positive Idiopathic Sporadic Ataxia of Unknown Etiology. <i>Cerebellum</i> , 0, , .	2.5	2
2402	Multimodal striatal neuromarkers in distinguishing parkinsonian variant of multiple system atrophy from idiopathic Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2172-2182.	3.9	4
2403	Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study "FARPRESTO". <i>Neurological Sciences</i> , 2022, 43, 6919-6928.	1.9	6
2405	Altered cerebral blood flow in patients with spinocerebellar degeneration. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	1
2406	Health-related quality of life in patients with multiple system atrophy using the EQ-5D. <i>Brain and Behavior</i> , 2022, 12, .	2.2	5
2407	Alterations of voxel-wise spontaneous activity and corresponding brain functional networks in multiple system atrophy patients with mild cognitive impairment. <i>Human Brain Mapping</i> , 2023, 44, 403-417.	3.6	5

#	ARTICLE	IF	CITATIONS
2408	Pearls & Oysters: Deep Phenotyping of Abnormal Eye Movements Advances the Detection of Gerstmann-Sträussler-Scheinker Syndrome. <i>Neurology</i> , 2022, 99, 957-961.	1.1	1
2409	Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 433-444.	2.6	2
2410	Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2301-2307.	3.9	7
2411	Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 761-773.	2.6	5
2412	Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	5
2413	Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping. <i>Cerebellum</i> , 2024, 23, 31-51.	2.5	1
2414	Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder. <i>Movement Disorders</i> , 2023, 38, 57-67.	3.9	2
2415	Responsiveness of UMSARS and other clinical measures in a longitudinal structured care clinic for multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 477-484.	2.5	2
2416	Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	0
2417	Rhythmic auditory cueing in atypical parkinsonism: A pilot study. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	2
2418	Alpha-Synuclein species in oral mucosa as potential biomarkers for multiple system atrophy. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	1
2419	Laboratory prognostic factors for the long-term survival of multiple system atrophy. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	2
2420	Multiple System Atrophy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1350-1363.	0.8	1
2421	Surgical Management of Synucleinopathies. <i>Biomedicines</i> , 2022, 10, 2657.	3.2	2
2422	The Assessment of Subregions in the Frontal Lobe May Be Feasible in the Differential Diagnosis of Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA). <i>Diagnostics</i> , 2022, 12, 2421.	2.6	3
2423	Monocytolipoprotein ratio has a high predictive value for the diagnosis of multiple system atrophy and the differentiation from Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	4
2424	Speech acoustic indices for differential diagnosis between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	6
2425	Diagnostic value of β -synuclein seeding amplification assays in β -synucleinopathies: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 99-109.	2.2	21

#	ARTICLE	IF	CITATIONS
2426	Prevalence and Clinical Characteristics of Dementia and Cognitive Impairment in Multiple System Atrophy: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, , 1-13.	2.8	0
2427	Nocturnal Pulse Event Frequency Is Reduced in Multiple System Atrophy. <i>Annals of Neurology</i> , 0, , .	5.3	2
2428	Editorial: Autonomic dysfunction in multiple system atrophy. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	0
2429	Drugs in the Treatment of Dystonia, Multisystem Atrophy, and Non-Parkinson Tremor. , 2022, , 2947-2962.		0
2430	Long-Term Clinical Efficacy of Human Umbilical Cord Blood Mononuclear Cell Transplantation by Lateral Atlanto-Occipital Space Puncture (Gongâ€™s Puncture) for the Treatment of Multiple System Atrophy. <i>Cell Transplantation</i> , 2022, 31, 096368972211365.	2.5	1
2431	Neuroimaging in multiple system atrophy. , 2023, , 311-354.		0
2432	Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2519-2530.	2.8	7
2433	The effect of continuous positive airway pressure (CPAP) on the quality of life in patients with multiple system atrophy. <i>Sleep and Breathing</i> , 0, , .	1.7	0
2434	Longitudinal evolution of motor and non-motor symptoms in early-stage multiple system atrophy: a 2-year prospective cohort study. <i>BMC Medicine</i> , 2022, 20, .	5.5	3
2435	Phosphorylated Î±-Synuclein Deposits in Cutaneous Nerves of Early Parkinsonism. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2453-2468.	2.8	4
2436	CNS Delivery of Nucleic Acid Therapeutics: Beyond the Bloodâ€™Brain Barrier and Towards Specific Cellular Targeting. <i>Pharmaceutical Research</i> , 2023, 40, 77-105.	3.5	9
2437	Pathomechanisms of depression in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2023, 130, 1-6.	2.8	3
2438	Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy. <i>Brain Pathology</i> , 2023, 33, .	4.1	4
2439	Deep learning signature of brain [18F]FDG PET associated with cognitive outcome of rapid eye movement sleep behavior disorder. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
2440	C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. <i>Neurobiology of Disease</i> , 2022, 175, 105927.	4.4	3
2441	Cerebellar impulsivityâ€™compulsivity assessment scale. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 48-57.	3.7	1
2442	Comparison of the second consensus statement with the movement disorder society criteria for multiple system atrophy: A single-center analysis. <i>Parkinsonism and Related Disorders</i> , 2023, 106, 105242.	2.2	1
2443	QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis. , 2023, 14, 204.		6

#	ARTICLE	IF	CITATIONS
2444	Cystatin C predicts cognitive decline in multiple system atrophy: A 1-year prospective cohort study. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	2
2445	Clinical outcomes and cognitive impairments between progressive supranuclear palsy and multiple system atrophy. <i>Brain and Behavior</i> , 2022, 12, .	2.2	3
2446	Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2023, 43, 565-580.	4.3	5
2447	Glutathione Depletion and MicroRNA Dysregulation in Multiple System Atrophy: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15076.	4.1	3
2448	The E46K mutation modulates α -synuclein prion replication in transgenic mice. <i>PLoS Pathogens</i> , 2022, 18, e1010956.	4.7	3
2449	The Effects of Deep Brain Stimulation in Patients with Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2595-2600.	2.8	4
2450	Multiple System Atrophy: Advances in Diagnosis and Therapy. <i>Journal of Movement Disorders</i> , 2023, 16, 13-21.	1.3	1
2451	Clinical polymorphism of multiple system atrophy: a clinical case series. <i>Almanah Kliničeskoj Mediciny</i> , 2022, 50, 310-314.	0.3	0
2452	Determinants of cognitive impairment in multiple system atrophy: Clinical and genetic study. <i>PLoS ONE</i> , 2022, 17, e0277798.	2.5	0
2453	Plasma sphingolipid abnormalities in neurodegenerative diseases. <i>PLoS ONE</i> , 2022, 17, e0279315.	2.5	6
2454	Psychosis treatment in a patient with Parkinsonian type multiple system atrophy using modified electroconvulsive therapy: a case report. <i>Psychogeriatrics</i> , 2023, 23, 364-367.	1.2	1
2456	The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant. <i>Diagnostics</i> , 2022, 12, 3022.	2.6	2
2458	Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. <i>Molecular Neurodegeneration</i> , 2022, 17, .	10.8	21
2459	Multiple system atrophy: diagnostic methods and biomarkers. <i>Annals of Clinical and Experimental Neurology</i> , 2022, 16, 54-61.	0.4	0
2460	Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders. <i>Movement Disorders</i> , 2023, 38, 267-277.	3.9	10
2461	Current Updates and Unmet Needs of Brain MRI-Based Artificial Intelligence Software for Patients With Neurodegenerative Diseases in the Republic of Korea. <i>Investigative Magnetic Resonance Imaging</i> , 2022, 26, 237.	0.4	0
2462	Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. <i>Insights Into Imaging</i> , 2023, 14, .	3.4	5
2463	Creutzfeldt-Jakob Disease Misdiagnosed as Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 496-500.	1.5	1

#	ARTICLE	IF	CITATIONS
2464	Pathological Validation of the <scp>MDS</scp> Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2023, 38, 444-452.	3.9	10
2465	Higher prevalence of idiopathic normal pressure hydrocephalus-like MRI features in progressive supranuclear palsy: An imaging reminder of atypical parkinsonism. Brain and Behavior, 2023, 13, .	2.2	3
2466	Î±-synuclein as a promising biomarker for developing diagnostic tools against neurodegenerative synucleinopathy disorders. TrAC - Trends in Analytical Chemistry, 2023, 159, 116922.	11.4	3
2467	Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?. Movement Disorders, 2023, 38, 558-566.	3.9	15
2468	Comparison of mean diffusivity, R2* relaxation rate and morphometric biomarkers for the clinical differentiation of parkinsonism. Parkinsonism and Related Disorders, 2023, 108, 105287.	2.2	2
2469	Dynamic postural balance indices can help discriminate between patients with multiple system atrophy and Parkinson's disease. Frontiers in Neurology, 0, 13, .	2.4	0
2470	iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated Î±-Synuclein Release. Cells, 2023, 12, 223.	4.1	1
2471	Morphological differences between the two major subtypes of multiple system atrophy with cognitive impairment. Parkinsonism and Related Disorders, 2023, 107, 105273.	2.2	1
2472	Structural and metabolic correlates of neuropsychological profiles in multiple system atrophy and Parkinson's disease. Parkinsonism and Related Disorders, 2023, 107, 105277.	2.2	3
2473	Multiple system atrophy-cerebellar: A case report and literature review. Radiology Case Reports, 2023, 18, 1121-1126.	0.6	0
2474	The characteristic of nonmotor symptoms with different phenotypes and onsets in multiple system atrophy patients. Journal of Clinical Neuroscience, 2023, 109, 1-5.	1.5	0
2475	Clique Network-Based Statistics for Detecting Altered Topological Structures in the Brain Network. , 2022, , .		1
2476	Functional connectome automatically differentiates multiple system atrophy (parkinsonian type) from idiopathic Parkinson's disease at early stages. Human Brain Mapping, 2023, 44, 2176-2190.	3.6	7
2477	Evolution of Clinical Outcome Measures and Biomarkers in Sporadic Adult-Onset Degenerative Ataxia. Movement Disorders, 2023, 38, 654-664.	3.9	5
2478	A case of the development of early mental and autonomic disorders in a patient with Parkinson's disease. differential diagnosis with atypical parkinsonism. Vestnik Nevrologii, Psihatrii I Neirohirurgii, 2023, , 40-43.	0.1	0
2479	Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients. Neurological Sciences, 2023, 44, 1613-1623.	1.9	2
2481	Loss of torsional quick eye movements during head roll in progressive supranuclear palsy: a new diagnostic marker. Journal of Neurology, 2023, 270, 2230-2236.	3.6	0
2482	The differences of orthostatic hypotension in patients with Parkinson's disease and multiple system atrophy. Frontiers in Neurology, 0, 14, .	2.4	0

#	ARTICLE	IF	CITATIONS
2483	The Peripheral Immune Traits Changed in Patients with Multiple System Atrophy. <i>Brain Sciences</i> , 2023, 13, 205.	2.3	1
2484	Cutaneous α -Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. <i>Neurology</i> , 2023, 100, .	1.1	22
2485	Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
2486	Parkinson's disease or multiple system atrophy: potential separation by quantitative susceptibility mapping. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, 175628642211438.	3.5	1
2487	Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 0, , .	3.9	1
2488	Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study. <i>European Radiology</i> , 2023, 33, 4540-4551.	4.5	4
2489	Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study. <i>Sleep Medicine</i> , 2023, 105, 1-8.	1.6	2
2490	Systematic assessment of plasma biomarkers in spinocerebellar ataxia. <i>Neurobiology of Disease</i> , 2023, 181, 106112.	4.4	3
2491	Neurodegenerative Aspects of Multiple System Atrophy. , 2022, , 1869-1892.		0
2492	Prediction of early-wheelchair dependence in multiple system atrophy based on machine learning algorithm: A prospective cohort study. <i>Clinical Parkinsonism & Related Disorders</i> , 2023, 8, 100183.	0.9	2
2493	Serum vitamin levels in multiple system atrophy: A case-control study. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	1
2494	Sympathetic and electrochemical skin responses in the assessment of sudomotor function: a comparative study. <i>Neurophysiologie Clinique</i> , 2023, 53, 102840.	2.2	5
2495	A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. <i>EBioMedicine</i> , 2023, 89, 104456.	6.1	6
2496	Baseline characteristics of the North American prodromal Synucleinopathy cohort. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 520-535.	3.7	15
2497	C9ORF72 repeat expansion is not associated with atypical parkinsonism in the Serbian population. <i>Genetika</i> , 2022, 54, 1313-1330.	0.4	0
2498	The genetic basis of multiple system atrophy. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	5
2499	Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 35-55.	1.8	0
2500	The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 3-20.	1.8	1

#	ARTICLE	IF	CITATIONS
2501	Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 95-106.	1.8	4
2502	Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies. Brain, 2023, 146, 3301-3318.	7.6	4
2503	Differential immunophenotypes of neuronal cytoplasmic inclusions in the dentate gyrus of multiple system atrophy and their association with clinicopathological features. Journal of Neuropathology and Experimental Neurology, 2023, 82, 302-311.	1.7	0
2504	Ataxias: Hereditary, Acquired, and Reversible Etiologies. Seminars in Neurology, 2023, 43, 048-064.	1.4	0
2505	Multiple system atrophy. Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova, 2023, 123, 144.	0.7	0
2506	Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes. Scientific Reports, 2023, 13, .	3.3	1
2507	±-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluidâ€”A Systematic Review and Metaâ€”Analysis. Movement Disorders Clinical Practice, 2023, 10, 737-747.	1.5	9
2508	Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. Journal of Neural Transmission, 2023, 130, 513-520.	2.8	0
2509	Association between Cognitive Impairment and Hippocampal Subfield Volumes in Multiple System Atrophy. Parkinson's Disease, 2023, 2023, 1-8.	1.1	0
2510	Postmortem Cerebellar Volume Is Not Reduced in Essential Tremor: A Comparison with Multiple System Atrophy and Controls. Journal of Parkinson's Disease, 2023, , 1-9.	2.8	1
2511	±-Synuclein conformers reveal link to clinical heterogeneity of ±-synucleinopathies. Translational Neurodegeneration, 2023, 12, .	8.0	4
2512	Clinical and imaging â€œred flagsâ€”for the diagnosis of multiple system atrophy lookalikes. Parkinsonism and Related Disorders, 2023, , 105372.	2.2	0
2513	Cognitive Impairment in Neurodegenerative Movement Disorders. Seminars in Neurology, 2023, 43, 081-094.	1.4	0
2514	Increased depressive symptoms in Parkinsonâ€™s disease during the COVIDâ€™19 pandemic: Preliminary findings from longitudinal analysis of the PHASE study. Clinical Parkinsonism & Related Disorders, 2023, 8, 100194.	0.9	0
2515	SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4609-4618.	0.8	4
2516	Parkinsonism and akineticâ€”rigid disorders. , 2013, , 567-585.		2
2517	Quick computer aided differential diagnostics based on repetitive finger tapping in Parkinsonâ€™s disease and atypical parkinsonisms. Heliyon, 2023, 9, e14824.	3.2	1
2518	Neuropsychological evaluation of phenoconversion risk in <sc>REM</sc> sleep behaviour disorder: A scoping review. Journal of Sleep Research, 0, , .	3.2	2

#	ARTICLE	IF	CITATIONS
2519	Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases. <i>Translational Neurodegeneration</i> , 2023, 12, .	8.0	2
2520	Motor assessment of patients with multiple system atrophy: underuse of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Clinical Autonomic Research</i> , 0, , .	2.5	0
2521	Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. <i>Brain</i> , 2023, 146, 3232-3242.	7.6	5
2522	Alterations in Restingâ€State <sc>MR</sc> Functional Connectivity of the Central Autonomic Network in Multiple System Atrophy and Relationship with Disease Severity. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1472-1487.	3.4	1
2523	Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2023, 448, 120614.	0.6	1
2524	Olfactory Bulb Volume, Olfactory Sulcus Depth in Parkinson's Disease, Atypical Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 794-801.	1.5	0
2525	Characteristics of Mild Cognitive Impairment and Associated Factors in MSA Patients. <i>Brain Sciences</i> , 2023, 13, 582.	2.3	1
2526	<sc>UMSARS</sc> Versus Laryngoscopyâ€Based Assessment of Dysphagia. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	1
2527	Dorsolateral Nigral Hyperintensity on 1. <sc>5â€T</sc> Versus <sc>3â€T</sc> Susceptibilityâ€Weighted Magnetic Resonance Imaging in Neurodegenerative Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	0
2528	Urodynamic Study in Multiple System Atrophy: A Retrospective Observational Study. <i>Brain & Neurorehabilitation</i> , 2023, 16, .	1.0	0
2530	High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. <i>EClinicalMedicine</i> , 2023, 59, 101920.	7.1	6
2531	Multiple System Atrophy. , 2022, , 1839-1867.		0
2532	Diagnostic Effectiveness of [123I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy. <i>Journal of Clinical Medicine</i> , 2023, 12, 3478.	2.4	0
2534	Deep learning regressor model based on nigrosome MRI in Parkinson syndrome effectively predicts striatal dopamine transporter-SPECT uptake. <i>Neuroradiology</i> , 0, , .	2.2	1
2535	The High Value of External Anal- and Urethral-Sphincter Electromyography in Differential Diagnosis with MSA-P, PD, and PSP. <i>Annals of Indian Academy of Neurology</i> , 2023, Publish Ahead of Print, .	0.5	1
2536	Exam 1: Section 1. , 2023, , 3-27.		0
2537	<sc>GRK2â€</sc> Targeted Knockdown as Therapy for Multiple System Atrophy. <i>Movement Disorders</i> , 2023, 38, 1336-1340.	3.9	2
2539	Characteristics of Anal Sphincter Electromyography in Patients with Multiple System Atrophy. <i>BIO Web of Conferences</i> , 2023, 60, 02019.	0.2	0

#	ARTICLE	IF	CITATIONS
2540	Sex and Gender Influence Urinary Symptoms and Management in Multiple System Atrophy. <i>Journal of Movement Disorders</i> , 2023, 16, 196-201.	1.3	1
2541	Propagative α -synuclein seeds as serum biomarkers for synucleinopathies. <i>Nature Medicine</i> , 2023, 29, 1448-1455.	30.7	46
2542	Coenzyme Q10 in Multiple System Atrophy. <i>Contemporary Clinical Neuroscience</i> , 2023, , 679-690.	0.3	0
2544	Large-scale activation likelihood estimation meta-analysis of parkinsonian disorders. <i>Brain Communications</i> , 2023, 5, .	3.3	0
2545	Gait analysis of patients with Parkinson-plus syndromes: a research article. <i>Bulletin of the National Research Centre</i> , 2023, 47, .	1.8	1
2546	Disease-Specific α -Synuclein Seeding in Lewy Body Disease and Multiple System Atrophy Are Preserved in Formaldehyde-Fixed Paraffin-Embedded Human Brain. <i>Biomolecules</i> , 2023, 13, 936.	4.0	2
2547	C9orf72 genetic screening in amyotrophic lateral sclerosis patients from Serbia. <i>Genetika</i> , 2023, 55, 1-18.	0.4	0
2548	Freezing of gait in Chinese patients with multiple system atrophy: prevalence and risk factors. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
2549	Constipation in multiple system atrophy: a pilot study in Chinese patients. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	0
2550	Gait-combined closed-loop brain stimulation can improve walking dynamics in Parkinsonian gait disturbances: a randomised-control trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 938-944.	1.9	1
2551	Cellular processing of α -synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. <i>Journal of Biological Chemistry</i> , 2023, 299, 104912.	3.4	3
2552	Identification of m.3243A>G mitochondrial DNA mutation in patients with cerebellar ataxia. <i>Journal of the Formosan Medical Association</i> , 2023, , .	1.7	3
2553	Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution. <i>Journal of Movement Disorders</i> , 0, , .	1.3	0
2554	Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for misdiagnosis. <i>European Journal of Neurology</i> , 2023, 30, 2602-2610.	3.3	1
2555	Diagnostic utility of movement disorder society criteria for multiple system atrophy. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	1
2556	Neurological update: non-motor symptoms in atypical parkinsonian syndromes. <i>Journal of Neurology</i> , 2023, 270, 4558-4578.	3.6	1
2557	Striatal dopamine transporter binding differs between dementia with Lewy bodies and Parkinson's disease with dementia. <i>Journal of the Neurological Sciences</i> , 2023, 451, 120713.	0.6	0
2558	Neurodegeneration, oxidative stress and lipid metabolism plasma biomarkers to differentiate Parkinson's disease from atypical parkinsonian syndromes. <i>Revue Neurologique</i> , 2023, 179, 961-966.	1.5	1

#	ARTICLE	IF	CITATIONS
2559	Asymmetrical putaminal atrophy in parkinsonism-predominant multiple system atrophy (MSA-P): A case report. <i>Radiology Case Reports</i> , 2023, 18, 2975-2977.	0.6	1
2560	Comparing Cerebellar tDCS and Cerebellar tACS in Neurodegenerative Ataxias Using Wearable Sensors: A Randomized, Double-Blind, Sham-Controlled, Triple-Crossover Trial. <i>Cerebellum</i> , 0, , .	2.5	2
2561	Temporal Relationship between Impairment of Cerebellar Motor Learning and Deterioration of Ataxia in Patients with Cerebellar Degeneration. <i>Cerebellum</i> , 0, , .	2.5	0
2562	Expiratory Muscle Strength Training in Multiple System Atrophy: A Pilot Study. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 1060-1065.	1.5	0
2563	Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2023, 13, 485-499.	2.8	2
2565	Image features of anti-SEZ6L2 encephalitis, a rare cause of ataxia and parkinsonism. <i>Journal of Neurology</i> , 0, , .	3.6	2
2566	GAA- <i>FGF14</i> ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response. <i>Brain</i> , 2023, 146, 4144-4157.	7.6	23
2567	Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. <i>Journal of Neurology</i> , 2023, 270, 4248-4261.	3.6	1
2568	Clinical correlates of fear of falling in progressive supranuclear palsy and multiple system atrophy. <i>European Journal of Neurology</i> , 2023, 30, 2261-2266.	3.3	1
2569	Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study. <i>Translational Neurodegeneration</i> , 2023, 12, .	8.0	2
2570	Applications of fMRI to Neurodegenerative Disease. , 2023, , 819-860.		0
2571	Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder. <i>Journal of Neurology</i> , 2023, 270, 4393-4402.	3.6	4
2572	Clinical availability of eye movement during reading. <i>Neuroscience Research</i> , 2023, , .	1.9	0
2573	Development and Validation of a Prognostic Model to Predict Overall Survival in Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	0
2574	Assessment of Aggregated and Exosome-Associated α -Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays. <i>Diagnostics</i> , 2023, 13, 2192.	2.6	1
2576	Establishment and clinical application evaluations of a deep mining strategy of plasma proteomics based on nanomaterial protein coronas. <i>Analytica Chimica Acta</i> , 2023, 1275, 341569.	5.4	0
2577	Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in α -synucleinopathies. <i>NeuroImage: Clinical</i> , 2023, 39, 103475.	2.7	1
2578	Is <i>REM</i> sleep behavior disorder changing? Secular changes versus referral patterns. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
2579	Strained face during sleep in multiple system atrophy: not just a bad dream. <i>Sleep</i> , 0, , .	1.1	0
2580	Improved interpretation of 18F-florzolotau PET in progressive supranuclear palsy using a normalization-free deep-learning classifier. <i>IScience</i> , 2023, 26, 107426.	4.1	2
2581	Preparing for Diseaseâ€”Modification Trials in Degenerative Cerebellar Ataxias: Which Endpoints to Choose?. <i>Movement Disorders</i> , 2023, 38, 917-923.	3.9	2
2582	Surface-Based Neuroimaging Pattern of Multiple System Atrophy. <i>Academic Radiology</i> , 2023, , .	2.5	1
2583	Automated Vowel Articulation Analysis in Connected Speech Among Progressive Neurological Diseases, Dysarthria Types, and Dysarthria Severities. <i>Journal of Speech, Language, and Hearing Research</i> , 0, , 1-22.	1.6	1
2584	Clinical and dopaminergic imaging characteristics of the FARPRESTO cohort of trialâ€”ready idiopathic rapid eye movement sleep behavior patients. <i>European Journal of Neurology</i> , 2023, 30, 3703-3710.	3.3	1
2585	No Correlation between Plasma <scp>GPNMB</scp> Levels and Multiple System Atrophy in Chinese Cohorts. <i>Movement Disorders</i> , 2023, 38, 1956-1961.	3.9	1
2586	Clinical effects of Lewy body pathology in cognitively impaired individuals. <i>Nature Medicine</i> , 2023, 29, 1964-1970.	30.7	14
2587	Multidimensional biomarkers for multiple system atrophy: an update and future directions. <i>Translational Neurodegeneration</i> , 2023, 12, .	8.0	1
2588	Identification of Parkinsonâ€™s disease and multiple system atrophy using multimodal PET/MRI radiomics. <i>European Radiology</i> , 2024, 34, 662-672.	4.5	3
2589	Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder. <i>Sleep</i> , 0, , .	1.1	0
2590	Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy. <i>Movement Disorders</i> , 2023, 38, 2121-2125.	3.9	2
2591	Autonomic failure: Clinicopathologic, physiologic, and genetic aspects. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 55-102.	1.8	0
2592	Anxiety and physical impairment in patients with central vestibular disorders. <i>Journal of Neurology</i> , 2023, 270, 5589-5599.	3.6	1
2593	Serum lipid levels are associated with orthostatic hypotension in multiple system atrophy patients. <i>Parkinsonism and Related Disorders</i> , 2023, 114, 105803.	2.2	0
2594	How do patients with Parkinsonâ€™s disease and cerebellar ataxia read aloud? -Eyeâ€”voice coordination in text reading. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
2595	Comparison of biospecimens for Î±â€”synuclein seed amplification assays in Parkinson's disease: A systematic review and network metaâ€”analysis. <i>European Journal of Neurology</i> , 2023, 30, 3949-3967.	3.3	1
2596	Frequency and phenotypic spectrum of spinocerebellar ataxia <scp>27B</scp> and other genetic ataxias in a Spanish cohort of lateâ€”onset cerebellar ataxia. <i>European Journal of Neurology</i> , 2023, 30, 3828-3833.	3.3	6

#	ARTICLE	IF	CITATIONS
2597	Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000207685.	1.1	0
2598	Mild cognitive impairment in multiple system atrophy: a brain network disorder. <i>Journal of Neural Transmission</i> , 0, , .	2.8	0
2599	Vagus Nerve Ultrasonography Helps Distinguish Multiple System Atrophy from Other Parkinsonian Syndromes. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 1525-1529.	1.5	0
2600	A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution. <i>Journal of Neurology</i> , 2024, 271, 553-563.	3.6	1
2601	What Is Neurodegeneration?. , 2023, , 1-13.		0
2602	DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. <i>Nature Aging</i> , 2023, 3, 1201-1209.	11.6	7
2603	Understanding the potential causes of gastrointestinal dysfunctions in multiple system atrophy. <i>Neurobiology of Disease</i> , 2023, 187, 106296.	4.4	1
2604	Levodopaâ€induced orthostatic hypotension in parkinsonism: A red flag of autonomic failure. <i>European Journal of Neurology</i> , 2024, 31, .	3.3	3
2605	Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinsonâ€™s Disease: A Multicenter Study. <i>Life</i> , 2023, 13, 1786.	2.4	1
2606	Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Followâ€Up. <i>Movement Disorders</i> , 2023, 38, 1567-1569.	3.9	0
2607	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	23
2608	Natural History and Phenotypic Spectrum of <sc>GAA</sc><i>FGF14</i></sc> Sporadic Lateâ€Onset Cerebellar Ataxia (<sc>SCA27B</sc>). <i>Movement Disorders</i> , 2023, 38, 1950-1956.	3.9	14
2609	The Dawn of In Vivo Gene Editing Era: A Revolution in the Making. <i>Biologics</i> , 2023, 3, 253-295.	4.1	1
2610	Digital Motor Biomarkers of Cerebellar Ataxia Using an RGB-Depth Camera-Based Motion Analysis System. <i>Cerebellum</i> , 0, , .	2.5	0
2611	Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study. <i>Clinical Autonomic Research</i> , 2023, 33, 635-645.	2.5	1
2612	Pain in Multiple System Atrophy a Systematic Review and Metaâ€Analysis. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 1738-1749.	1.5	0
2615	Adherence to continuous positive airway pressure for the treatment of obstructive sleep apnea in neurodegenerative diseases: A systematic review. <i>Sleep Medicine Reviews</i> , 2023, 71, 101836.	8.5	2
2616	Î±-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2023, 117, 105807.	2.2	6

#	ARTICLE	IF	CITATIONS
2617	Synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 175-202.	1.8	0
2618	Variation of respiratory and pulse events in multiple system atrophy. Parkinsonism and Related Disorders, 2023, 115, 105817.	2.2	0
2620	Deterioration of Cough, Respiratory, and Vocal Cord Functions in Patients with Multiple System Atrophy. Neurology International, 2023, 15, 1227-1237.	2.8	0
2622	Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, <scp>crossâ€correlation</scp> study. Journal of Neurochemistry, 2023, 167, 168-182.	3.9	1
2623	Swallowing Characteristics in Patients with Multiple System Atrophy Analyzed Using FEES Examination. Dysphagia, 0, , .	1.8	0
2624	Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy. Journal of Parkinson's Disease, 2023, , 1-14.	2.8	0
2625	Risk of hospitalization in synucleinopathies and impact of psychosis. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
2626	Striatal and thalamic automatic segmentation, morphology, and clinical correlates in Parkinsonism: Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Psychiatry Research - Neuroimaging, 2023, 335, 111719.	1.8	0
2627	Emotion Recognition in Multiple System Atrophy â€“ An exploratory Eye-Tracking Study. Journal of Movement Disorders, 0, , .	1.3	0
2628	Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers. Frontiers in Neurology, 0, 14, .	2.4	2
2629	Effects of Rehabilitative Intervention for Augmenting Cough Function in Patients with Multiple System Atrophy. Progress in Rehabilitation Medicine, 2023, 8, n/a.	0.9	0
2630	Quantitative cellular changes in multiple system atrophy brains. Neuropathology and Applied Neurobiology, 2023, 49, .	3.2	0
2631	Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank. Neurology, 2023, 101, .	1.1	3
2632	Cardiac 18F-dopamine positron emission tomography predicts the type of phenoconversion of pure autonomic failure. Clinical Autonomic Research, 2023, 33, 737-747.	2.5	0
2633	The role of exosomes in the diagnosis of Parkinson's disease. Heliyon, 2023, 9, e20595.	3.2	2
2634	Comparison of tandospirone and escitalopram as a symptomatic treatment in Multiple System Atrophy-cerebellar ataxia: An open-label, non-controlled, 4 weeks observational study. Journal of Psychiatric Research, 2023, , .	3.1	0
2635	Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder. European Journal of Neurology, 2024, 31, .	3.3	1
2636	Covering Basic Needs on Molecular Imaging. Movement Disorders Clinical Practice, 2024, 11, 10-13.	1.5	0

#	ARTICLE	IF	CITATIONS
2637	How Certain Are You When Making the Diagnosis of Multiple System Atrophy?. <i>Neurology</i> , 2023, 101, 1081-1082.	1.1	0
2638	Urinary Dysfunction in Multiple System Atrophy. , 2023, , 747-759.		0
2639	The Î±-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. <i>Nature Communications</i> , 2023, 14, .	12.8	5
2640	The Frequency of Intermediate Alleles in Patients with Cerebellar Phenotypes. <i>Cerebellum</i> , 0, , .	2.5	0
2641	Modified version of unified multiple system atrophy rating scale for remote video-based assessments. <i>Npj Parkinson's Disease</i> , 2023, 9, .	5.3	0
2642	Prevalence and prognostic significance of malnutrition in early-stage multiple system atrophy. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	0
2643	Cognitive and motor profiles as prodromal markers in predicting phenoconversion and phenotype in isolated REM sleep behavior disorder. <i>Sleep Medicine</i> , 2023, 112, 262-272.	1.6	0
2644	Neuropathological features of levodopa-responsive parkinsonism in multiple system atrophy: an autopsy case report and comparative neuropathological study. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	0
2645	Differentiation of speech in Parkinsonâ€™s disease and spinocerebellar degeneration using deep neural networks. <i>Journal of Neurology</i> , 2024, 271, 1004-1012.	3.6	0
2646	Spoken Language Alterations can Predict Phenoconversion in Isolated <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder: A Multicenter Study. <i>Annals of Neurology</i> , 2024, 95, 530-543.	5.3	0
2648	Sleep Dysfunction and Sleep-Disordered Breathing in Miscellaneous Neurological Disorders. , 2023, , 525-553.		0
2649	Corneal confocal microscopy demonstrates varying degrees of neurodegeneration in atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2023, 117, 105899.	2.2	1
2650	Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study. <i>Movement Disorders</i> , 2024, 39, 119-129.	3.9	0
2651	Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2024, 51, 1023-1034.	6.4	0
2652	Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases. <i>NeurologÃa (English Edition)</i> , 2023, 38, 609-616.	0.4	0
2653	Imaging Differential Diagnosis of Neurodegenerative Disorders. , 2023, , 325-358.		1
2654	Longitudinal evolution of sleep disturbances in early multiple system atrophy: a 2â€year prospective cohort study. <i>BMC Medicine</i> , 2023, 21, .	5.5	1
2655	Multi-parametric radiomics of conventional T1 weighted and susceptibility-weighted imaging for differential diagnosis of idiopathic Parkinsonâ€™s disease and multiple system atrophy. <i>BMC Medical Imaging</i> , 2023, 23, .	2.7	1

#	ARTICLE	IF	CITATIONS
2656	Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes. <i>Antioxidants</i> , 2023, 12, 2104.	5.1	0
2657	Cortical microvascular raspberries and ageing: an independent but not exclusive relationship. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	5.2	0
2658	Detecting ferroptosis and immune infiltration profiles in multiple system atrophy using postmortem brain tissue. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
2659	Follow-Up Findings in Multiple System Atrophy from [123I]Ioflupane Single-Photon Emission Computed Tomography (SPECT): A Prospective Study. <i>Biomedicines</i> , 2023, 11, 2893.	3.2	1
2660	Luxembourg Parkinsonâ€™s study -comprehensive baseline analysis of Parkinsonâ€™s disease and atypical parkinsonism. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	0
2661	Genetic landscape of Parkinsonâ€™s disease and related diseases in Luxembourg. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	0
2662	Correlations between serotonin impairments and clinical indices in multiple system atrophy. <i>European Journal of Neurology</i> , 2024, 31, .	3.3	0
2663	Dramatic improvement in freezing of gait with levodopa in a patient with vascular parkinsonism. <i>Annals of Movement Disorders</i> , 2023, 6, 152-155.	0.3	1
2664	Orthostatic Hypotension in Multiple System Atrophy: Related Factors and Disease Prognosis. <i>Journal of Parkinson's Disease</i> , 2023, 13, 1313-1320.	2.8	1
2665	Exploring the links among peripheral immunity, biomarkers, cognition, and neuroimaging in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.4	0
2666	Cough Correlates of Functional Swallow Outcomes in Atypical Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2024, 11, 265-275.	1.5	0
2667	Blepharoclonus in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2024, 14, .	1.6	0
2668	Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Crossâ€Sectional Study. <i>Movement Disorders</i> , 2024, 39, 391-399.	3.9	0
2669	Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid. <i>ACS Chemical Neuroscience</i> , 2024, 15, 582-592.	3.5	0
2670	Distinct forebrain regions define a dichotomous astrocytic profile in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2024, 12, .	5.2	0
2671	Monash-Alfred protocol for assessment of atypical parkinsonian syndromes (MAP-APS). <i>BMJ Neurology Open</i> , 2024, 6, e000553.	1.6	0
2672	The association between plasma GPNMB and Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2024, 120, 106001.	2.2	0
2673	Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. <i>Acta Neuropathologica</i> , 2024, 147, .	7.7	1

#	ARTICLE	IF	CITATIONS
2674	Abnormal Ocular Movement in the Early Stage of Multiple-System Atrophy With Predominant		

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

#	ARTICLE	IF	CITATIONS
2694	FastEval Parkinsonism: an instant deep learning-assisted video-based online system for Parkinsonian motor symptom evaluation. <i>Npj Digital Medicine</i> , 2024, 7, .	10.9	0
2696	Associations of sleep-related variables with reverse dipping patterns of blood pressure in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2024, 121, 106046.	2.2	0
2697	Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study. <i>Parkinsonism and Related Disorders</i> , 2024, 121, 106047.	2.2	0
2698	The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis. <i>Journal of Neurology</i> , 2024, 271, 2639-2648.	3.6	0
2699	Cerebellar Volumetry in Ataxias: Relation to Ataxia Severity and Duration. <i>Cerebellum</i> , 0, , .	2.5	0
2700	Rates of change of pons and middle cerebellar peduncle diameters are diagnostic of multiple system atrophy of the cerebellar type. <i>Brain Communications</i> , 2023, 6, .	3.3	0
2701	α -Synuclein seed amplification technology for Parkinson's disease and related synucleinopathies. <i>Trends in Biotechnology</i> , 2024, , .	9.3	0
2702	Frequency and outcomes of gastrostomy insertion in a longitudinal cohort study of atypical parkinsonism. <i>European Journal of Neurology</i> , 2024, 31, .	3.3	0
2703	Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
2704	Noise Pareidolia Test in Parkinson's Disease and Atypical Parkinsonian Syndromes: A Retrospective Study. <i>Cureus</i> , 2024, , .	0.5	0
2705	Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism. <i>Parkinson's Disease</i> , 2024, 2024, 1-5.	1.1	0
2706	Prevalence of multiple system atrophy: A literature review. <i>Revue Neurologique</i> , 2024, , .	1.5	0
2707	Patient-perceived progression in multiple system atrophy: natural history of quality of life. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 0, , jnnp-2023-332733.	1.9	0
2708	Putting a strain on the brain: An update on synucleinopathy pathogenesis. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2016, , .	0.1	0
2709	Comparative Performance of Susceptibility Map-Weighted MRI According to the Acquisition Planes in the Diagnosis of Neurodegenerative Parkinsonism. <i>Korean Journal of Radiology</i> , 2024, 25, 267.	3.4	0
2710	Multiple System Atrophy. , 2024, , 211-225.		0
2711	A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. <i>Nature Communications</i> , 2024, 15, .	12.8	0
2712	Electroencephalographic spectro-spatial covariance patterns related to phenoconversion in isolated rapid eye movement sleep behavior disorder and their longitudinal trajectories in α -synucleinopathies. <i>Sleep</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
2713	Corneal confocal microscopy may help to distinguish Multiple System Atrophy from Parkinsonâ€™s disease. Npj Parkinson's Disease, 2024, 10, .	5.3	0
2714	Contribution of <scp>MRI</scp> for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty. Movement Disorders, 0, , .	3.9	0
2715	The Movement Disorder Society Criteria: Its Clinical Usefulness in Multiple System Atrophy. Internal Medicine, 2024, , .	0.7	0
2716	Presynaptic Dopaminergic Imaging Characterizes Patients with <scp>REM</scp> Sleep Behavior Disorder Due to Synucleinopathy. Annals of Neurology, 0, , .	5.3	0
2717	FGF14 GAA repeat expansion and ZFH3 GGC repeat expansion in clinically diagnosed multiple system atrophy patients. Journal of Neurology, 0, , .	3.6	0
2718	Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. Journal of Neurology, 2024, 271, 2324-2344.	3.6	0
2719	Reduced maximal range of ocular movements and its response to acute levodopa challenge in Parkinson's disease. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0
2720	Skin Biopsy Detection of Phosphorylated Î±-Synuclein in Patients With Synucleinopathies. JAMA - Journal of the American Medical Association, 2024, 331, 1298.	7.4	0